Search the web
Sign In
New User? Sign Up
cut · Cancer UroTherapy
? Already a member? Sign in to Yahoo!

Yahoo! Groups Tips

Did you know...
Real people. Real stories. See how Yahoo! Groups impacts members worldwide.

Best of Y! Groups

   Check them out and nominate your group.
Having problems with message search? Fill out this form to ensure your group is one of the first to be migrated to the new message search system.

Messages

  Messages Help
Advanced
Messages 1408 - 1438 of 1448   Newest  |  < Newer  |  Older >  |  Oldest
Messages: Show Message Summaries   (Group by Topic) Sort by Date v  
#1438 From: "salvationscience" <salvationscience@...>
Date: Sat Sep 5, 2009 12:27 am
Subject: THE BIBLICAL WATER OF LIFE: THE EFFICACY OF URINE INJECTIONS
salvationsci...
Offline Offline
Send Email Send Email
 
THE BIBLICAL WATER OF LIFE: THE EFFICACY OF URINE INJECTIONS
http://www.salvationscience.com
cut@yahoogroups.com

--- In cut@yahoogroups.com, Joseph Eldor <a1b2c3d4@...> wrote:

Dear Mr. Ang,
I suggest you to read it in the following articles (No. 65-70).
Best regards,
Joseph Eldor, MD

           "Subcutaneous urine injections was practiced in 1912 by
           Duncan (65) from New York under the name of auto-pyotherapy
           for urinary infections, and in 1919 by Wildbolz (65) from
           Bern for diagnostic purposes. Cimino (66) from Palermo
           reported in 1927 on the use of auto uro-therapy for urinary
           infections. Rabinowitch (67) in 1931 described this
           auto-urine therapy for gonarthritis. Jausion et al. (68)
           used this kind of therapy in 1933 for desensitization and
           endocrinological problems. They treated with auto urotherapy
           injections patients who suffered from migraine, pruritus,
           asthma, urticaria, eczema, psoriasis, etc. Day (69)in 1936
           treated patients with acute and subacute glomerulonephritis
           by injection of an autogenous urinary extract. Sandweiss,
           Saltzstein and Farbman (70) reported in 1938 that an extract
           from urine of pregnant women has a prophylactic and
           therapeutic effect on experimental ulcers in dogs."

           65. Jausion H. Sur l'auto-ouro-therapie. Journal D'Urologie
           1935;39:58-59
           66. Cimino T. Premiers essais de vaccine-proteine-therapie
           des infections non gonococciques ni tuberculeuses des voies
           urinaires a l'aide des injections sous-cutanees de l'urine
           purulente du sujet, sterilisee par l'ebullition
           (ouro-therapie). Rivista Sanitaria 1927;186
           67. Rabinowitch IM. Auto-urine-therapy in gonarthritis.
           Vratchebnaia gazeta 1931;35:677-8
           68. Jausion H, Giard R, Martinaud G. L'auto-ouro-therapie.
           La Presse Medicale 1933;76:1467-1470
           69. Day HB. Treatment of glomerulonephritis by antigen.
           Lancet 1936;1456-9
           70. Sandweiss DJ, Saltzstein HC, Farbman AA. The prevention
           or healing of experimental ulcer in Mann-Williamson dogs
           with the Anterior-Pituitary-Like hormone (Antuitrin-S). Am J
           Dig Dis 1938;5:24-30

http://www.csen.com/theory/cancer.htm
http://www.salvationscience.com
cut@yahoogroups.com
***************************************************************

#1437 From: Joseph Eldor <a1b2c3d4@...>
Date: Mon Aug 31, 2009 1:34 pm
Subject: Re: Urine Injections
csen_interna...
Offline Offline
Send Email Send Email
 
Dear Mr. Ang,
I suggest you to read it in the following articles (No. 65-70).
Best regards,
Joseph Eldor, MD
 
 
          65. Jausion H. Sur l'auto-ouro-therapie. Journal D'Urologie
          1935;39:58-59
          66. Cimino T. Premiers essais de vaccine-proteine-therapie
          des infections non gonococciques ni tuberculeuses des voies
          urinaires a l'aide des injections sous-cutanees de l'urine
          purulente du sujet, sterilisee par l'ebullition
          (ouro-therapie). Rivista Sanitaria 1927;186
          67. Rabinowitch IM. Auto-urine-therapy in gonarthritis.
          Vratchebnaia gazeta 1931;35:677-8
          68. Jausion H, Giard R, Martinaud G. L'auto-ouro-therapie.
          La Presse Medicale 1933;76:1467-1470
          69. Day HB. Treatment of glomerulonephritis by antigen.
          Lancet 1936;1456-9
          70. Sandweiss DJ, Saltzstein HC, Farbman AA. The prevention
          or healing of experimental ulcer in Mann-Williamson dogs
          with the Anterior-Pituitary-Like hormone (Antuitrin-S). Am J
          Dig Dis 1938;5:24-30
"Subcutaneous urine injections was practiced in 1912 by
          Duncan (65) from New York under the name of auto-pyotherapy
          for urinary infections, and in 1919 by Wildbolz (65) from
          Bern for diagnostic purposes. Cimino (66) from Palermo
          reported in 1927 on the use of auto uro-therapy for urinary
          infections. Rabinowitch (67) in 1931 described this
          auto-urine therapy for gonarthritis. Jausion et al. (68)
          used this kind of therapy in 1933 for desensitization and
          endocrinological problems. They treated with auto urotherapy
          injections patients who suffered from migraine, pruritus,
          asthma, urticaria, eczema, psoriasis, etc. Day (69)in 1936
          treated patients with acute and subacute glomerulonephritis
          by injection of an autogenous urinary extract. Sandweiss,
          Saltzstein and Farbman (70) reported in 1938 that an extract
          from urine of pregnant women has a prophylactic and
          therapeutic effect on experimental ulcers in dogs."
 
 
----- Original Message -----
Sent: Monday, August 31, 2009 4:12 PM
Subject: Urine Injections

Dear Dr. Eldor:

        Would you be so kind to please advise me in the protocol of injecting urine.
.<<Subcutaneous urine injections was practiced in 1912 by Duncan (1) from New York under the name of auto-pyotherapy for urinary infections, and in 1919 by Wildbolz (1) from Bern for diagnostic purposes. Cimino (2) from Palermo reported in 1927 on the use of auto uro-therapy for urinary infections. Rabinowitch (3) in 1931 described this auto-urine therapy for gonarthritis.
Jausion et al. (4) used this kind of therapy in 1933 for desensitization and endocrinological problems. They treated with auto urotherapy injections patients who suffered from migraine, pruritus, asthma, urticaria, eczema, psoriasis, etc. Day (5)in 1936 treated patients with acute and subacute glomerulonephritis by injection of an autogenous urinary extract. Sandweiss, Saltzstein and Farbman (6) reported in 1938 that an extract from urine of pregnant women has a prophylactic and therapeutic effect on experimental ulcers in dogs.>>

My case study comes from  http://www.curezone.com/forums/fm.asp?i=1163383   Martin lara's testimonials, but i have not been able to contact Mr. lara by phone since i need the information/advice/protocol/instructions for a friend who fits more or less the conditions of  "Juana Lucia" I have to be circumspect on how to proceed with this (since i have tried oral ingestion and rectal implants already and she responded well..)

Your assistance is very much appreciated.

Thank you very much,

dickson ang




#1436 From: "salvationscience" <salvationscience@...>
Date: Thu Aug 13, 2009 2:57 am
Subject: What is Oxidative Therapy? by Clif Arrington M.D.
salvationsci...
Offline Offline
Send Email Send Email
 
What is Oxidative Therapy? by Clif Arrington M.D.
http://www.anti-agingmd.com
http://www.salvationscience.com

Oxidative Therapy is simply treating the body with extra oxygen. Treatment
methods include forcing extra oxygen gas (O2) into the lungs under pressure
(hyperbaric oxygen), mixing blood with ozone gas (O3) and the intravenous
infusion of liquid hydrogen peroxide (H2O2). The addition of extra oxygen has
many benefits for both prevention and treatment of disease.

Remember how hydrogen peroxide foams up when applied to an open wound? Those
foaming bubbles are pure oxygen produced by hydrogen peroxide reacting with a
blood enzyme catalase. A small amount of hydrogen peroxide can produce a very
large amount of oxygen. Areas of the body suffering oxygen deficiency due to
poor circulation benefit greatly from the addition of this extra oxygen.

OXIDATION is an extremely important energy producing chemical reaction in the
body using various forms of oxygen. Like nuclear energy, this powerful oxidative
energy must be tightly controlled to prevent damage to surrounding normal
tissue. Anti-oxidants in the form of vitamins and enzymes protect the body from
oxidative damage. The immune system however uses oxidative energy as a weapon to
directly kill infectious agents such as bacteria, virus, yeast and parasites.

Intravenous Hydrogen Peroxide was first used by Dr. T. H. Oliver in 1920 to
successfully treat patients during an epidemic of influenzal pneumonia. He
published his results in the British Medical Journal, Lancet. 70 years later
this old treatment was rediscovered by Charles Farr M..D.,Ph.D. whose modern day
research resulted in the scientific paper "Therapeutic Use of Intravenous
Hydrogen Peroxide." This paper is the protocol for all physicians who administer
intravenous hydrogen peroxide. There have been no reports of serious side
effects using this protocol.

Oxidative therapy using hydrogen peroxide has been reported in the scientific
literature and by physicians to be of benefit in the following conditions:

Heart and Blood Vessel Diseases
Peripheral Vascular Disease
Cerebral Vascular Disease
Cardiovascular Disease
Coronary Spasm (Angina)
Heart Arrhythmias
Gangrene of Fingers and Toes
Raynaud's Syndrome
Temporal Arteritis
Vascular and Cluster Headaches
Pulmonary Diseases
Chronic Obstructive Lung Disease
Emphysema
Asthma
Bronchiectasis
Chronic Bronchitis
Infectious Diseases
Influenza
Herpes Zoster (shingles)
Herpes Simplex (fever blister)
Systemic Chronic Candidiasis
Chronic Fatigue Syndrome
(Ebstein_Barr Virus)
HIV (AIDS) Infections
Acute and Chronic Viral Infections
Chronic Bacterial Infections
Parasitic Infections
Immune Disorders
Multiple Sclerosis
Rheumatoid Arthritis
Diabetes Mellitus Type II
Hypersensitive Persons (Environmental and Universal Reactors)
Parkinsonism
Alzheimer
Migraine Headaches
Chronic Pain Syndromes
Pain of Metastatic Carcinoma
Blood and Lymph Node Cancers

How is this therapy administered? Weak, very pure Hydrogen Peroxide (0.0375% or
lower concentration) is added to a saline solution, the same as used for
intravenous feeding in hospitals. This is infused in doses of 250 ml into a vein
in the arm, slowly over a period of 1 to 2 hours. Treatments are usually given
about once a week in chronic illness, but can be given daily in patients with
acute illness such as pneumonia or flu. Physicians may recommend 10 to 20
treatments depending on the condition of the patient and the illness being
treated. Some patients, especially with chronic illness, may need to take follow
up treatments in series of 5 to 10 treatments, or may need indefinite
maintenance on a regular monthly schedule.

http://www.anti-agingmd.com
http://www.salvationscience.com
************************************************************

#1435 From: Joseph Eldor <a1b2c3d4@...>
Date: Mon Aug 10, 2009 4:47 pm
Subject: Immunotherapy for liver tumors: present status and future prospects
csen_interna...
Offline Offline
Send Email Send Email
 

 
Review

Immunotherapy for liver tumors: present status and future prospects

Pablo Matar1,3 email, Laura Alaniz2,3 email, Viviana Rozados1 email, Jorge B Aquino2,3 email, Mariana Malvicini2 email, Catalina Atorrasagasti2 email, Manuel Gidekel4 email, Marcelo Silva2 email, O Graciela Scharovsky1 email and Guillermo Mazzolini2,3 email

1Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Santa Fe 3100, (2000) Rosario, Argentina

2Gene Therapy Laboratory, Liver Unit, School of Medicine, Austral University, Av. Presidente Perón 1500, (B1629ODT) Derqui-Pilar, Buenos Aires, Argentina

3CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Buenos Aires, Argentina

4VentureL@b, Escuela de Negocios, Universidad Adolfo Ibañez, Av. Diagonal Las Torres 2700, Peñalolen 791000, Santiago, Chile

author email corresponding author email

Journal of Biomedical Science 2009, 16:30doi:10.1186/1423-0127-16-30

The electronic version of this article is the complete one and can be found online at: http://www.jbiomedsci.com/content/16/1/30

Received: 28 October 2008
Accepted: 6 March 2009
Published: 6 March 2009

© 2009 Matar et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors. Progress in immune-based strategies has opened new therapeutic avenues using a number of techniques destined to eliminate malignant cells. In the present review, we overview current knowledge on the importance, successes and difficulties of immunotherapy in liver tumors, including preclinical data available in animal models and information from clinical trials carried out during the lasts years. This review shows that new options for the treatment of advanced liver tumors are urgently needed and that there is a ground for future advances in the field.

Background

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide [1]. Unfortunately, the incidence and mortality associated with HCC is increasing steadily [2] as a consequence of epidemics of hepatitis C virus (HCV) and hepatitis B virus (HBV). HCV and HBV infections are causally associated with the majority of HCC in the world [3].

Current therapeutic options are extremely disappointing since less than 30% of the patients evaluated in referral medical institutions can receive a curative therapy, consisting in either resection or transplantation [4]. Thus, in the majority of advanced HCC cases surgery is not possible and the prognosis is dismal due to underlying cirrhosis as well as to poor tumor response to chemotherapeutic agents [4-6].

Unfortunately, advanced colorectal carcinoma (CRC) depict similar scenario [7]. Colorectal carcinoma is one of the most common malignancies and a leading cause of cancer-related death [1]. Hepatic metastases are present in 15–25% of patients at the time of CRC diagnosis [8]. Surgical resection, which is accepted as first-line CRC treatment, cannot be performed in the majority of patients [9]. Following diagnosis, the median survival of untreated patients with liver metastases is 6–12 months [10]. The application of new chemotherapeutic cocktails, including irinotecan or oxaliplatin, result in higher rates of objective responses and survival [11-15] and the recent incorporation of monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptors provides additional, although limited, improvement in patients survival [15,16].

Thus, new strategies are needed for treatment of patients with advanced liver tumors and immunotherapy approaches might play a significant role among them. Cancer immunotherapy can be defined as a set of techniques aimed to eliminate malignant tumors through mechanisms involving immune system responses [17,18]. The goal of cancer immunotherapy is to understand how to direct against tumors similar kind of extremely potent immune responses such as those naturally occurring against microbial antigens, and subsequently how to apply these results to human cancer diseases. It has been observed in patients with HCC that the presence of a lymphocyte infiltrate is associated with a better prognosis after resection and transplantation [19]. Similarly, presence of lymphocyte infiltration in tumors was correlated with patient survival in CRC: survival rate of patients with large numbers of CD3+-T cells was 5-years higher [20,21].

There is a limited clinical experience regarding the application of immunotherapy in liver tumors contrary to more immunogenic tumors such as melanoma, lymphoma or renal cell carcinoma. Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors (Fig. 1). Unfortunately, the presence of chronic HCV or HBV infection complicates the success of immunotherapy in patients with HCC because these viruses were found to be able to modulate the immune response against tumors and to counteract the immune system of the host [22-24].

thumbnailFigure 1. Immunotherapeutic strategies for liver tumors: administration of recombinant cytokines, adoptive transfer of tumor-reactive T cells generated in vitro, gene therapy with cytokines and costimulatory molecules, immunotherapy with dendritic cells, stimulation with immunogenic vaccines or antibodies.

The immune system and the induction of antitumor immunity – basic concepts

The immune system is clearly capable of recognizing and eliminating tumor cells, although cancer cells are considered as poorly immunogenic [25]. Compelling evidence suggests that immune cells can eventually play a crucial role in the control of cancer. First, both occasional spontaneous tumor regressions have been described in immunocompetent hosts while increased cancer incidence has been reported in immunocompromised individuals [26]. Second, tumor immunity was demonstrated experimentally in several animal models [27]. Third, the immune system often recognizes the presence of tumors, as reflected by an accumulation of immune cells at tumor sites [28].

Despite the ability of the immune system to react against cancer cells, the presence of a tumor indicates that the developing cancer can avoid detection or to escape the immune response [29]. Mechanisms used to elude recognition include tumor-induced impairment of antigen presentation, activation of negative co-stimulatory signals, and production of immunosuppressive factors [30]. In addition, cancer cells may promote the expansion and/or recruitment of regulatory cells that may contribute to the immunosuppressive network; these populations include regulatory T cells (Treg), myeloid suppressor cells, and distinct subsets of immature and mature regulatory dendritic cells [31].

All of the previously mentioned mechanisms were shown to be induced in the liver by hepatitis viruses [32,33] and a concomitant chronic HCV/HBV infection in HCC patients would probably make the scenario for immunotherapeutic approaches more complicated.

The immunosurveillance and the immunoediting hypothesis

In the last 30 years we have witnessed a dramatic change in basic concepts related to tumor immunology, from the strict theory of tumor immunosurveillance postulated by Burnet and Thomas [34,35] to the very recent immunoediting concept developed by Schreiber and colleagues [36]. Using a broader look at tumor immunology, these authors have elegantly described tumor progression as a process following three phases: elimination; equilibrium and, finally, escape, in which tumor cells develop several strategies to avoid their immune-mediated elimination. The variety of processes by which tumors evade the immune response is surprisingly large. Even though cancer cells express new or inappropriate antigens, tumors of diverse origin develop common and/or unique mechanisms that enable them to escape from the immune system.

The liver: an immunological privileged organ

Mechanisms of tolerance and their implications in cancer are of central interest in immunology. The liver is an especial organ for its immunological privileged status which is a consequence of several unique immunological properties causing antigen tolerance rather than immunity [37,38] and relative resistance against liver allograft rejection [39], allowing that 20% of allotransplanted patients could be withdrawn from long-term immunosuppression [40]. Aggressive autoimmune hepatitis is a somewhat uncommon clinical manifestation of systemic autoimmune disease [41]. Moreover, it has been observed in animal models that naïve liver reactive T cells ignore antigens derived from or expressed in the liver [42], generating tolerance to them [37]. It is important to note that effector T-cells alone may not be sufficient for disease induction without additional inflammatory and costimulatory signals. A potential role for TLR3 has been reported as one of the critical mechanisms of hepatic immune privilege [43].

As it was excellently reviewed by Abe and Thomson [38], liver immunoprivilege properties are likely due to its unique repertoire of antigen-presenting cell (APC) populations, consisting of Kupffer cells (KCs), liver sinusoidal endothelial cells (LSECs) and dendritic cells (DCs). KCs represent 80–90% of liver resident macrophages and are very efficient in clearing LPS from gut-derived blood circulation but less efficient in activating CD4+ cells. LSECs were shown to efficiently separate leukocytes from hepatocytes [44], are able to express factors involved in T cell death, induce differentiation of CD4+ towards the Th2 anti-inflammatory phenotype and were found to co-stimulate Tregs and inhibit allogeneic T cells. DCs are located in portal areas or circulate through liver sinusoids towards lymph draining vessels, and upon maturation increase their expression levels of IL-12 and CCR7, two molecules involved in CD4+ T cell differentiation towards the Th1 pro-inflammatory phenotype and in DC trafficking towards secondary lymphoid organs, respectively. From all liver APCs, DCs are the most potent to elicit immune responses. Due to the fact that KCs and LSECs constitutively express IL-10 and TGF-beta anti-inflammatory cytokines, T cell differentiation is affected and APC maturation inhibited in the liver [45,46]. As a consequence, the DCs are less immunostimulatory than in spleen [47,48].

In addition, hepatic stellate cells (also known as Ito cells) were shown to be involved in liver immunological processes only in case of chronic liver injury. They are induced to transdifferentiate into myofibroblasts and to secrete a number of cytokines and chemokines, such as transforming growth factor beta (TGF-beta) [49,50]. In fact, activated hepatic stellate cells have been shown to closely interact with lymphocytes [51] and to have potent antigen-presenting properties [52]. Furthermore, stellate cells from hepatitis patients have been shown to get further activated by lymphocyte proximity, especially by CD8+ cells, and to phagocyte CD45+ cells [53]. Those facts suggest that stellate cells are likely implicated in the down-regulation of the immune response in HCV/HBV-derived cirrhosis and might also be involved in HCC. These findings open new therapeutic opportunities aimed to specifically targeting hepatic stellate cells in advanced cirrhosis and HCC.

Finally, when HCC coexists with HBV/HCV derived cirrhosis, these viruses as shown in chronic hepatitis, would likely exert direct and indirect effects on further downregulation of the immune response through complex and not fully understood mechanisms. They might influence the activity of hepatic stellate cells as well as that of resident and recruited immune cells, such us DCs, through direct viral protein interaction [54-57]. As reviewed by Liu et al. [33] in chronic B/C-viral hepatitis a reduction in the myeloid and plasmacytoid DC liver populations, down-regulation in IL-12 and IFN-gamma levels, an up-regulation of IL-10 and an impairment in DCs capacity to prime naïve T cells may account for the insufficient immune response observed. Similarly, a reduction in circulating DC numbers was found in the peripheral blood of patients with either chronic-B-hepatitis [58] or chronic-C-hepatitis [59,60]. HBV/HCV viruses would likely contribute to the DC impaired allostimulatory and IL-12 production capacities observed in HCC patients [61], although this remains to be elucidated.

Hepatic tumors escape from the immune response

Hepatic tumors use two main strategies to escape from the immune response – attack and defense – the first is designed to attack the immune cells, hence avoiding their antitumor action and the other to defend tumor cells by enabling them to pass unnoticed by the immune response (Table 1).

Table 1. Mechanisms of hepatic tumor-immune escape.

Attack strategies

Fas ligand (FasL), a type II transmembrane protein reported to induce apoptosis of Fas-bearing cells [62] was shown to confer immunological privilege to certain tissues and organs such as eye, placenta and central nervous system [63-65]. More recently, the interaction of FasL or its secreted isoform (sFASL) produced by tumor cells, with their specific Fas receptor, expressed on T lymphocytes, was implicated in tumor cell evasion from immune surveillance [66]. The α-fetoprotein (AFP), an oncofetal protein overexpressed in some HCC, was shown to induce Fas-L and tumor necrosis factor [TNF]-related apoptosis expression in HCC Bel7402 cells, as well as TRAIL receptor and Fas in lymphocytes [67,68]. Another pathway developed to attack immune cells involves the interaction of PD-1 (programmed death-1) with its ligands PD-L1 and PD-L2. Immunotherapy with an expression plasmid encoding the extracellular domain of PD-1 (sPD-1) in H22 HCC cells was shown to improve the immune response against tumors [69]. One further mechanism might implicate Galectin-1 (Gal-1) – a β-galactoside binding protein with immunoregulatory properties, which is known to play a role in cytotoxic immune cells elimination. It is likely that Gal-1 contributes to tumor immune escape by killing activated T cells [70,71]. In fact, the expression of Gal-1 was shown to be induced in primary HLF, HuH7 and HepG2 cells [72].

Defense strategies

The pressure that the immune system exerts on the growth of tumor cells seems to have led them to develop several protection mechanisms against any immune attack. It has been shown that human HCC-related factors not only induce and expand the regulatory CD4+CD25+ T cell population (Tregs), but also enhance their suppressor ability [73]. A high prevalence of Tregs infiltrating HCC seems to be an unfavorable prognostic indicator [74]. Another mechanism frequently used by tumors is the down-regulation of MHC-I [75], B7-1/B7-2 co-stimulatory molecules [76] or transporter associated with antigen processing (TAP)1/2 molecules in human HCC [77]. In addition, HCC cells might escape from CTL-induced apoptosis by increasing Bcl-2 and decreasing Bcl-xs expression [78] and/or raising the Survivin level, an important member of the inhibitor of apoptosis (IAP) family [79,80].

Indoleamine 2,3 dioxygenase (IDO) catalyses the degradation of the essential amino acid tryptophan and synthesizes immunosuppressive metabolites [81]. Larrea and colleagues [82] reported that IDO constitutes an important mediator of peripheral immune tolerance in chronic hepatitis C virus (HCV) infection. Induction of IDO expression may reduce T-cell reactivity to viral antigens in chronic HCV infection and may also influence the immune response against HCC in patients chronically infected with HCV. Understanding of the immune-escape mechanisms should help us to design immunotherapy protocols to increase the efficacy of therapeutic success.

Systemic use of immunostimulatory cytokines

There is a broad experience regarding the use of cytokines to induce immune and inflammatory responses against cancer [83,84]. Cytokines have been shown to act through different mechanisms: i) stimulation of antitumor immune responses; ii) induction of tumor cell apoptosis (e.g. through induction of TRAIL) [85]; iii) interference in uncontrolled proliferation of cancer cells, and iv) anti-angiogenesis.

One of the most explored cytokines is interferon alpha (IFN-α) [86,87]. The IFN-α antitumor mechanism of action includes direct effect on tumor cells, induction of lymphocyte and macrophage cytotoxic activities and anti-angiogenesis [88,89]. Two controlled trials comparing IFN-α with symptomatic treatment in patients with HCC were reported. In one of them the use of high doses of IFN-α (50 MU/m2, tiw) resulted in a response rate of 36% [90]. In the other trial, in which lower doses of IFN-α (3 MU/m2, tiw) were administered, the response rate was poor (7%) [91]. Even though it is clear that the different responses are related to the administered doses, the toxicity associated with the higher IFN-α dose is not acceptable, especially for patients with end-stage liver disease. Nevertheless, systemic administration of IFN-α [92] or IFN-β [93] should be considered as a supportive treatment after hepatectomy or tumor ablation, which may prevent or delay tumor relapses in patients with HCC [94]. A combination of IFN-α and chemotherapy was applied to patients for treatment of advanced HCC [95,96] and metastatic CRC to the liver [97]; however, randomized controlled studies failed to demonstrate that combination protocol results in improved outcome when compared to chemotherapy treatment alone [98,99].

Interleukin-2, an immunostimulatory cytokine, has been administered alone or in combination with other treatments against liver tumors. The non-controlled nature of most studies precludes from any definitive conclusion. Systemic IL-2 was able to produce objective responses against HCC when given alone [100] or in combination with melatonin [101] or lymphokine activated killer (LAK) cells [102]. On the other hand, hepatic artery infusion of interleukin 2, with or without chemotherapy, induced objective remissions in 5% to 15% of liver metastases from CRC [95,103,104]. In a phase II clinical trial, Correale and colleagues showed that the combination of polychemotherapy with granulocyte macrophage colony-stimulating (GM-CSF) factor and low-dose IL-2 in colorectal carcinoma patients, results in high number of objective responses and low toxicity [105].

There is one report on combination of hepatic trans-arterial chemotherapy with IFNγ plus IL-2 in patients with advanced HCC [106]. The achieved objective responses highlight some biological effect of this treatment combination. In another study, when IL-2 was administered together with IFNγ and GM-CSF to advanced HCC patients, clinical results were poor [107]. However, in spite of some stimulating results, the clinical development of IL-2 has been proved unsuitable because in parallel to their efficacy the results involved severe toxicity, including systemic vascular leak syndrome.

No trials were reported on the application of other cytokines such as IL-12, TNFα, or TRAIL, known to have a potential effect against primary or metastatic liver cancer in humans. Nevertheless, concerns were raised following reports on the development of severe toxicity after systemic treatment with IL-12 or TNFα [108,109] in other type of tumors.

Although being able to obtain some positive outcomes in the treatment of liver tumors, systemic application of cytokines is accompanied by toxic effects which can be overcome by local delivery. A possible role of some of the immunostimulatory cytokines, e.g. IL-12, could be reasonable in the context of vaccination as an adjuvant administered at low doses.

Immunostimulating monoclonal antibodies

In the field of cancer therapy mAbs can act directly against tumor cells or indirectly by interfering with several processes such as survival, cellular proliferation or angiogenesis. The immunostimulating monoclonal antibodies which are those corresponding to the latter group, are defined as a new family of drugs aimed to augment immune responses. They consist in either agonistic or antagonistic mAbs which are aimed to bind key immune system receptors, thereby enhancing antigen presentation, providing co-stimulation or counteracting immune-regulation [110].

Regulation of T-cell responses

T-cells express several co-signalling molecules, typically cell-surface glycoproteins classified as co-stimulators or co-inhibitors [111,112]. The outcome of T-cell responses depend on the balance between co-stimulatory and co-inhibitory molecules. Thus, antigenic signalling in the absence of co-stimulatory molecules results in suboptimal immune activation and may lead to T-cell deletion or unresponsiveness. Monoclonal antibodies targeting co-stimulatory molecules expressed on T-cells may act agonistically, working as surrogate ligands and augmenting T-cell proliferation and survival. Alternatively, mAbs may act antagonistically, counteracting the inhibitory effects of co-inhibitor molecules or Treg-cells.

Costimulation with agonistic mAbs

Diverse costimulatory molecules appear to regulate T-cell response, working specifically at different time points [113,114]. Antibodies against CD28 are known to potentiate antitumor immunity in combination with bi-specific antibodies that bind to both the tumor antigen and the TCR-CD3 complex [112]. Some anti-CD28 antibodies, termed superagonist antibodies, can activate T-cells without concomitant TCR engagement. Unfortunately, concerns were raised following reports of severe toxicity in a Phase I dose-escalation trial with an anti-CD28 mAb (TGN1412) [115].

Another costimulatory molecule, CD137 (also known as 4-1BB), is a member of the TNF-receptor superfamily, expressed in antigen-activated T-cells (CD4+, CD8+, Treg and NK cells), DCs, cytokine-activated NK cells, eosinophils, mast cells and, intriguingly, endothelial cells of some metastatic tumors [116-118]. The natural ligand for CD137 (CD137 ligand) is constitutively produced by activated APCs. Agonistic anti-CD137 Abs strongly promote survival of T-cells and prevent activation-induced cell death [119,120]. Antitumor effects of anti-CD137 mAbs were first recognized by Melero et al. [121] in established Ag104 sarcoma and P815 mastocytoma. These effects are thought to be involved in the activation of naive T-cells which are specific for tumor antigens cross-presented by DCs. Repeated systemic injections of agonistic anti-CD137, in two mouse models of CRC, induced tumor eradication in 3 out of 5 mice [122]. Unfortunately, this therapeutic modality may have serious drawbacks. Niu and colleagues found that a single injection of anti-CD137 given to BALB/c or C57BL/6 control mice led to the development of a series of anomalies such as splenomegaly, lymphadenopathy, hepatomegaly, multifocal hepatitis, anemia, altered trafficking of B cells and CD8+ T-cells, loss of NK cells, and a 10-fold increase in bone marrow cells bearing the phenotype of hematopoietic stem cells [123].

OX40 (also known as CD134 and TNR4) is another member of the TNF receptor family, specifically expressed in activated CD4+ and CD8+ T lymphocyte, B-cells, DCs and eosinophils [124]. OX40 ligand (OX40L) is expressed in activated APCs and can also be found in activated T-cells and in endothelial cells [125]. OX40 seems to be particularly important to ensure T-cell long-term survival, probably through up-regulation of the anti-apoptotic proteins Bcl-xL and Bcl-2 [126]. Weinberg [127] showed that systemic OX40 ligation increases tumor immunity, with a role for CD4+ cells in the B16 melanoma model. Phase I clinical trials, using a murine anti-human OX40 mAb, have been initiated in patients with advanced cancer of multiple tissue origins; however, it can not be administered in several repeated doses because of its xenogeneic nature, which is likely to trigger immune responses against murine sequences [128].

Thus, agonistic mAbs have been found to produce some benefits in treatment of liver tumors although their systemic application causes serious undesired secondary effects. Intratumoral application of low doses of them might overcome some of the systemic delivery problems.

Counteracting immunoregulation with antagonistic mAbs

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is an inhibitory receptor with a structural homology to the co-stimulatory receptor CD28 [111,129]. Under antigenic stimulation, ligand binding to CTLA-4 generates inhibitory signals mediating reduction in T-cell proliferation and in IL-2 secretion. Administration of antagonistic anti-CTLA-4 mAbs demonstrated antitumor effects in different murine tumor models including colon, prostate and renal carcinomas, as well as fibrosarcoma and lymphoma [130,131].

As mentioned earlier, PD-1 and its ligands B7-H1 (also known as PD-L1) and B7-DC (also known as PD-L2) [111,132] deliver inhibitory signals to T cells. Administration of mAbs anti-PD-1 and B7-H1 produced CTL-mediated antitumor effects in mice [133].

The finding that HCC-associated antigen HAb18G/CD147, a member of the CD147 family, enhances tumor invasion and metastasis through induction of matrix metalloproteinases [134] led to the development of an anti-CD147 therapy. By using an orthotopic model of HCC in nude mice, Ku and colleagues [135] showed that the application of two different anti-CD147 mAbs (HAb18 and LICARTIN) resulted in consistent inhibition of both tumor and metastasis growth.

In animal models, immunostimulatory mAbs antitumor effects were demonstrated when used either alone or in combination with radiotherapy or chemotherapy [136,137]. Clinical experience with mAbs is scarce; however, several immunostimulatory mAbs have now been introduced in clinical trials and early results suggest that they might enhance antitumor responses with accepted toxicity. Therapy with immunostimulatory antibodies alone or in combination with other strategies should be carefully designed in order to avoid induction of autoimmune toxicity as a consequence of uncontrolled stimulation of the immune system effector arm.

Gene transfer of cytokines and costimulatory molecules. Genetic vaccination

Gene therapy is a promising novel therapeutic strategy for treatment of several heritable and non-heritable human diseases [138,139]. Since about 20 years ago, when the first clinical trial was initiated, and after more than 1300 clinical trials performed all around the world http://www.wiley.co.uk/genmed/clinical/ webcite, we learned that the core concept of gene therapy may be applicable: genes introduced into patients can be safely expressed [140]. However, we have also learned that vector efficiency in clinical applications is not as good as expected [141,142]. Cancer represents almost 70% of the clinical trials conducted in patients and 25% of these studies consisted in the application of cytokine genes.

Gene transfer of immunostimulatory cytokines (e.g. IL-2, IL-4, IL-6, IL-7; IL-12, INF-γ, TNF-α, GM-CSF) was shown to overcome the immune tolerance against tumors, facilitating their eradication in some cases [143-145] (Table 2). Two main approaches have been used [144]: i) direct injection of vectors expressing cytokines/chemokines/costimulatory molecules into tumor lesions, or ii) use of tumor cells/DCs transduced ex vivo with vectors expressing cytokines/costimulatory molecules.

Table 2. Gene transfer immunostimulatory molecules.

Interleukin 12 (IL-12) is a potent cytokine that showed antitumor activity in a number of tumor models [146,147]. Multiple action mechanisms mediating its activity are known, including the activation of NK cells, cytotoxic T lymphocytes and the induction of a TH1 type of response [146]. It also inhibits tumor angiogenesis and enhances the expression of adhesion molecules on endothelial cells, thus facilitating the homing of activated lymphocytes to the tumor [148,149]. However, IL-12 was shown to eventually induce severe toxicity when administered systemically as a recombinant protein [150]. Thus, unspecific toxic effects of systemic IL-12 administration might be solved by the use of gene therapy strategies, allowing local production of IL-12 at the tumor milieu and resulting in high local levels with low systemic concentrations [151]. Consistently, the potential usefulness of IL-12 gene transfer for liver tumors treatment in animal models was demonstrated by different groups including ours [152-154]. We also reported that intratumor injection of an adenovirus encoding IL-12 genes (AdIL-12) into rats with orthotopic HCC induced the complete tumor elimination in the majority of animals [155]. Potent effects of this vector have also been shown in a very aggressive multifocal HCC model developed in rats, by treatment with DENA [155,156] as well as in mice bearing hepatic metastases of colorectal carcinoma [157,158] and in woodchucks chronically infected with woodchuck hepatitis virus (WHV) [159]. The toxicity observed under high IL-12 levels is partly due to induction of IFN-γ overproduction [160]. An encouraging result is that IL-12 gene transfer in combination with another vector expressing the chemokine IP-10 (AdIP-10) allowed the reduction in the AdIL-12 dose with a similar outcome efficacy [161]. The underlying mechanism is the following: lymphocytes get attracted to tumors due to a local IP-10 expression and subsequently they are activated by IL-12. In addition, a combination of IL-12 with MIP3α demonstrated similar synergistic antitumor effects [162].

The effects of IL-12 gene transfer were assessed in patients with advanced gastrointestinal carcinomas in a phase I clinical trial consisting mainly in liver tumors. Patients were administered with up to 3 intratumor injections of AdhIL-12[163]. Treatment feasibility and safety were studied. Even though maximal tolerated dose has not been reached, some evidence of biological and antitumor activities were observed. One partial response, two minor regressions and six stabilizations were achieved. In four out of 10 patients, a significant lymphocyte infiltrate was observed in injected tumors.

It has been stated that abnormal elevated levels of Th2 cytokines such as IL-10 are able to skew an immune response that favors tumor growth [164]. In contrast, Lopez et al. [165] have recently shown that tumor cell vaccines producing a combination of IL-10 and IL-12 act synergistically in eradicating established CRC, with the underlying mechanisms being not fully addressed.

Systemic injection of recombinant IL-2 used extensively in clinical oncology for patients with metastatic renal carcinoma and melanoma has shown low efficacy and high toxicity. A phase I-II clinical trial consisting in the administration of a recombinant adenovirus encoding for IL-2 gene was carried out in patients with advanced digestive carcinomas [166]. Only one of the treated patients showed a positive tumor response with necrosis of the tumor mass.

Molecules such as HLA-B7 are essential to promote specific T-cell responses. A reduced expression of MHC-I was observed in CRC. In an attempt to make CRC more visible to the immune system, Rubin et al [167] carried out a phase I clinical trial consisting in an indirect intralesional gene transfer of both HLA-B7 and β2-microglobulin into CRC hepatic metastases. Treatment with a single plasmid construction encoding for both genes in a lipid formulation (Allovectin-7) was feasible and safe in 15 patients, however, details regarding antitumor effect have not been reported. Such an approach could produce significant therapeutic improvements if aimed to deliver functionally relevant genes.

The interaction between CD40 ligand (CD40L, CD154) and its receptor CD40, expressed in DCs, is essential for the initiation of cellular and humoral immune responses. Gene transfer of CD40-L led to regression of established CRC [168] and HCC [169] in a CD8+ T cell dependent manner.

Replication-selective viral agents (oncolytic virotherapy) hold promise as a novel cancer treatment platform. Oncolytic virotherapy is based on the ability of these vectors to selectively replicate in cancer cells as a result of different mechanisms of action [170]. This novel class of targeting viral vectors exerts direct antitumor effects, but can also be engineered to produce immunostimulatory genes, such as GM-CSF, augmenting its efficacy. A potent in vivo antitumor effect of an oncolytic vector carrying HSV and GM-CSF genes has been demonstrated against murine CRC CT26 and murine HCC Hepa 1.6 [171].

The mutant adenovirus dl1520, also called ONYX-015, was the first described oncolytic adenovirus [172]. It contains a deletion in the E1B 55 K gene that achieves preferential replication in cancer cells by different mechanisms. In the case of liver tumors, this virus showed a partial antitumor effect on murine models but no evident antitumor effect was found when applied to HCC patients. Two separate clinical trials showed that ONYX-015 has limited therapeutic effect as monotherapy in patients with liver tumors, especially if systemic routes are used [173,174]. Other oncolytic adenoviruses have been developed, and show promising results in animal models of HCC. However, their performances in clinical trials have not been tested so far [175].

In conclusion, gene transfer of cytokines and the use of oncolytic viruses are two developing immunotherapy strategies which hold promise in treatment of liver tumors. The former strategy is being widely applied and after further improvements might assure sufficient tumor levels of inflammatory cytokines circumventing toxic systemic effects. The latter strategy is in early stages of development and it largely needs to be applied into the clinics.

Immunotherapy with dendritic cells

The armamentarium for immunotherapy protocols has been boosted by the identification of DCs as protagonists of antigen presentation [176]. The final outcome of DC cross-presentation could be either T-cell activation or T-cell tolerance, depending on its activation/maturation status [177]. Thus, while mature DCs are able to induce antitumor immunity, antigen presentation by immature DCs results in the induction of tolerance [177]. In addition, IL-4 which is overexpressed in the liver under recurrent hepatitis C [178] was shown to influence DCs to induce CD4+ T cell differentiation into the Th2 lineage and to suppress DC response to IFN-gamma [179]. Up to now, several clinical studies consisting in the application of DCs were performed and, as a general outcome, no significant side effects were observed in the majority of these trials with important biological effects showing the augmentation of cellular immune responses against tumor antigens [180].

Direct injection of DCs into tumor tissue has been exploited experimentally and clinically with diverse results [181-183]. Chi KH and colleagues [184] conducted a phase I trial in patients with advanced HCC after conformal radiotherapy. Intratumoral injections of autologous immature naïve DCs prior and after radiotherapy resulted in 2 partial and 4 minor responses. Induction of specific immune responses against AFPs and enhancement in NK activity were observed.

DCs ex vivo-engineered to produce IL-12 were shown to induce antitumor immunity in mice [182,183]. Similar results were reported after application of DCs genetically modified to express IL-7 [185] or IL-15 [186]. A phase I clinical trial consisting in the intratumoral injection of autologous DCs, transfected with Ad-IL-12, in patients with metastatic gastrointestinal carcinomas was carried out [187]. This strategy was feasible and very well tolerated in doses up to 50 × 106 DCs. One partial response and 2 stabilizations were observed. In 3 out of 10 treated patients, a marked increased in CD8+ T lymphocyte infiltrates was found, and in 5 of them NK activity was significantly induced. One of the possible reasons behind the limited antitumor activity might be that DCs would likely be retained within the malignant tissue due to increased intratumoral levels of IL-8 expression as well as other chemotaxis signals, preventing their mobilization to the secondary lymphoid organs for further amplification of immune responses. Consistently, scintigraphic tracking of injected 111In-labelled DCs showed retention of DCs inside tumors [188].

As previously discussed, CD40-L is a costimulatory molecule expressed mainly on activated CD4+ T cells, which is essential for the initiation of antigen-specific T-cell responses [189]. Crystal and colleagues [190,191] showed elimination of CRC nodules after intratumoral administration of CD40-L exogenously expressing DCs. Although this approach has not yet been applied in clinical trials, it seems promising.

Another technique employed to load antigens to DCs consists in the cellular transfection with mRNA molecules. Chu et al. transfected total mRNA from CT26 CRC cells to DCs and showed strong specific CTL activity as well as protective immunity in vivo [192]. Immunization of CEA-transgenic mice, using mature DCs loaded with an anti-idiotype antibody that mimics CEA, resulted in a potent antitumor response against CEA-expressing CRCs, while immunization with DCs loaded with CEA showed less potent response [193]. Morse et al. reported a phase I clinical trial consisting in the administration of autologous DCs loaded with CEA RNA (peptide CAP-1) into 21 patients with resected CRC liver metastases [194]. The procedure was well tolerated, one patient had a minor response, and one had stable disease. More recently, the same group carried out another phase I study in 14 patients (12 CRC and 2 non-small lung cancer) on the effects of immunotherapy combined with DCs transduced with a fowlpox vector encoding CEA and costimulatory molecules. Immunization of these patients was safe and it was able to activate potent CEA-specific immune responses. In a phase I clinical trial with the aim of increasing the amount of circulating DCs, Fong et al. incubated DCs with the hematopoietic growth factor Flt3 ligand before injecting DCs loaded with CEA-derived peptide into 12 patients with colon or non-small cell lung cancer [195]. Two patients showed objective responses and two had stable disease.

Stift and colleagues reported that vaccinations with autologous DCs pulsed with tumor lysates in a cohort of advanced cancer patients (including two with HCC) was safe and feasible [196]. Delayed-type hypersensitivity (DTH) skin test was positive in the majority of vaccination-treated patients and induction of IFN-γ producing T cells was achieved in 4 other patients (not HCC). Another similar DC-based strategy was applied by Iwashita and colleagues [197]. They carried out a phase I clinical trial in patients with advanced HCC. DC-based strategy consisted in the subcutaneous injection of DC pulsed with tumor extract in 10 patients. One patient showed a partial response and in 2 of them AFP levels were decreased. Seven out of 10 showed positive DTH tests for KLH. Tamir and colleagues [198] evaluated the effectiveness of tumor-lysate loaded DC vaccines in the treatment of advanced CEA-positive CRCs.

Itoh et al. combined both DCs pulsed with a CEA peptide (restricted to HLA-A24) and adjuvant cytokines (IFN-α and TNF-α) in the treatment of patients with CEA-expressing metastatic tumors [199]. Ten HLA-A24 patients with advanced digestive tract or lung cancer were treated. No significant adverse effects were observed and the disease in 2 positive DTH test was stabilized [200]. A few years later, Ueda and colleagues conducted a phase I clinical study in which DCs previously pulsed with a CEA-derived peptide were administered to HLA-A24-restricted patients. Eighteen compatible patients were enrolled. No severe toxicity was observed. In some patients, stabilization of the disease and decrease in CEA levels were reported. Accordingly, patients with clinical responses were positive in skin tests and developed specific CTLs [201]. Finally, Babatz and colleagues demonstrated that immunotherapy with DCs pulsed with a CEA-derived peptide is able to induce specific IFN-gamma producing CD8+ T cells [202].

We and others have observed that DCs and NK cell interaction plays an important role in tumor immunity [187,203,204]. In this regard, Osada and colleagues found in patients with metastatic CRC that immunization with DCs transduced with a fowlpox vector encoding CEA was able to increase NK activity in 4 of 9 patients [205]. Importantly, increased NK activity was correlated with clinical response. In order to in vivo-activate DCs and thereby avoiding ex vivo manipulation, Furumoto et al. injected MIP3α chemokine together with CpGs inside CRC tumors [206]. They observed an increase in DC number within tumors which were finally eradicated through the development of specific CTLs.

The use of cytokines as a vaccine adjuvant has been shown to be a promising option for cancer therapy, due to its potential effectiveness against disseminated disease without causing systemic toxicity [207-211]. However, the weakness of these strategies lies in: 1) the need of culturing autologous cancer cells from each patient, 2) the problems in the selection of positively modified cancer cells, 3) the lack of an efficient APC activity in tumor cells and, 4) the limited amount of tumor cells that precludes repeated immunizations. Investigators have looked into other strategies to carry cytokines genes or tumor antigens (such as the use of allogeneic tumor cell lines) but, unfortunately, allogeneic tumor cells may lack sole TAA present within the patient's own tumor, thus reducing its efficacy.

In conclusion, different strategies involving DCs have been developed during the lasts years. Although for some of them no clinical trials have been conducted yet, for other strategies a proportion of patients responded to treatment with minor tumor regression or stabilization, with variable induction of the immune response. Further studies are required for improving the benefits of manipulating the main kind of APCs involved in immune reactions.

Contribution of adoptive T-cell therapy strategies

In several animal models, solid tumors were shown to be susceptible to elimination after infusion of large amounts of tumor-specific T-lymphocytes [212]. However, the translation of these enthusiastic successes into patients are not yet feasible, partly due to difficulties in generating tumor antigen-specific T-cells ex vivo [213].

Adoptive therapy involves the transfer of ex vivo expanded and stimulated immune effector cells to tumor-bearing hosts, aiming at augmenting the antitumor immune response [212,214]. In general, adoptive therapy is accomplished by harvesting cells from the peripheral blood, tumor sites (tumor infiltrating lymphocytes), or draining lymph nodes from which, the effector cells could eventually be expanded ex vivo, in either a specific or non-specific fashion.

One of the major aims of the adoptive T-cell therapy is the identification of tumor-associated antigens (TAAs) that are ectopically expressed or overexpressed in tumor cells relative to normal tissues or, tumor-specific antigens (TSAs) that are expressed exclusively in tumor cells. Despite aberrant expression of TAAs in tumor cells, many of these proteins are also expressed at some level in non-malignant adult tissues and, as a consequence, the immune system may recognize TAAs as self-antigens and limit the T-cell immune response. In addition, as previously discussed the liver immune system usually generates tolerance to proteins expressed by its own cells and HCC induces immune response suppression [215]. Moreover, it was demonstrated that many malignant tumors find the way of down-regulating, modifying or losing its own antigens, in order to avoid immune recognition [29].

No TSA with high prevalence have been identified for liver tumors, so far. PLAC-1, which in normal tissues is only expressed in placenta, was recently found to be expressed in 1/3rd to 1/4th of the analyzed human HCC samples and 3,8% of patients were shown to present humoral responses against this antigen [216]. Among TAAs described in HCC the most important one is AFP. Several AFP-based immunotherapeutic approaches have been applied against HCC [217,218]. Additional TAAs recently found to be expressed in HCC are several members of the tumor-specific "cancer-testis" antigens (the MAGE, GAGE and BAGE genes, NY-ESO, CTA, TSPY and FATE/BJ-HCC-2, among others) [219-221];, Aurora-A [222], SCCA [223], and Glypican-3. In between them, Glypican-3, a specific immunomarker for HCC that can be used to distinguish it from benign hepatocellular mass lesions, is highly immunogenic in mice and can induce effective antitumor immunity with no evidence of autoimmunity [224]. Several TAA antigens are also known for CRC liver tumors, including CEA and CP1 [225]. Clinical studies must be conducted in order to evaluate the potential use of these antigens in immunotherapy for liver tumors.

The lack of TSAs for HCC may be the most important limit to immunotherapy applications aimed to specifically target liver tumor cells. Several technological strategies such as serologic recombinant expression cloning (SEREX), gene expression profiling and proteomics, are being applied to discover any of those specific markers [226] but, until now, the results are limited [227].

Another important negative factor limiting the success of this type of immunotherapy is the low survival of adoptively transferred T-lymphocytes in cancer patients is. Currently, some strategies are being evaluated to increase the proliferation rate of transferred T-cells, including pre-treatment with cyclophosphamide [228].

T cells are the cellular model predominantly chosen for adoptive cellular therapy, although a role for NK cells and other cytokine-induced lymphocytes have also been investigated. Pilot clinical trials of adoptive T cell immunotherapy were initiated in cancer soon after the discovery of IL-2 (in the late 1970s), which enabled large-scale culture of T cells [229]. Although certain clinical success has been observed in melanoma, renal cancer, and lymphoma [230,231], phase II studies in HCC patients have shown objective response rates of only about 20% [232,233].

To date, no randomized clinical trials, but one, had demonstrated efficacy of adoptive T cell transfer approaches. Takayama et al. [234] reported benefits of adoptive transfer with an adjuvant setting for HCC after surgical resection of the primary tumor. In this study, autologous peripheral blood T cells were pre-cultured in medium supplemented with CD3-specific antibody and IL-2, and cell infusion was shown to reduce the risk of cancer recurrence by 41% when compared to a control group receiving only surgery. However, this trial remains unconfirmed, and the mechanism involved in the antitumoral effect remains unknown.

In order to enhance the effector capacity of tumor-specific T cells, different cytokines such as IL-18 and IL-12, were tested as potential biological response modifiers in the setting of adoptive immunotherapy. Nakamori et al. [235] demonstrated that adoptive transfer of IL-18-transduced cytotoxic T-lymphocytes in combination with IL-12 showed marked inhibitory effects on primary tumors and metastasis in a mouse model of orthotopic CRC.

Synergistic effect of combined therapy

Combinatorial strategies against cancer could either consist in a simultaneous application of different immunotherapeutic approaches or in a combination of classic chemo- or radio-therapeutic protocols with immunologic tools. Some chemotherapeutical agents were shown to induce upregulation of tumor-associated antigen expression (such as CEA) or to reduce tumor cell resistance to specific cytotoxic T lymphocytes. Some of these combinations have been found to produce synergistic rather than additive effects.

The immune-inhibitory mechanisms developed by tumor cells, such as overproduction of immunosuppressive cytokines (TGF-β and IL-10) or induction of Treg cells, are important obstacles that a successful cancer immunotherapy strategy has to face. Inhibition of one or more of these mechanisms appear to be a good strategy to induce antitumor immunity [236]. Elimination or inhibition of Treg activity by low-dose cyclophosphamide [237] or antibodies against CD25 or CTLA-4 may modify tumor immunosuppressive microenvironment, thereby increasing the efficacy of immunotherapy.

It has been shown, both in mice and humans, that pre-treatment with cyclophosphamide, known to induce lymphodepletion, results in a sustained function of adoptively transferred T-cells. Adoptive transfer efficacy can also be enhanced by alternative immunotherapies such as cytokine administration [238] and in some cases by standard cytotoxic chemotherapy and radiotherapy [239,240].

Preclinical models support the rationale for combining cancer vaccines with conventional therapies, such as radiation, chemotherapy, surgery, hormone therapy, as well as other immunotherapies. One of the most promising results was obtained from clinical trials combining antibodies against CTLA-4 with other immunotherapies such as application of GM-CSF-transduced tumor-cell vaccines. This treatment resulted in the alteration of the intratumor balance of Tregs-T effector cells and in tumor rejection [241]. Further research is required to optimize the combination of different immunotherapies to obtain maximal clinical benefits.

What have we learned from the clinic? Conclusion

Conducting immunotherapy clinical trials in patients with liver tumors is challenging and several strategies have been opened for clinical applications. However, the high efficacy of different immunotherapy strategies at eliminating liver tumors in animal models is in contrast with the very limited results achieved in patients. There are many explanations to why immunotherapy strategies fail or have little impact on patient survival. In general, for all solid tumors, the common scenario chosen to test immunotherapeutic protocols almost always involves patients with advanced diseases that precludes, or at least decreases, the possibility of success. Then, due to the advanced status of the cancer disease, the immune system of the majority of treated patients is deteriorated and unable to recognize tumor antigens. For the specific case of HCC and partially to CRC liver tumors, apart from the immunological privilege status of the liver, there are some particular aspects that add further difficulties when aiming for a clinical response such as the immunosuppressant effect of chronic HBV/HCV infection on cells of the immune system (e.g. DCs) or complications derived from developed cirrhosis which usually undermine efforts to stimulate the immune response. There is a general agreement in that different forms of immunotherapy should be tested for overall clinical benefits along with conventional treatment regimens evidencing improvements in survival. It would be desirable to evaluate the possibility of immunotherapy strategies as neoadjuvancy in patients at early stages of the disease such as after surgical removal of HCC and hepatic metastases of CRC, two diseases with increased likelihood of recurrence. Finally, new ways of long-term local delivery of signals inducing CD4+ T cell differentiation towards the Th1 lineage or vaccination against liver tumor antigens would eventually overcome the drawbacks of the pro-tolerogenic liver influence and the impairment or reduced immune response capacity caused by HBV/HCV viruses.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MP and VR: The immune system and the induction of antitumor immunity – basic concepts; Contribution of adoptive T-cell therapy strategies. JBA: The liver: an immunological privileged organ. OGS and JBA: Immunostimulating monoclonal antibodies. LA and MM: Immunotherapy with dendritic cells. GM: Introduction; The liver: an immunological privileged organ; Systemic use of immunostimulatory cytokines; Gene transfer of cytokines and costimulatory molecules; Genetic vaccination; Conclusions.

MG did a deep revision of the English grammar and style because English is not our native language. CA constructed the figure and the tables. MS was involved in the analysis and revision of the data included in the paper. GM outlined the topics of the manuscript and invited to each author to write specific chapters of the paper. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Miguel Rizzo and Soledad Arregui for their technical assistance. GM work is supported in part by grants from Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) (PICT-2005/34788 and PICTO-CRUP-2005/31179), Agencia Española de Cooperación Internacional and Programa Bicentenario-Banco Mundial, Conicyt, Chile CTE-06 (MG). LA work is supported in part by Mitzutani Foundation. CA and MM are fellows from ANPCyT. GM acknowledges the continuous support of Mrs. Ines Bemberg.

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.

    CA Cancer J Clin 2005, 55:74-108. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  2. El-Serag HB, Mason AC: Rising Incidence of Hepatocellular Carcinoma in the United States.

    N Engl J Med 1999, 340:745-750. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma.

    Gastroenterology 2008, 134:1752-1763. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma.

    Lancet 2003, 362:1907-1917. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

    J Hepatol 2001, 35:421-430. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  6. Bruix J, Sherman M: Management of hepatocellular carcinoma.

    Hepatology 2005, 42:1208-1236. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  7. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Colorectal cancer.

    Lancet 2005, 365:153-165. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  8. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study.

    Cancer 2007, 109:718-726. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  9. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A, Muller HH: Surgical resection of liver metastases of colorectal carcinoma: short and long-term results.

    Semin Oncol 2000, 27:112-119. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  10. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors influencing the natural history of colorectal liver metastases.

    Lancet 1994, 343:1405-1410. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

    J Clin Oncol 2000, 18:2938-2947. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

    Lancet 2000, 355:1041-1047. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  13. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

    J Clin Oncol 2004, 22:23-30. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

    N Engl J Med 2000, 343:905-914. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

    N Engl J Med 2004, 350:2335-2342. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    N Engl J Med 2004, 351:337-345. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  17. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC: Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

    J Clin Invest 2004, 113:1515-1525. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  18. Gilboa E: The promise of cancer vaccines.

    Nat Rev Cancer 2004, 4:401-411. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  19. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ: Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation.

    J Hepatol 2006, 45:246-253. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  20. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

    Cancer Res 1998, 58:3491-3494. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

    Science 2006, 313:1960-1964. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  22. Bertoletti A, Ferrari C: Kinetics of the immune response during HBV and HCV infection.

    Hepatology 2003, 38:4-13. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  23. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection.

    Nat Rev Immunol 2005, 5:215-229. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  24. Dustin LB, Rice CM: Flying under the radar: the immunobiology of hepatitis C.

    Annu Rev Immunol 2007, 25:71-99. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  25. Rosenberg SA: Progress in human tumour immunology and immunotherapy.

    Nature 2001, 411:380-384. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

    Nature 2001, 410:1107-1111. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  27. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting.

    Annu Rev Immunol 2004, 22:329-360. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  28. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

    N Engl J Med 2003, 348:203-213. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  29. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.

    Cancer Immunol Immunother 2007, 56:1687-1700. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  30. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.

    Immunol Rev 2002, 188:97-113. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  31. Zou W: Regulatory T cells, tumour immunity and immunotherapy.

    Nat Rev Immunol 2006, 6:295-307. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  32. Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, Langhans B, Sauerbruch T, Spengler U: Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.

    Hepatology 2006, 44:945-954. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  33. Liu B, Woltman AM, Janssen HL, Boonstra A: Modulation of dendritic cell function by persistent viruses.

    J Leukoc Biol 2008, 85(2):205-214. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  34. Burnet FM: The concept of immunological surveillance.

    Prog Exp Tumor Res 1970, 13:1-27. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  35. Thomas L: On immunosurveillance in human cancer.

    Yale J Biol Med 1982, 55:329-333. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  36. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting.

    Immunity 2004, 21:137-148. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  37. Luth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Bruck W, Wraith DC, Herkel J, Lohse AW: Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs.

    J Clin Invest 2008, 118:3403-3410. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  38. Abe M, Thomson AW: Antigen processing and presentation in the liver. In Liver Immunology: Principles and Practice. Edited by: Gershwin ME, Vierling JM, Manns MP. Totowa: Humana Press Inc; 2007:486. OpenURL

    Return to text

  39. Kamada N, Davies HS, Roser B: Reversal of transplantation immunity by liver grafting.

    Nature 1981, 292:840-842. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  40. Seyfert-Margolis V, Turka LA: Marking a path to transplant tolerance.

    J Clin Invest 2008, 118:2684-2686. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  41. Diamantis I, Boumpas DT: Autoimmune hepatitis: evolving concepts.

    Autoimmun Rev 2004, 3:207-214. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  42. Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H: Break of T cell ignorance to a viral antigen in the liver induces hepatitis.

    J Immunol 2000, 165:2415-2422. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  43. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, Harris NL, Junt T, Odermatt B, Clavien PA, Pircher H, Akira S, Hengartner H, Zinkernagel RM: Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

    J Clin Invest 2006, 116:2456-2463. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  44. Limmer A, Sacher T, Alferink J, Kretschmar M, Schonrich G, Nichterlein T, Arnold B, Hammerling GJ: Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment.

    Eur J Immunol 1998, 28:2395-2406. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  45. Crispe IN: Hepatic T cells and liver tolerance.

    Nat Rev Immunol 2003, 3:51-62. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  46. Bissell DM, Wang SS, Jarnagin WR, Roll FJ: Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.

    J Clin Invest 1995, 96:447-455. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  47. De Creus A, Abe M, Lau AH, Hackstein H, Raimondi G, Thomson AW: Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin.

    J Immunol 2005, 174:2037-2045. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  48. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP: Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

    J Immunol 2004, 172:1009-1017. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  49. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF: Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

    Gastroenterology 2007, 132:1937-1946. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  50. Friedman SL: Liver fibrosis – from bench to bedside.

    J Hepatol 2003, 38(Suppl 1):S38-53. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  51. Muhanna N, Horani A, Doron S, Safadi R: Lymphocyte-hepatic stellate cell proximity suggests a direct interaction.

    Clin Exp Immunol 2007, 148:338-347. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  52. Viñas O, Bataller R, Sancho-Bru P, Ginès P, Berenguer C, Enrich C, Nicolás JM, Ercilla G, Gallart T, Vives J, Arroyo V, Rodés J: Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation.

    Hepatology 2003, 38:919-929. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  53. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R: Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis.

    Hepatology 2008, 48:963-977. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  54. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

    Gastroenterology 2001, 120:512-524. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  55. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borras-Cuesta F, Prieto J: Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

    J Virol 2003, 77:10862-10871. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  56. Waggoner SN, Hall CH, Hahn YS: HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production.

    J Leukoc Biol 2007, 82:1407-1419. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  57. Zimmermann M, Flechsig C, La Monica N, Tripodi M, Adler G, Dikopoulos N: Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes.

    J Hepatol 2008, 48:51-60. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  58. Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS: Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2).

    J Gastroenterol Hepatol 2005, 20:234-242. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  59. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N: Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.

    J Infect Dis 2004, 190:1919-1926. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  60. Wertheimer AM, Bakke A, Rosen HR: Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease.

    Hepatology 2004, 40:335-345. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  61. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M: Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma.

    J Hepatol 1999, 31:323-331. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  62. Curtin JF, Cotter TG: Live and let die: regulatory mechanisms in Fas-mediated apoptosis.

    Cell Signal 2003, 15:983-992. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  63. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.

    Immunity 1996, 5:7-16. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  64. Ohshima K, Nakashima M, Sonoda K, Kikuchi M, Watanabe T: Expression of RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible role in immune privilege.

    Clin Exp Immunol 2001, 123:481-486. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  65. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege.

    Immunol Today 1997, 18:240-244. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  66. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U: Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

    Br J Cancer 2001, 85:1047-1054. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  67. Li M, Liu X, Zhou S, Li P, Li G: Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.

    BMC Cancer 2005, 5:96. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  68. Li MS, Ma QL, Chen Q, Liu XH, Li PF, Du GG, Li G: Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.

    World J Gastroenterol 2005, 11:2564-2569. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  69. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH: Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.

    J Immunol 2004, 173:4919-4928. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  70. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.

    Cancer Cell 2004, 5:241-251. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  71. Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scharovsky GO: The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression.

    Cancer Immunol Immunother 2002, 50:597-603. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  72. Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, Kimura F, Wakatsuki T, Yamamoto M: Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements.

    Int J Oncol 2003, 23:1575-1583. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  73. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR: Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.

    Lab Invest 2007, 87:582-590. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  74. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

    Clin Cancer Res 2007, 13:902-911. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  75. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA: Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma.

    Hepatology 1996, 23:1181-1188. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  76. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y: Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.

    J Gastroenterol Hepatol 2004, 19:1121-1127. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  77. Matsui M, Machida S, Itani-Yohda T, Akatsuka T: Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.

    J Gastroenterol Hepatol 2002, 17:897-907. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  78. Chiu CT, Yeh TS, Hsu JC, Chen MF: Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.

    Dig Dis Sci 2003, 48:670-676. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  79. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C: Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome.

    Mod Pathol 2004, 17:1378-1385. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  80. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M: Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

    Int J Gastrointest Cancer 2005, 35:53-60. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  81. Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

    Curr Opin Immunol 2006, 18:220-225. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  82. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-Cuesta F, Lasarte JJ, Prieto J: Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.

    J Virol 2007, 81:3662-3666. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  83. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy.

    Nat Rev Cancer 2004, 4:11-22. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  84. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumour-cell death and immunogenicity: a question of choice.

    Immunol Today 1997, 18:32-36. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  85. Humphreys RC, Halpern W: Trail receptors: targets for cancer therapy.

    Adv Exp Med Biol 2008, 615:127-158. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  86. Ahmed FY, Cassidy J: The treatment of advanced colorectal cancer with interferon-alpha: a review.

    Expert Opin Investig Drugs 1999, 8:13-18. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  87. Kirkwood J: Cancer immunotherapy: the interferon-alpha experience.

    Semin Oncol 2002, 29:18-26. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  88. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

    Proc Natl Acad Sci USA 1995, 92:4562-4566. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  89. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM: Interferon-alpha in tumor immunity and immunotherapy.

    Cytokine Growth Factor Rev 2002, 13:119-134. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  90. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

    Hepatology 1993, 17:389-394. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  91. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodes J, Bruix J: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.

    Hepatology 2000, 31:54-58. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  92. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.

    Ann Intern Med 2001, 134:963-967. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  93. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.

    Hepatology 2000, 32:228-232. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  94. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

    Ann Intern Med 2003, 138:299-306. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  95. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

    J Clin Oncol 2003, 21:421-427. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  96. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

    Cancer 2002, 94:435-442. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  97. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, et al.: Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

    J Clin Oncol 1993, 11:1737-1745. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  98. Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H: Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

    Eur J Cancer 1999, 35:380-385. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  99. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, et al.: Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

    Oncology 2000, 58:227-236. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  100. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A: Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

    Am J Clin Oncol 2002, 25:224-226. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  101. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maestroni GJ: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.

    Eur J Cancer 1994, 30A:167-170. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  102. Ishikawa T, Imawari M, Moriyama T, Ohnishi S, Matsuhashi N, Suzuki G, Takaku F: Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

    J Cancer Res Clin Oncol 1988, 114:283-290. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  103. Okuno K, Hirohata T, Nakamura K, Jinnai H, Shigeoka H, Koh K, Shindo K, Yasutomi M: Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer.

    Clin Ther 1993, 15:672-683. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  104. Lygidakis NJ, Savanis G, Pothoulakis J, Kapetanakis A: Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours.

    Anticancer Res 1994, 14:643-646. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  105. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

    J Clin Oncol 2005, 23:8950-8958. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  106. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.

    J Interferon Cytokine Res 1995, 15:467-472. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  107. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C: Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma.

    J Immunother 2002, 25:489-499. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  108. Hieber U, Heim ME: Tumor necrosis factor for the treatment of malignancies.

    Oncology 1994, 51:142-153. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  109. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O: TRAIL in cancer therapy: present and future challenges.

    Expert Opin Ther Targets 2007, 11:1299-1314. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  110. Zhu Y, Chen L: Cancer therapeutic monoclonal antibodies targeting lymphocyte co-stimulatory pathways.

    Curr Opin Investig Drugs 2003, 4:691-695. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  111. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited.

    Annu Rev Immunol 2005, 23:515-548. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  112. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

    Cell 1992, 71:1093-1102. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  113. Riley JL, June CH: The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

    Blood 2005, 105:13-21. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  114. Bertram EM, Dawicki W, Watts TH: Role of T cell costimulation in anti-viral immunity.

    Semin Immunol 2004, 16:185-196. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  115. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

    N Engl J Med 2006, 355:1018-1028. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  116. Myers LM, Vella AT: Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation.

    Trends Immunol 2005, 26:440-446. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  117. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB. Analysis of expression and function.

    J Immunol 1993, 150:771-781. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  118. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

    Cell Immunol 1998, 190:167-172. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  119. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

    J Exp Med 1997, 186:47-55. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  120. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.

    J Immunol 1999, 162:5037-5040. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  121. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

    Nat Med 1997, 3:682-685. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  122. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I: Immunotherapy and immunoescape in colorectal cancer.

    World J Gastroenterol 2007, 13:5822-5831. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  123. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS: Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

    J Immunol 2007, 178:4194-4213. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  124. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27.

    Cytokine Growth Factor Rev 2003, 14:265-273. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  125. Watts TH: TNF/TNFR family members in costimulation of T cell responses.

    Annu Rev Immunol 2005, 23:23-68. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  126. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

    Immunity 2001, 15:445-455. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  127. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C, Shields J: Engagement of the OX-40 receptor in vivo enhances antitumor immunity.

    J Immunol 2000, 164:2160-2169. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  128. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy.

    Nat Rev Cancer 2007, 7:95-106. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  129. Teft WA, Kirchhof MG, Madrenas J: A molecular perspective of CTLA-4 function.

    Annu Rev Immunol 2006, 24:65-97. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  130. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade.

    Science 1996, 271:1734-1736. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  131. Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

    Annu Rev Immunol 2001, 19:565-594. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  132. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

    Nat Rev Immunol 2004, 4:336-347. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  133. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

    Cancer Res 2005, 65:1089-1096. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  134. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN: HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma.

    Mol Cancer Res 2007, 5:605-614. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  135. Ku XM, Liao CG, Li Y, Yang XM, Yang B, Yao XY, Wang L, Kong LM, Zhao P, Chen ZN: Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147.

    Scand J Immunol 2007, 65:435-443. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  136. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

    Cancer Res 1998, 58:5301-5304. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  137. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

    Clin Cancer Res 2005, 11:728-734. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  138. Miller AD: Human gene therapy comes of age.

    Nature 1992, 357:455-460. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  139. Mulligan RC: The basic science of gene therapy.

    Science 1993, 260:926-932. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  140. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989–2004-an overview.

    J Gene Med 2004, 6:597-602. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  141. Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, Gao G, High KA, Leen AM, Lemoine NR, McNeish IA, Meneguzzi G, Peschanski M, Roncarolo MG, Strayer DS, Tuszynski MH, Waxman DJ, Wilson JM: Progress and prospects: gene therapy clinical trials (part 2).

    Gene Ther 2007, 14:1555-1563. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  142. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials (part 1).

    Gene Ther 2007, 14:1439-1447. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  143. Cao L, Kulmburg P, Veelken H, Mackensen A, Mezes B, Lindemann A, Mertelsmann R, Rosenthal FM: Cytokine gene transfer in cancer therapy.

    Stem Cells 1998, 16(Suppl 1):251-260. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  144. Qian C, Liu XY, Prieto J: Therapy of cancer by cytokines mediated by gene therapy approach.

    Cell Res 2006, 16:182-188. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  145. Schmidt-Wolf GD, Schmidt-Wolf IG: Cytokines and gene therapy.

    Immunol Today 1995, 16:173-175. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  146. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity.

    Nat Rev Immunol 2003, 3:133-146. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  147. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy.

    Cytokine Growth Factor Rev 2002, 13:155-168. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  148. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.

    J Exp Med 1995, 182:155-162. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  149. Mazzolini G, Narvaiza I, Bustos M, Duarte M, Tirapu I, Bilbao R, Qian C, Prieto J, Melero I: Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment.

    Mol Ther 2001, 3:665-672. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  150. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

    Blood 1997, 90:2541-2548. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  151. Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with interleukin-12.

    Curr Pharm Des 2003, 9:1981-1991. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  152. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O: IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response.

    Gene Ther 1999, 6:1705-1712. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  153. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, Prieto J: Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

    Cancer Gene Ther 1999, 6:514-522. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  154. Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Carbone C, Chernajovsky Y, Podhajcer OL: Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.

    Cancer Res 2000, 60:6696-6703. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  155. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

    Hepatology 2001, 33:52-61. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  156. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

    Hepatology 2001, 33:52-61. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  157. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X, Duarte M, Melero I, Prieto J: Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level.

    Hum Gene Ther 2000, 11:113-125. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  158. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.

    Proc Natl Acad Sci USA 1996, 93:11302-11306. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  159. Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Damen U, Tennant B, Scherer C, Graham FL, Roggendorf M: Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.

    J Natl Cancer Inst 2001, 93:472-479. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  160. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, Ruiz J, Prieto J, Melero I: Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

    Gene Ther 2001, 8:259-267. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  161. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.

    J Immunol 2000, 164:3112-3122. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  162. Mazzolini G, Narvaiza I, Martinez-Cruz LA, Arina A, Barajas M, Galofre JC, Qian C, Mato JM, Prieto J, Melero I: Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

    Gene Ther 2003, 10:1067-1078. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  163. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olagüe C, Sola J, Sádaba B, Lacasa C, Melero I, Qian C, Prieto J: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

    J Clin Oncol 2004, 22:1389-1397. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  164. Clerici M, Shearer GM, Clerici E: Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm.

    J Natl Cancer Inst 1998, 90:261-263. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  165. Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL: IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.

    J Immunol 2005, 175:5885-5894. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  166. Gilly FN, Beaujard A, Bienvenu J, Trillet Lenoir V, Glehen O, Thouvenot D, Malcus C, Favrot M, Dumontet C, Lombard-Bohas C, Garbit F, Gueugniaud PY, Vignal J, Aymard M, Touraine Moulin F, Roos M, Pavirani A, Courtney M: Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report.

    Hepatogastroenterology 1999, 46(Suppl 1):1268-1273. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  167. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.

    Gene Ther 1997, 4:419-425. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  168. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J: In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.

    Gene Ther 2000, 7:1467-1476. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  169. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C: Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma.

    Hepatology 2001, 34:72-81. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  170. Liu TC, Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses.

    Gene Ther 2008, 15(12):877-884. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  171. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y: Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

    Surgery 2007, 141:520-529. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  172. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

    Science 1996, 274:373-376. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  173. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, Mitry R, Havlik R, Seth P, Hartwigsen J, Bhushan R, Nicholls J, Jensen S: Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

    Cancer Gene Ther 2002, 9:254-259. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  174. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF: Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

    J Clin Oncol 2003, 21:1498-1504. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  175. Hernandez-Alcoceba R, Sangro B, Prieto J: Gene therapy of liver cancer.

    Ann Hepatol 2007, 6:5-14. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  176. Banchereau J, Steinman RM: Dendritic cells and the control of immunity.

    Nature 1998, 392:245-252. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  177. Reis e Sousa C: Dendritic cells in a mature age.

    Nat Rev Immunol 2006, 6:476-483. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  178. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, Chouzenoux S, Soubrane O, Calmus Y, Conti F: Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway.

    Lab Invest 2008, 88:973-985. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  179. Sriram U, Biswas C, Behrens EM, Dinnall JA, Shivers DK, Monestier M, Argon Y, Gallucci S: IL-4 suppresses dendritic cell response to type I interferons.

    J Immunol 2007, 179:6446-6455. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  180. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer.

    Curr Opin Immunol 2005, 17:163-169. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  181. Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG: Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

    Cancer Res 1999, 59:2802-2805. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  182. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.

    Cancer Res 1999, 59:4035-4041. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  183. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, Bustos M, Qian C, Prieto J: Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.

    Gene Ther 1999, 6:1779-1784. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  184. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.

    J Immunother 2005, 28:129-135. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  185. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS, Dubinett SM: Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication.

    Hum Gene Ther 2000, 11:53-65. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  186. Vera M, Razquin N, Prieto J, Melero I, Fortes P, Gonzalez-Aseguinolaza G: Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.

    Mol Ther 2005, 12:950-959. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  187. Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I: Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

    J Clin Oncol 2005, 23:999-1010. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  188. Feijoó E, Alfaro C, Mazzolini G, Serra P, Peñuelas I, Arina A, Huarte E, Tirapu I, Palencia B, Murillo O, Ruiz J, Sangro B, Richter JA, Prieto J, Melero I: Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.

    Int J Cancer 2005, 116:275-281. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  189. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity.

    Annu Rev Immunol 1998, 16:111-135. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  190. Kikuchi T, Miyazawa N, Moore MA, Crystal RG: Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.

    Cancer Res 2000, 60:6391-6395. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  191. Kikuchi T, Moore MA, Crystal RG: Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.

    Blood 2000, 96:91-99. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  192. Chu XY, Chen LB, Zang J, Wang JH, Zhang Q, Geng HC: Effect of bone marrow-derived monocytes transfected with RNA of mouse colon carcinoma on specific antitumor immunity.

    World J Gastroenterol 2005, 11:760-763. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  193. Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M: Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.

    Cancer Res 2004, 64:4995-5003. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  194. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

    Clin Cancer Res 1999, 5:1331-1338. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  195. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

    Proc Natl Acad Sci USA 2001, 98:8809-8814. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  196. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M: Dendritic cell-based vaccination in solid cancer.

    J Clin Oncol 2003, 21:135-142. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  197. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K, Kitano S: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.

    Cancer Immunol Immunother 2003, 52:155-161. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  198. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G: Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.

    Cancer Immunol Immunother 2007, 56:2003-2016. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  199. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

    Clin Cancer Res 1999, 5:1331-1338. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  200. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.

    Cancer Immunol Immunother 2002, 51:99-106. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  201. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.

    Int J Oncol 2004, 24:909-917. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  202. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Kohne CH, Ehninger G, Schmitz M, Bornhauser M: Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

    Cancer Immunol Immunother 2006, 55:268-276. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  203. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB: Natural killer-dendritic cell cross-talk in cancer immunotherapy.

    Expert Opin Biol Ther 2005, 5:1303-1315. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  204. Rodriguez-Calvillo M, Duarte M, Tirapu I, Berraondo P, Mazzolini G, Qian C, Prieto J, Melero I: Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12.

    Exp Hematol 2002, 30:195-204. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  205. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA: NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.

    Cancer Immunol Immunother 2006, 55:1122-1131. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  206. Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

    J Clin Invest 2004, 113:774-783. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  207. Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK: Current immunotherapeutic strategies in colon cancer.

    Surg Oncol Clin N Am 2007, 16:873-900. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  208. von Mehren M: Colorectal cancer vaccines: what we know and what we don't yet know.

    Semin Oncol 2005, 32:76-84. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  209. Prieto J, Qian C, Sangro B, Melero I, Mazzolini G: Biologic therapy of liver tumors.

    Surg Clin North Am 2004, 84:673-696. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  210. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE: Biological treatment for liver tumor and new potential biomarkers.

    Dig Dis Sci 2008, 53:836-843. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  211. Elkord E, Hawkins RE, Stern PL: Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy.

    Expert Opin Biol Ther 2008, 8:385-395. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  212. Ho WY, Yee C, Greenberg PD: Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

    J Clin Invest 2002, 110:1415-1417. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  213. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

    Nat Rev Cancer 2008, 8:299-308. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  214. June CH: Principles of adoptive T cell cancer therapy.

    J Clin Invest 2007, 117:1204-1212. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  215. Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, Xing Q, Yu X, Gong L, Yin YH, Zhang Y, Chen WF: The immunosuppressive tumor microenvironment in hepatocellular carcinoma.

    Cancer Immunol Immunother 2008.PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  216. Dong XY, Peng JR, Ye YJ, Chen HS, Zhang LJ, Pang XW, Li Y, Zhang Y, Wang S, Fant ME, Yin YH, Chen WF: Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients.

    Int J Cancer 2008, 122:2038-2043. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  217. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, Eisele S, Encke J, Blum HE, Geissler M: Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice.

    Gastroenterology 2000, 119:1104-1112. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  218. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.

    Cancer Res 1999, 59:3064-3067. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  219. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS, Sheu JC: Expressions of cancer-testis antigens in human hepatocellular carcinomas.

    Cancer Lett 2001, 164:189-195. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  220. Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaneyoshi T, Toshikuni N, Kariyama K, Nakayama E, Tsuji T: Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma.

    J Hepatol 2000, 32:612-617. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  221. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, Niho Y: High frequency of the MAGE-1 gene expression in hepatocellular carcinoma.

    Hepatology 1996, 24:1437-1440. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  222. Jeng YM, Peng SY, Lin CY, Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma.

    Clin Cancer Res 2004, 10:2065-2071. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  223. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S: Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma.

    Int J Cancer 2005, 116:579-583. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  224. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.

    Clin Cancer Res 2004, 10:8630-8640. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  225. Liu FF, Dong XY, Pang XW, Xing Q, Wang HC, Zhang HG, Li Y, Yin YH, Fant M, Ye YJ, Shen DH, Zhang Y, Wang S, Chen WF: The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients.

    Gastroenterology 2008, 134:998-1006. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  226. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP: Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.

    J Proteome Res 2005, 4:2062-2069. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  227. Evdokimova VN, Butterfield LH: Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer.

    Expert Opin Biol Ther 2008, 8:325-336. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  228. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

    Clin Cancer Res 2007, 13:644-653. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  229. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

    J Immunol 1980, 125:1487-1493. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  230. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

    N Engl J Med 1987, 316:889-897. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  231. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuk I, Ross S, Krane RJ: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.

    Lancet 1990, 335:994-998. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  232. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y: Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.

    Hepatology 1989, 10:349-353. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  233. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al.: Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.

    Cancer 1991, 68:2391-2396. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  234. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

    Lancet 2000, 356:802-807. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  235. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H: Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.

    Clin Cancer Res 2003, 9:2357-2365. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  236. Curiel TJ: Tregs and rethinking cancer immunotherapy.

    J Clin Invest 2007, 117:1167-1174. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  237. Rico M, Matar P, Zacarías Fluck M, Giordano R, Scharovsky O: Low dose Cyclophosphmide (Cy) treatment induces a decrease in the percentage of regulatory T cells in lymphoma-bearing rats.

    Proc Am Assoc Cancer Res 2007, 48:233. OpenURL

    Return to text

  238. Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

    J Exp Med 1982, 155:968-980. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  239. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ: Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

    Cancer Res 2002, 62:1462-1470. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  240. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.

    J Immunol 2003, 170:6338-6347. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  241. Quezada SA, Peggs KS, Curran MA, Allison JP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

    J Clin Invest 2006, 116:1935-1945. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text


#1434 From: "salvationscience" <salvationscience@...>
Date: Sat Aug 1, 2009 1:18 am
Subject: THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
salvationsci...
Offline Offline
Send Email Send Email
 
THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
IN BEAUTIFUL GUADALAJARA, MEXICO! !HAY JALISCO!
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.paraisodelasalud.org
http://www.salvationscience.com

I recently posted the message you see below, having forgotten to proof-read it,
so it had a lot of mistakes. This is the now-corrected version of that article.
There is no Rasa Tantra Sadhana, without first practicing Urine Therapy for many
years. Therefore, in the Damar Tantra, Siva included the chapter on Shivambu
Chikitsa, entitled, "The Shivambu Kalpa Vidhi".

When prejudice bagan against this practice, it went underground, and still can
be found in the enigmatic parables of Our Lord Jesus Christ (or that incarnation
of our eternal Lord Sivaji). As the public became more hostile to the True
Sanatana Dharma, it went deeper underground. Finally, the secret itself was
lost. Now the only secret is: They they forgot what the secret was!
Jai Om. - Sw. Tantrasangha

THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
IN BEAUTIFUL GUADALAJARA, MEXICO!
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.paraisodelasalud.org
http://www.salvationscience.com

Please forgive the many errors in spelling and grammar here. As you know, the
first language of Mexico is Spanish. Obviously, Sra. Rodriguez is trying to
translate what she wants to say, so that you and others may benefit, thereby,
from this highly efficaceous free therapy, freely and easily available to all.
But greed and timidity get in the way.

And let us never forget that the best cure is also a "preventative medicine" to
keep you in good health. Nature's own Naturopathy is far superior to man's
artificial chemicals and the whole greedy patent process, which gave rise to
such medical menace madness. Priests, politicians and physicians profit more
from their own failures.

Like Jesus said: "I have come that ye may have Life and have it more
abundantly." That means He would Save you from suffering by Way of a Longer,
Happier Life. Jesus once cured a man, then told him: "Your sins are forgiven".
They asked Him how He could forgive another man's sins. Jesus asked: "Is he not
now cured of his disease?"

When you no longer pay the dues, you know longer owe the debt. Try to see the
concepts which words only represent, for, if you don't, there will be only words
without meaning - what Jesus called "the letter of the Law without the Spirit of
the Law". You must know the meanings of words, define things, specifically, etc.
No vagaries.

Martin Luther King Jr. looked forward to the day when: "Men will be judged not
by the color of their skin but by the content of their character". For now, good
theological character only makes Americans mad. You are expected to be a moral
coward and to conform to an erroneous theological norm. Your moral courage only
makes cowards jealous.

Your Righteousness is measured by your Honesty, Intelligence, and Compassion.
These attributes cause you to care about the moral issues of good and bad, right
and wrong, and true and false. Those who don't care about doing the right thing,
are already wrong. Moral cowardice is the root cause of this hell on earth.

For now, Righteousness means about as much to Americans as it does to a pig.
That is why Americans "quarantined the cure" and have promoted a shorter, more
miserable life, instead of what our beloved Lord Jesus Christ intended. We fight
for life, while our enemies fight for death. The devil has chosen to oppose us.

It's all because the devil despises the good, and, psychologically, is a
"suicidal crime waiting to happen", as is anybody preferring harm over help.
That Dark Daze would be, in effect, a Mass Murder-Suicide. What terrorism
isworse than the one who would force you to "bite the bullet" of erroneous
theology which saves not?
Jai Om. - Sw. Tantrasangha
--------------------------

WORLD INFORMATION ABOUT UROTHERAPY

ALL HUMAN BEINGS HAVE DRUNK THERE OWN URINE IN THE WOMB
OF THEIR OWN BLESSED MOTHER. IT IS OUR PRIMORDIAL FOOD.

In the natural biological heaven of the human reproduction, inside the maternal
womb while the formation of our body took place. The first step was the
formation of mother cells, the heart, brain, kidneys, bones, basic organs, nerve
cells that receives and transmit, and, above all, the coordination between
sensorial organs and the incredible balance of genetic information, biochemist,
cell reproduction, and the bio-energetic stimulant. Inside the maternal womb, we
are in complete peace and harmony preparing ourselves to come out to a new life
in the exterior.

The man's perfect time on earth is during the gestation period.
The Urotherapy is literally a gift from God, it is part of nature.
There is no human on earth that has not taken his or her own urine, we are born
inside a womb and after six weeks, he or she will start urinating a few drops
into the amniotic liquid, that is water and his or her own urine!

Through the umbilical cord, the baby receives from the mother special nutrients
as immunoglobulin, vitamins, but most of all oxygen.

When the baby reaches the age of 5 months, they urinate from 400 to 500 ml. Each
day inside the amniotic sac, and between 8 to 9 months the baby urinates 20 to
30 times every 24 hours.

98% of the composition of the Urine is water. Therefore, 1% is elements - are
cells and filaments, and the other 1% is more than 1000 healing chemical
substances in form of ions. Powerful substances found in milligrams, that carry
the genetic information of what works well or not in the body. When you take
your own urine, you take an auto vaccine.

In other words Urotherapy is part of be beginning of life and we believe that we
grow up with nature. It is a wonderful cycle of life that should never be
interrupted.

Who can live without water?…………Nobody
For that reason the water is an element ....SACRED
Who can live without air ?.................Nobody
For that reason the air is an element…SACRED
Who can live without the sun.................Nobody
For that reason the sun is an element…SACRED
Who can live (prenatally) without taking the urine inside the
mother?...........................Nobody
For that reason the urine is an element…SACRED.

HISTORY OF THE UROTHERAPY

Etiologically speaking Urotherapy means: Treatment utilizing our own urine . The
word URO comes from the Greek that means urine and Therapy means treatment. The
Urotherapy has always existed, is the oldest therapy of humanity and one of the
first therapies created by God, it is older than Chinese Medicine. One of the
oldest therapies utilized by man and applied with wisdom by mystics and
intuition.

Urotherapy was born in all Countries at the same time. In the Old Testament it
is mentioned in Proverbs chapter 5 versus 15 thru 18th. These remedies are
written in the oldest written book known as The "Gootour Schastar"(?) from 6000
years B.C.(!), with recopies, medications, treatments based on drinking or
applying his or her urine.

THE UROTHERAPY has always existed, it is a method commonly known as Urine
Therapy to different cultures long times past such as the
Egyptian pharaohs, Tibet Lamas, Greeks and Romans. In Mexico, the Native Indians
also had valued information and knowledge in regards to this type of therapy. In
the European Continent, they also have stories of Greek Doctors that utilized
the Urine for healing wounds.

In the book No. 28 of the encyclopedia's NATURALIS HISTORY, (Natural History) of
the Roman writer, C. Plinius Secundus writes about the treatment with urine in
wounds for dog bites and snakes, as well as venomous spiders, skin diseases,
along with eye infections, burns and scars.*

* The Historie of the World, Commonly called,
THE NATURALL HISTORIE OF C. PLINIUS SECUNDUS.
Translated into English by PHILEMON HOLLAND
Doctor in Physic, 1601

Orient as well as Occident were familiar with this treatment.

INDIA HAS A SACRED BOOK

That has existed more than 500 years from the past, and it is called Damar
Tantra, with a chapter about the Shivambu Kalpa (therapy of auto-urine). Hindu
version from before Christ were written in Sanskrit. It is a description of the
therapeutic systems by utilizing the Urine Therapy directed by the god Shiva to
the goddess Parvati. Where the god Shiva describes its benefits to his wife
Parvati in this precious book that has a very interesting content of 108 verses
that speaks about what happens to the human body through the years when you
practice the Urinetherapy.

The Damar Tantra* states: "He whoever continues with this practice for twelve
years will live as much as the moon and the stars and there is no danger with
animals like serpents, because no poison can kill you. Your body will be
liberated from aging and its destruction, and you will have the strength of
10,000 elephants and will free the body of all illnesses."*

* The Shivambu Kalpa Vidhi from the Damar Tantra, is found several times in The
Tantrayudha of Salvation Science.

IN MANY COUNTRIES OF THE AMERICAN CONTINENT

As in Argentina, Peru, the natives from the mountains Serrano Andina, Mapuches
in Chile and other communities of the Trahumaras in México, along with areas in
U.S.A. continue to practice this therapy to this days.

Nowadays in Mexico, there are valued verbal and written testimonies from people
that had recommended this treatment for burns, such as soldiers during war time
that had burns due to the gunpowder, so they applied their own urine to
alleviate the pain. The NASA Astronauts and survivors from disasters such as
earthquakes and shipwrecks, have saved their lives in these types cases of
emergency by drinking their own urine.

For stomach aches, wounds, along with bites from venomous animals or insects,
grandmothers have recommended putting baby diapers on skin for the spots, and we
have two books from the year's 1514 and 1552 that stated that native Indians
used their urine for healings. The
first book is called:

CODIGO BADIANO

In México, Martin de la Cruz, Aztec physician in 1552, in the
Badiano Code, makes specific references to the urine treatment.

En la curación de heridas en la cabeza se usaban: orina (URINE) –para lavarla–,
matlaxíhuitl. The Aztecs used to call the urine "huitztly", they used it for
the treatment of spiders and serpent's bites, as well as any other poisonous
animal or insect, along with other uses for the urine treatments.

For hemorrhages, they applied urine with maguey secretion, also in treatment for
scars. - Florentin Code, lib. X, f. 113r.

NEW SPAIN GENERAL HISTORY OF THINGS
("HISTORIA GENERAL DE LAS COSAS DE NUEVA ESPANA")
BY PADRE BERNARDINO DE SAHAGUN, 1514)

Written by Fray Bernardino de Sahagún in the year 1514. He is one of the Priests
that came with Hernán Cortes to México and learned from the Native Indians whom
used the Urine therapy from pages 585, 585, 587, 593, 594 Cáp. XXVIII and
states:

For the pain of the "horquilla" that usually starts in the hair, the best way is
to cut the hair as short as possible and scrape it well, along with washing it
with urine, then apply a plant called
"Nanacae", to remove the herb it needs to be washed with urine.

When you cut the hair it needs to be washed with urine.…to combat dandruff cut
the hair very short and then wash it with urine.

For the illness of "postilla" and "sarna" that normally starts in the head area,
you must use the same remedy as before adding these add ional healing agents….
following washing with urine the head area apply the avocado seed's grounded up.
Etc. Etc.

In this Century, many people have come to know this wonderful secret. Hospitals
in the Unites States and Europe actually are creating several medications with
the urine, along with Pharmaceutical Industries that are purchasing the urine of
several people to manufacture medications, cosmetics, as well as dental
toothpaste.

Carmen Thomas, a German reporter states that some pharmaceutical firms have
united to the "Shangay" movement. The urine is recollected in public latrines,
and is sold to companies that manufacture medications by extracting the
Urokinase, and then they export it. - (Published in the Newspaper "El Diario"
dated 26th of April of 1996. InGuadalajara, Jalisco. México).

In 1971 in the University of Medicine of Kyoto Japan, it was discovered that the
antibodies in the urine, such as "interokin", "renina" and "prostaglandin", are
important hormones used to combat infections or malign tumors.

In the Unites States, a scientific team from Harvard University discovered
several hormones from the Urine that are called "S.P.U". and "interferón", which
are being released during the sleep time and re-utilized as antibodies,
anticoagulant for circulatory problems, and they act as pain relief and a
stimulant for the hormones. The melatonin is a substance that helps with memory,
as well as other substances. The Urotherapy helps to improve the immunological
system, which, as a result, brings on cures of many illnesses.

In 1992 Hayashibara Institute of Chemistry in Japan, discovered, during a formal
study investigation, that urine had many important substances for our health
such as the one called, "Interferon" that has analgesic effects and is a natural
antibody.
----------------------

THE SCIENTIFIC PRINCIPAL OF THE UROTHERAPY

One's antibodies are in one's blood. For the patient that has a
determinate disease, at the same time you may find specific antigen in the urine
(sinnce urine is a blood derivative). The antigen (the biochemical immune
response to the antigen) is that which the patient eliminates in his urine. It
is a non-toxic protein, produced by the body itself. When a daily intake of this
urine is taken, the immune system of the body reacts and "learns" to combat the
external agents, along with this it is very efficient in the elimination of
cancer cells.

THE UROTHERAPY IS AN AUTO-VACCINE THAT ACTS AS INMUNO-MODULAR -
VERY SPECIFIC AND PERSONAL.

The Urinary Antigen in the urine of the patient, being a natural protein that
the body eliminates, has no risk or side effects and can be taken in combination
with other natural resources, allowing us to diminish slowly the
inmunosupressors and chemotherapy medications required (in modern Allopathic
medicine).

We have the ability to create our own vaccine by all the micro-organisms that
infect our systems, and form toxins and endotoxins (antigens), and stimulate our
immunologic system to form antitoxins (antidotes, antibodies), which are
discarded thru the urine, and
when we take it back inside us, we force the bacteria to take their own toxins,
that is why we say "poison kills poison" (the basic Law of Innoculation, first
mentioned in the Srimad Bahagavatam, Canto I, when Krishna states that the same
thing that causes a disease, can be used to cure it. Better yet, as an
innoculation, it can prevent the disease from happening.)

The Urotherapy is an auto-vaccine that has the same elements of our own illness;
it has an antiviral action, antineoplastic, antispasmodic, diuretic,
antiallergenic, anticonvulsive, and cardiovascular stimulant, anti-
inflammatory, bactericidal and antifungal as well.

UROTHERAPY AND ITS BIOCHEMICAL ACTION IN CANCER

Immunologic system, stimulated to cellular and humoral (bioplasma?) level.
Blocks the reproduction of tumor cells.
Breaks the tumor's protection because the urine has specific "antigens".
Diminishes the release of toxic substances, promoting its elimination by
reducing the free radicals.
Diminishes the damage from Chemotherapy and Radiation Therapy,
by increasing the cells' defense.
Increases the (efficacy of the) immune system.
Has an Inmunomodular function.
Promotes changes in the Psychobioenergetic equilibrium of the patient.

THE UROTHERAPY FOR THE TREATMENT OF OTHER ILLNESSES

The Urotherapy has proven to be satisfactory for the treatment of the following
illnesses:
Systematic Lupus Erythematosus
Rheumatic Illness
Poliarteritis Node
Hemolytic Anemia Type Acquired Autoimmune
Malign lymphoma
Chronic Anemia
Immunological Neutropenia
Thrombocytopenic Purple
Uveitis or Coriorentitis
Esclerosis Multiple
Polineuritis Idiopathic
Leukemia mielocitica
Severe Leukemia linfocitic
Thyroid or Hashimoto's illness
Graves' illness
Addison illness
Arthritis Rheumatoid
Espondilitis Anquilosant
Miastenia Gravis
Dermatomiositis
Sclerodermia (sclerosis Progressive systematic
Síndrome Guillen Barre
Síndrome de Sjogren
Colitis Ulcerative
Active Chronic Hepatitis
Primary Cirrosis gallbladder
Glomerulo nefritis by inmune complex
Dermatitis by contact
Eczema A topic
Itching
Psoriasis
Schizoaffective syndrome (one type of the schizophrenia)
Autism
Rinitis Allergic
Asma Bronquitis
Alveolitos
Carcinoembriogenics
Metaplasia scave Tumors
Severe Displacía
Insistu Cáncer
Metastátic Cáncer in bones
Invasive Carcinoma
Metastátic Cáncer
Prostate Cáncer
HIV <AIDS>
Human Papiloma
Pillory Helicobacter
Diabetes

MOTHER CELLS, UROTHERAPY, & EMBRYONIC STEM CELL THERAPY

The mother cells are obtained from two ways: Embryos in the first phase of
development, or the reserves that the adult organism maintains with the purpose
to repair the damage that is done to the tissues. The investigators state that
only the "embryo" cells have the capability to convert into vital organs or any
tissue (plural potentials). An example is the hematopoyetic cells that exist on
the
bone marrow that transform into blood cells, like white, red as well as
plaquets.

After all the application of this transference, techniques from adult
mother cells for the change and repair of the damaged tissues (Embryonic Stem
Cell Therapy) is yet too new. In reality, there is a substance of great
importance that we have forgotten: it is the liquid (bioplasma) that surrounds
the cells that also carries the genetic information (and is secreted as Genetic
Efflux) and the biochemical element. The Amniotic liquid also carries specific
substances the fetus drinks that has the genetic information too.

(We drink Genetic Efflux in our own mother's womb, so it is our "Primodial Food
and Medicine". Like the Holy Bible states:
"...The Tree of Life: Its fruit for food and its leaf for medicine." In other
words, Jai Om. - Sw. Tantrasangha)

EMBRYONIC CELLS

These are obtained from the blastocist, in this case the embryo is a mass of 150
cells with a ball shape. Some of these cells form the sphere that is inside
liquid, which has the cellular mass, a group of mother cells, these cells are
pluripotential. In other words they can create any body tissue, which is why it
has a great therapeutic potential. After the eight week, the fetus will urinate
inside the sac and is part of the amniotic liquid that carries all the genetic
information that is recycled and comes out with new information.

• THE SCIENTIFIC PRINCIPLE OF THE UROTHERAPY (Immunal, hormonal, enzymztic, Urea
as a protein substitute, etc.)

• THE MYSTIC PRINCIPLE OF THE UROTHERAPY (As in its marital application, which
we call Rasa Tantra.)

• THE HOMEOPATHIC PRINCIPLE OF THE UROTHERAPY (Once again pertaining to the
Immune Principle that "like fights like". In other words, urine contains
antigens and antibodies which bolster immunity to those very same microbes. The
Srimad Bhagavatam, Canto I, states:
"Is it not true that by taking into the body the same thing which made it sick,
the disease is thereby cured?" This is the Law of Innoculation: By giving you a
weakened or similar microbe, you will then be able to fend it off when it is
more virulent.
Jai Om. - Sw. Tantrasangha.)

www.paraisodelasalud.org
SONIA RODRIGUEZ, BIOCHEMIST, RE: FASTING WITH URINE

FASTING IS IMPORTANT

The fasting is a very important task since the urine intake produces acidosis in
the organism that reflects a movement of the defense mechanisms that neutralize
the toxins and repair the cells.

http://www.paraisodelasalud.org
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.salvationscience.com
**************************************************************

#1433 From: "salvationscience" <salvationscience@...>
Date: Sat Jul 18, 2009 12:23 am
Subject: URINE THERAPY FOR SURVIVING FAMINE AND DISEASE
salvationsci...
Offline Offline
Send Email Send Email
 
URINE THERAPY FOR SURVIVING FAMINE AND DISEASE
http://www.salvationscience.com

Welcome to the group, Patrick. Tell us about what the Irish think about Urine
Therapy. I tell folks to go to my site at: salvationscience.com, for some
experimental variations of Urine Therapy, which have met with the unjust calumny
of a nation. We have suffered a "defamation of character", and we now seek to
"clear our name" of these slanderous, malicious accusations.

Years ago, when I was catching a connecting flight at Moscow International, a
soldier told me: "You have showed us how to survive a nuclear war." To me, Urine
Therapy explains how one might survive prolonged famine, probably induced by by
a loss of technology, as in the frying of all above-ground circuitry by the
electro-magnetic pulse of a nuclear weapon.

Urine Therapy is God's own life insurance policy for us. I have walked many
poverty-stricken back alleys in India, and have seen thousands of sick, starving
beggars. It seems difficult for wealthy, spoiled, arrogant Americans to imagine
such misfortune. Their lack of preparation increases the dangers of such a
catastrophe happening to them, as a "recompense".

What could be more patriotic than to help the people of the world by warning
them of this impending danger? And what could be more treasonous against God and
country than to oppose such altruistic efforts? The people must have physical
security. Good intelligence is to see the Truth and to support it, instead of
taking bribes to do wrong.

You mentioned that your esteemed Irish brethren are concerned about a pandemic,
possibly a virus like the one that killed tens of millions in 1918-19. For the
possibility of contagious, virulent epidemics, you must advise our beloved Irish
people to buy a colloidal silver maker, and to take colloidal silver with a
urine fast.
Jai Om. - Sw. Tantrasangha
----------------------------------------

--- On Fri, 7/17/09, Dr. Rakshak Mal Lodha <rakshakmal@...> wrote:

From: Dr. Rakshak Mal Lodha <rakshakmal@...>
Subject: i am from ireland
To: "Rakshak Mal Lodha" <lodhas-urine-therapy@googlegroups.com>
Date: Friday, July 17, 2009, 8:40 AM

From: patrick bolland
Sent: Thursday, July 16, 2009 4:19 PM
To: urine_therapy@yahoogroups.com
Subject: [UT List] i am from ireland

hello
i am from ireland and i have found the group very good as you know people are
geting very worry about swine flu. i would like any advice you can gave about
what to do with urine .I use it every day and i use a mini trampoline to help me
with the toxin. I feel very good since i take urine.thank for the group it has
help,me a lot because its not some thing you can talk to people about  patrick

http://www.salvationscience.com
******************************************************************

#1432 From: "salvationscience" <salvationscience@...>
Date: Wed Jun 24, 2009 4:33 pm
Subject: PROJECT GENESIS: THE INTRAVENOUS SERUM UNION
salvationsci...
Offline Offline
Send Email Send Email
 
PROJECT GENESIS: THE INTRAVENOUS SERUM UNION
OF A MAN AND WOMAN OF THE SAME BLOOD TYPE
http://www.salvationscience.com

This is a collection of past messages about Project Genesis - the fast-track
easy method for a man and woman to mix their two bioplasmas into one composite
whole - half his, half hers. This Serum Union of the two bioplasmas is the Vajra
or Diamond of Hermetic-Tantric theology. It is summarized in the Hindu concepts
of Shushumna or Triveni - The Gnostic Holy Trinity of man, wife, and the "Inner
Child" of their mutual Genetic Rejuvenation.

This is what Pundit Gopi Krishna called, "The Biological Basis of Religion and
Genius" (the title to one of his many great books). Jesus did not teach
sit-on-your-butt no-brainer meditation. You were told to first be "Born Again of
water, then of Spirit". John the Baptist said: "I Baptize you with water, and
one comes who will Baptize you with the fire of the Holy Spirit". Don't neglect
the requisite physical Kriyas or purifications.

Meditation was meant to come spontaneously from the Dwij, Rebirth, or
Resurrection of the Body and the Higher Consciousness it Engenders. This is a
higher, more complete form of Salvation - much better for abating suffering than
any other method. Meditation is good, but we recommend that you Save your bodies
first. The Samadhi or Nirvana of Sahaja Dyun or natural meditation will ensue.
Genetic Rejuvenation from Serum Union, is a psychedelic human entheogen.
Jai Om. - Sw. Tantrasangha
------------------

PROVE RASA TANTRA & PROJECT GENESIS BY EXPERIMENTAL RESEARCH
RE: SALVATION SCIENCE: THE SCIENCE OF SALVATION FROM SUFFERING
RE: THE WORLD'S RELIGIOUS SCRIPTURES JOIN IN RASA TANTRA
RE: SCIENTIFIC EXPERIMENTAL RESEARCH MUST FOLLOW
THE MOUNTAIN OF SCRIPTURAL & SCIENTIFIC EVIDENCE
Re: Center for Islam and Science and Institute of Islamic Sciences
Also: Scientific Verification of Vedic Knowledge in Hinduism
http://www.salvationscience.com

This message corrects the faulty URL's in the former message, called
Salvation Science. We renamed it, because the previous message did
not properly go onto the message board of many groups. It is our
hope that many of you will acknowledge past theological mistakes, so
that you can correct them.

Like Jesus said: "Before I can fill (the inside of) your cups (with
Shivambu), you must first empty them." Our opponents are in a
hysterical State of Denial about the mountain of scriptural and
scientific evidence, contained in the 219 volumes of The Tantrayudha
of Salvation Science.

They actually fear and hate it, so they won't read about what they
don't want to know. Sectarian fundamentalists have a delusion of
grandeur that, if they DON'T read the material, they are free to
slander what they know nothing about.

They vainly imagine that their ignorant, arrogant intolerance is
their "faith and purity". They should confess their sins and repent,
or they will have hell to pay for it. It is for your own good that
we lambast your "erroneous zones".

Only sectarian fundamentalist fools will argue over the
differences between the "outside of the cups" of the many religions,
after being spoon-fed the non-sectarian Truth about Salvation
Science. Pay your dues, read The TantraYudha, get educated, and get
Saved.

Regarding the following links: Please write these people, and spread
the Gospel Gnosis of Sanatana Tantra Dharma. Swamiji can't do it all
by himself! Direct all to our website at salvationscience.com.
Conforming to the "blaspheming Goliath" majority will profit you
nothing.

Will you not stand up for Truth and defend God's Own Bequeathed
Heritage for you and your loved one's? It is your Birthright to
attain Salvation and to know how to do it. But first, you must study
what you have long suppressed.

Save the world from blasphemers and their heretical doctrines, which
cannot Save anyone from anything. Don't conform to erroneous norms.
Join the Tantrayudha - the Tantra MahaJihad of peace and love. No
terrorists allowed! Ahimsa: No harm to be done.

World Peace must begin within each personal, individual heart.
Otherwise, this will be another millennium of Global Frustration-
Aggression Syndrome, in which demons will single out the most
helpful and unselfish for special punishment!

Confess your sins and repent, for the good of all. Put an end to the
socio-economic boycott of the Gnosis, and stop persecuting those who
bring it to you. In the end, the love you take will be the love you
make. Jai Om. - Sw. Tantrasangha
------------------------------------

Center for Islam and Science

The Website describes its self in the following words: "Center for
Islam and Science (CIS) is dedicated to the promotion of research
and diffusion of knowledge on all aspects of Islam and science. CIS
encourages a creative exploration of the Islamic worldview of
science, fusion of contemporary scholarship with the traditional
sources of Islamic thought and a renewed link with the intellectual
tradition of Islam. CIS supports activities aimed at enhancing our
religious and scientific understanding of nature and the human
condition." It contains a number of articles about the lives and
accomplishments of major Muslim Thinkers of the past as well as
contemprary personalities.
http://www.cis-ca.org

Institute of Islamic Sciences
Islamization of Knowledge
http://www.islamicscience.org
----------

Scientific Verification of Vedic Knowledge in Hinduism

--- In yogasutrasofpatanjali@yahoogroups.com, Hari S <om.hari99@...>
wrote:

Hello Everyone,

Here is scientific explanation of Indian Vedic culture and our
immortal heritage, it is a must see for all.

http://in.youtube.com/watch?v=rY4Q2xx7BTc (if you can't see video at
least read comments to get an idea what the video is all about)
http://in.youtube.com/watch?v=G2vhCPBjqcA&feature=related
http://in.youtube.com/watch?v=FMlisMg4VPo&feature=related

As American accent is used in videos if you are facing difficulties
understanding it then the text and images of the videos are
available at:

http://tinyurl.com/yc57et
http://www.archaeologyonline.net/artifacts/scientific-verif-
vedas.html
http://tinyurl.com/yc57et

Please please forward it all your friends.
thank you, Hari S

http://www.salvationscience.com
------------------------

ATTAINING PEACE BY WAY OF HEALTH AND HIGHER CONSCIOUSNESS
RE: FIGHTING AGAINST INTOLERANT, IGNORANT ARROGANCE
RE: WHAT ANTICHRIST DEVILS DO IN THEIR SPARE TIME
RE: ALL SIDES AGAINST THE MIDDLE PATH OF SHUSHUMNA
http://www.salvationscience.com

Jesus said: "I am the Way, the Truth, and the Life". You can have
the Peace which comes from Genetic Rejuvenation and Higher
Consciousness, or you will suffer through myriad dangerous
conflicts. The choice is yours: Do you wnat to be helpful, or do
you, like those damn terrorists in Mumbai, want only to "fuck 'em
up"? Hundreds of innocent people were killed or maimed.

Heed this warning from Jesus: "Do unto others as you would have them
do unto you, for as you sow, so shall you reap". I know that this
scriptural quote best applies to most of you: "They will fall into
the same pit they dug for others." Confession of Sins and Long
Penance is wise. This especially applies to those who, lacking
compassion, needlessly harm others.

As we see, like countless times before, those who don't give a damn
about the welfare of others, have committed another sectarian
fundamentalist atrocity. In the minds of those of all sectarian
fundamentalist sides, it doesn't matter at all that they have
suppressed all evidence for the theoretical possibility for a much
Longer, Happier Life.

Swamiji has long recommended that we seek peace "through the back
door" of Genetic Rejuvenation and Higher Consciousness: To "Shock
and Awe" the "enemy" with Longer Life instead of instant death.
Until you allow that to happen, you will always be faced with a
multitude of false directives, maniacal mandates and erroneous
norms, to which you vainly imagine you are expected to conform.

Our opponents may not have attacked anyone with firearms, but they
sure as hell were an accomplice to the suppression of the mountain
of scriptural and scientific evidence for Rasa Tantra and Project
Genesis, as found in the 219 volumes of the Tantrayudha of Salvation
Science. And they are an accessory to Interference with an
Investigation into this matter.

They have caused this Obstruction of Justice by actively or passively
blocking the scientific experimental research necessary to either
prove or disprove our Theory of the Efficacy of Rasa Tantra and
Project Genesis. This puts them in the homicidal-suicidal position of
preventing the survival of themselves and others - another Mass
Murder-Suicide by all against each other.

The insanity of this is only superceded by its dishonor. Always
remember: If you knowingly conform to an erroneous norm, you will
have hell to pay for it. The unfortunate city of Mumbai has
suffered, indirectly, as a result that ALL SECTARIAN SIDES ARE
AGAINST THE MIDDLE PATH OF PRANA IN SHUSHUMNA! It is time for our
egocentric, zenophobic brethren to open their minds.

They should read and learn about the Non-Sectarian Gnosis of Tantra
Vidya, and renounce all unnecessary conflict resulting from arrogant
intolerance. Find peace, and stop slandering the Peace-Makers! You
must peacefully rid yourselves of all religious doctrines which
cannot Save anyone from anything. Until then, conflict between
bestial minds will remain the proverbial consequence.
Jai Om. - Sw. Tantrasangha
-------------------

THE GREAT YIN-YANG UNION: MEIOSIS IN GENETIC REJUVENATION
RE: THE BIBLICAL "ADAM AND EVE AS ONE FLESH"
http://en.wikipedia.org/wiki/Meiosis
http://www.salvationscience.com

I apologize for mistakenly using the word "mitosis", which describes
non-sexual cell division. I meant to use the word, "meiosis", for
sexual reproduction, in which the male and female share chromosomes
and the genetic information attached to them, for the purpose of
creating a New Being.

Since Rasa Tantra (the Biblical Marriage Supper) and Project Genesis
are a Union of the two bioplasmas of man and woman, one must conclude
that the effect we are trying to Engender is similar to the Joining
of sperm and egg. This is what we call Conception, Fertilization, or
Sexual Reproduction. I haven't given much study to the scientific
studies of this, since it is difficult to comprehend.

Nevertheless, it is good to have a rough idea of what we are looking
for when we rejoin a man and woman. The newly-formed Embryo is called
a Zygote, which has characteristics of both partners. In its early
stage, the Zygote is sexless or Androgynous, since neither sexual
differentiation predominates, and the organism is at its maximum
blend of the two sexes and their Genomes.

When trying to ascertain if the Rebirth has occurred, we should look
first to the outer characteristics of hair color, skin texture,
physical energy, etc. We must also re-map the Genome or Genetic Code,
looking for changes in DNA, genes and chromosomes. This is how we can
determine the Truth, concerning our hypothesis that, by recombining
male and female, we are "Born Again of water and Spirit", as Jesus
calls it.

Since the practice of Rasa Tantra was unknown and is still not
practiced, we are dealing with an old phenomenon, once forgotten, and
now Revived. Of particular interest, is that Meiosis may be, not in
single-celled sperm and egg, joined as one, but throughout the entire
bodies of both partners, who have joined their separate bioplasmas
into one single body of water.

Mitosis - the non-sexual cell division, which goes on within each of
us all the time, causes no interruption in our daily cellular
activity. We don't notice it, but Intrinsic Mutagenesis, a sort of
innate genetic mutation, continues over time, manifesting as the
Senescence, usually thought to be normal for aging organisms.

Meiosis puts an end to these accumulated harmful genetic mutations
and occurs, genetically, only as a newly-Conceived Zygote. Since
Mitosis causes no disruptions for an organism, perhaps the same holds
true for Meiosis, when it occurrs like Mitosis - throughout the
entire body. That is what rational minds are looking for, when they
say this all-important concept from the Bible and Koran: "The
Resurrection of the dead from the grave".

The body ages, and time marks us with increasing physical, mental and
emotional defects, caused by senescence. A wise man once said: "It is
not time, but falling water, which wears away the (Philosopher's)
Stone". And the Holy Bible states: "I give you a white stone
(purified body) with a new name (New Genome or Gene Name)". For
example, Sita and Ram become SitaRam SataNam (the "True Name" of
God).

The physical degeneration of aging continues without interrupting
one's life. Can Physical Regeneration happen in the same Way? Someone
once said: "If you want to find the Way to Immortality, just take the
Adam and Eve movie, and run it backwards": Stop the outflow of
fluids, eat only of the Tree of Life, put an end to the separation of
male and female seeds and the bruises caused by the 'enmity between
their seeds', be Rejoined As One Flesh, become Immortal, and enjoy
the granting of every Right Wish. Jai Om. -Sw. Tantrasangha

http://en.wikipedia.org/wiki/Meiosis

Meiosis
From Wikipedia, the free encyclopedia

In biology or life science, meiosis (pronounced my-oh-sis) is a
process of reduction division in which the number of chromosomes per
cell is cut in half. In animals, meiosis always results in the
formation of gametes. The word "meiosis" comes from the Greek verb
meioun, meaning "to make small," since it results in a reduction in
chromosome number in the gamete cell.

Meiosis is essential for sexual reproduction and therefore occurs in
all eukaryotes (including single-celled organisms) that reproduce
sexually. A few eukaryotes, notably the Bdelloid rotifers, have lost
the ability to carry out meiosis and have acquired the ability to
reproduce by parthenogenesis. Meiosis does not occur in archaea or
bacteria, which reproduce via asexual processes such as mitosis or
binary fission. Each cell has half the number of chromosomes as the
parent cell.

During meiosis, the genome of a diploid germ cell, which is composed
of long segments of DNA packaged into chromosomes, undergoes DNA
replication followed by two rounds of division, resulting in four
haploid cells. Each of these cells contain one complete set of
chromosomes, or half of the genetic content of the original cell. If
meiosis produces gametes, these cells must fuse during fertilization
to create a new diploid cell, or zygote before any new growth can
occur. Thus, the division mechanism of meiosis is a reciprocal
process to the joining of two genomes that occurs at fertilization.
Because the chromosomes of each parent undergo genetic recombination
during meiosis, each gamete, and thus each zygote, will have a
unique genetic blueprint encoded in its DNA. Together, meiosis and
fertilization constitute sexuality in the eukaryotes, and generate
genetically distinct individuals in populations.

In all plants, and in many protists, meiosis results in the
formation of haploid cells that can divide vegetatively without
undergoing fertilization. In these groups, gametes are produced by
mitosis.

Meiosis uses many of the same biochemical mechanisms employed during
mitosis to accomplish the redistribution of chromosomes. There are
several features unique to meiosis, most importantly the pairing and
genetic recombination between homologous chromosomes.

http://en.wikipedia.org/wiki/Meiosis
http://www.salvationscience.com
---------------------

THE MISSING 12TH PRINCIPLE OF INTRINSIC MUTAGENESIS (SEE #12)
RE: HOW TO CHOOSE FOOD SUPPLEMENTS FOR URINE FASTING OR TANTRA
http://www.salvationscience.com

1. The food should be as pure as possible, containing no artificial
chemicals and no dead animal bodies.

2. The food should be as meager and, therefore, as concentrated as
possible.

3. The food should be as liquid as possible. Avoid solids. Pure
water is necessary.

4. If the food is solid, it should be in the form of a fine powder.

5. Biblical quotes: "I give you honey, oil, and fine flour for
food." "All those left in the land, butter and honey will they eat."
Moses led us to the "Promised Land (the Resurrected Body?), flowing
with milk and honey". "I give you dainty food, that ye eat not
much." "Let your table be a snare unto you." "Those who break the
fast must die the death."

6. Padmasambhava adds molasses, fruit juices and curd (yogurt, kefir
also). Milk is the obvious mainstay. Cow urine is a traditional
supplement in India. Wheat grass juice is good. Buttermilk is good,
especially because it has salt, and it covers an empty stomach.

7. The powders can be: soya, brewers yeast (not active), lecithin,
whey, powdered milk, synthetic food-grade Urea, and dried spirulina,
chlorella, or blue-green algae. The protein in these
powders "leavens the bread", meaning it raises therapeutic,
nutritional bile and urea.

8. Recall that the Resurrected body is attained by ridding the body
of excess carbon and by fasting on liquids - to become
a "Breatharian", only this time the "breath" or Prana is urine. The
recycling, as in Urine Therapy and Tantra, will increase the
efficacy of these calorie-restricted diets and fasts.

9. My Paramguruji said that, in the end, one might survive entirely
on what comes from the body and is then recycled. Excrement is NOT
one of the sacraments of Genetic Efflux, although it has been baked
for consumption, during high famines. My guru said NOT to consume
dung. I agree.

10. The time necessary to complete a Urine Fast: According to John
Armstrong, the best fast duration, for curing disease with Urine
Therapy, is thirty days. The Bible states: "Forty days", "42
months", or "seven years". The food supplements will save you from
starvation on such extended fasts. One can fast on water until one's
ribs protrude, at which time one must avoid further weight loss.

11. One should remember our Third Experimental Protocol, after Urine
Therapy and Urine Tantra (Rasa Tantra): Project Genesis - The
intravenous connecting of a man and woman, with the same blood type.
Also, urine can be freeze-dried.

12. This is the missing principle, missing in our original message.
The principle that there is a gradual, harmful "Intrinsic
Mutagenesis" (genetic errors in the DNA, increasing with time, which
we call disease or Senescence, a byproduct of aging), caused by the
gradual dilution and pollution of the bioplasma, and hence, the
Genome or DNA Genetic Code. To counter this, one's food should be as
similar to one's physical biochemistry as possible. This is why
urine is called "Pavamana", meaning "pure food". In the case of
Tantra, one attempts to match the biochemistry of one's partner, so
all Genetic Efflux is necessary, since the "Rebirth"
or "Resurrection" involves the pairing off of the male and female
chromosomes, thus generating a New Genome, which can be detected
with modern DNA testing techniques. The body's Intrinsic
Biochemistry includes one's serum hormones, enzymes, antigens,
antibodies, Urea, and of course, one's own DNA Genetic Code or "Gene
Name". Like the Book of Revelations states: "I give you a white
stone (purified bioplasma) with a NEW NAME on it." And like some
wise man said: "It is not time, but falling water that wears away
the stone."

13. The Tantrayudha was written, so that you would have adequate
scientific and scriptural information (Secondary Analysis) to
develop an Experimental Research Design, and to warrant such
experimentation. The world is the "braying ass" which denied these
facts, without investigating the evidence, thus leaving the world
with no alternative but death, when it had a real chance for a
Longer, Happier Life. Nuts! Jai Om. - Sw. Tantrasangha
--------------------

PROJECT GENESIS & THE MARRIAGE SUPPER OF THE LAMB OF GOD

The "Marriage Supper", as mentioned in the Biblical Book of the
Revelation of John, is only Rasa Tantra by another name. It is what
makes the many otherwise different and disparate religions a single
non-sectarian Science of Salvation from Suffering by attaining a
Longer and Happier Life.

Project Genesis is the intravenous joining of a male and a female of
the same blood type. Preferably, the two procedures could both be
conducted at the same time. The joining of the male and female DNA,
via the interchange and commingling of their own Genetic Efflux,
which, when exchanged and consumed, as in Tantra, becomes bioplasma
within the bodies of the two yoga aspirants.

Project Genesis is particularly interesting, because it directly
joins the two bioplasmas (which includes the blood), without the
diluting process of the stomach and digestive organs. One can see the
difference between the two processes by comparing the difference
between the effects of ingesting a drug and the intravenous injection
of the same drug.

For example, intravenous injections would be several times more
potent than eating and ingesting the same substance in the same
amount. Combining the two protocols might accelerate the process.
Some Alchemical treatises warn about the physical changes happening
too quickly, but it would certainly be reassuring to the "doubting
demon" within us, to see quick and early results.

Project Genesis is no substitute for Rasa Tantra, unless the couple
are fasting and eliminating solids from the diet and carbon from the
body. Project Genesis is an I.V. procedure connecting veins and
arteries. It does not utilize injections. Both procedures are
entirely experimental. We have presented the scriptural, scientific
and Urine Therapy evidence to substantiate our theories and to
instigate further experimental research. Jai Om. - Sw. Tantrasangha
--------------------

SCIENCE & SCRIPTURES: THE TWO "ROCKS" UPON WHICH THE TRUE FAITH IS
BUILT
http://search.yahoo.com/search?p=scientific+method&fr=ush-groups

Of course I don't mean the falsification os science, like the
American FDA receiving bribes to ban the natural herb sweetener,
Stevia, while advocating the poison Aspartame (Nutrasweet),
manufactured by the powerful pesticide company, Monsanto. The adverse
affects of Aspartame can be found on your search engine. Just search
for: Aspartame side effects toxicity. No, we are not advocating such
aberrations of capitalism, but of real honest rational enquiry into
the Truth of the matter - not someone's lies to cover up the Truth
for a bribe!

We find allusions, allegories, and descriptions of Rasa Tantra in the
scriptures, whereby we develop our Experimental Research Design. Then
we begin the trials and tests of our theories or hypotheses, to
determine the efficacy, if any, of such a procedure. The Four
Righteous Character Attributes are: Knowledge, Reason, Honesty, and
Compassion. For Knowledge, we exhibit the scriptural and scientific
evidence. For Reason, we study these facts, preferably found in the
many volumes of the Tantrayudha. For Honesty, we must not be in a
state of denial, in which we knowingly or unknowingly and
subconsciously seek to protect some secret agenda of attachment to
past unproven opinions. Compassion is what makes us go to all this
trouble to find a cure for the infinite sufferings of this dying
world.

Up till now, our opponents have not given us any kind of rebuttal,
which would be impossible anway, until our Theological Theories are
proven or disproven in actual practice. Those who oppose us despise
our Righteousness, and, like strong-arm Mafia thugs, "twist our arms"
and threaten us with how much "muscle they are packing" with
their "Blaspheming Goliath" majority of opinions against Rasa Tantra
and Project Genesis. They do this without any real thoughtful,
rational, reasonable rebuttal, but with threats and insults! Folks,
if they enjoy making good people suffer with such relish, do you need
any further proof of the evil of their immoral motives? And not one
single logical rebuttal in all those thousands of slaps to the
healer! Nothing but: Ignorance, Irrationality, Dishonesty, and Hate!

When the devil threatens you, you will know he is in trouble. Or, as
Paul Twitchell said: "The church won't give up without a fight. When
they have to use the police to enforce their lies, you will know they
are in trouble". I have faced this PERSECUTION WITHOUT DISCUSSION for
a full quarter century. It only increased my faith to see how much
those conformists of bad character had singled out this Divine
Doctrine for persecution, even using the same identical insults
worldwide, to torture anyone who tried to undo the trouble they had
caused for their own fellow man. And they did it with such relish! It
is now a matter of historical record. Repent!
Jai Om. - Sw. Tantrasangha

http://search.yahoo.com/search?p=scientific+method&fr=ush-groups
-------------------------

RASA TANTRA & PROJECT GENESIS ARE THE ONLY THEORIES FOR PHYSICAL
IMMORTALITY.
http://in.search.yahoo.com/search?fr=slv1-fp&p=physical+immortality

Read everything you can about Physical Immortality, and you will find
our own two Hermetic Protocols are the only Experimental Research
Designs for Physical Immortality in existence. In addition, these
Experimental Protocols are the only ones even proposing the possibility for
alleviation or Salvation from the Eight Sufferings of: 1. Hunger 2. Disease 3.
Senescence 4. Untimely Death 5. Emotional Depression 6. Low Mental Intelligence
7. Spiritual Entrapment of Consciousness in the physical dimension, and 8. The
Eternal Round (Samsara) of incarnations into suffering. So, what do our
opponents have to offer? Jai Om. - Sw. Tantrasangha

http://in.search.yahoo.com/search?fr=slv1-fp&p=physical+immortality
----------------------------

PROJECT GENESIS

These are the two entirely unknown Genetic Therapies we mentioned.
One is a form of Urine Therapy, in which man and woman exchange their
Genetic Material. The other is a method whereby the blood streams of
a man and woman, of the same blood type, are connected. The first
method is the secret basis of all ancient religions, and the other is
a recent invention by Hermetic Scientist, Karen Douglas Snow. They
both follow the Theory of Fertilizatiuon of Conjoined Sperm and Egg.
They are different from Embryonic Stem Cell Therapy in that the
Fertilization is to occur throughout the bodies of the couple, and,
thus, these Theoretical, Experimental Therapies, although simpler,
hold the possibility for more remarkable results, such as
Rejuvenation and Psychic Alterations, concurrent with a New Genetic
Code, expressing the chromosomes of both partners in the process. If
you reread your world scriptures, you will find frequent mention of
these facts, albeit not as plainly stated as by yours truly.. Dr. J.

http://www.salvationscience.com
**************************************************************

#1431 From: "salvationscience" <salvationscience@...>
Date: Tue Jun 23, 2009 6:03 pm
Subject: ALCHEMICAL CONFESSIONS OF THE HOLY ROMAN CATHOLIC SAINTS, PART V
salvationsci...
Offline Offline
Send Email Send Email
 
ALCHEMICAL CONFESSIONS OF THE HOLY ROMAN CATHOLIC SAINTS, PART V
COLLECTANEA CHEMICA ed. by A.E. Waite [1893]
http://www.sacred-texts.com/alc/cc/index.htm

ON THE ALCHEMICAL MARRIAGE OF CHRISTIAN ROSENKREUTZ

This is actually written by a Master of our own Protestant Brotherhood of the
Rosie Cross. This particular text is different because of its more explicit
explanations of the "Art of Hermes".

In Alchemical tractates, there is little or no difference between those written
before or after the Protestant Reformation of Henry VIII and Martin Luther in
the early 1500's.

These works on Alchemy are all Christian texts, pertaining to both Catholic and
Protestant Gnostics. Their value to us is according to how specific and accurate
the teachings are.

We are drowning in an ocean of confusing symbology, in which we can only be
Saved by teachers who openly give us the literal Truth. It is no longer
necessary to hide the Truth from the unworthy.

If they love lies and don't want Truth, the don't deserve its Heavenly benefits,
and surely are hell-bent for perdition's flames. It is not good to be bad. Jai
Om. - Sw. Tantrasangha
-------------------

Collectanea Chemica, ed. by A.E. Waite, [1893], at sacred-texts.com

THE SECRET OF THE IMMORTAL LIQUOR CALLED ALKAHEST
OR IGNIS-AQUA By EIRENÆUS PHILALETHES (THOMAS VAUGHN),
Brotherhood of the Rosie Cross
http://www.sacred-texts.com/alc/cc/cc03.htm

Communicated to his Friend, a Son of Art, and now Philosopher.

By Question and Answer.

p. 10 p. 11

THE SECRET OF THE LIQUOR ALKAHEST.

1. Question.—What is the Alkahest?

Answer.—It is a Catholic and Universal Menstruum, and, in a word, may be called
(Ignis-Aqua) a Fiery Water, an uncompounded and immortal ens, which is
penetrative, resolving all things into their first Liquid Matter, nor can
anything resist its power, for it acteth without any reaction from the patient,
nor doth it suffer from anything but its equal, by which it is brought into
subjection; but after it hath dissolved all other things, it remaineth entire in
its former nature, and is of the same virtue after a thousand operations as at
the first.

2. Q.—Of what substance is it?

A.—It is a noble circulated salt, prepared with wonderful art till it answers
the

p. 12

desires of an ingenious artist; yet it is not any corporal salt made liquid by a
bare solution, but is a saline spirit which heat cannot coagulate by evaporation
of the moisture, but is of a spiritual uniform substance, volatile with a gentle
heat, leaving nothing behind it; yet is not this spirit either acid or alkali,
but salt.

3. Q.—Which is its equal?

A.—If you know the one, you may without difficulty know the other; seek
therefore, for the Gods have made Arts the reward of industry.

4. Q.—What is the next matter of the Alkahest?

A.—I have told you that it is a salt; the fire surrounded the salt and the water
swallowed up the fire, yet overcame it not; so is made the philosopher's fire,
of which they speak; the vulgar burn with fire, we with water.

5. Q.—Which is the most noble salt?

A.—If you desire to learn this, descend into yourself, for you carry it about
with

p. 13

you, as well the salt as its Vulcan, if you are able to discern it.

6. Q.—Which is it, tell me, I pray you?

A.—Man's blood out of the body, or man's urine, for the urine is an excrement
separated, for the greatest part, from the blood. Each of these give both a
volatile and fixed salt; if you know how to collect and prepare it, you will
have a most precious Balsam of Life.

7. Q.—Is the property of human urine more noble than the urine of any beast?

A.—By many degrees, for though it be an excrement only, yet its salt hath not
its like in the whole universal nature.

8. Q.—Which be its parts?

A.—A volatile and more fixed; yet according to the variety of ordering it, these
may be variously altered.

9. Q.—Are there any things in urine which are different from its inmost specific
urinaceous nature?

A.—There are, viz., a watery phlegm, and sea salt which we take in with our

p. 14

meat; it remains entire and undigested in the urine, and by separation may be
divided from it, which (if there be no sufficient use of it in the meat after a
convenient time) ceaseth.

10. Q.—Whence is that phlegm, or insipid watery humidity?

A.—It is chiefly from our several drinks, and yet everything hath its own
phlegm.

11. Q.—Explain yourself more clearly.

A.—You must know that the urine, partly by the separative virtue, is conveyed
with what we drink to the bladder, and partly consists of a watery Teffas (an
excrementitious humour of the blood), whence being separated by the odour of the
urinaceous ferment, it penetrates most deeply, the saltness being unchanged,
unless that the saltness of the blood and urine be both the same; so that
whatsoever is contained in the urine besides salt is unprofitable phlegm.

12. Q.—How doth it appear that there is a plentiful phlegm in urine?

p. 15

A.—Thus suppose; first, from the taste; secondly, from the weight; thirdly, from
the virtue of it.

13. Q.—Be your own interpreter.

A.—The salt of urine contains all that is properly essential to the urine, the
smell whereof is very sharp; the taste differs according as it is differently
ordered, so that sometimes it is also salt with an urinaceous saltness.

14. Q.—What have you observed concerning the weight thereof?

A.—I have observed thus much, that three ounces, or a little more, of urine,
taken from a healthy man, will moderately outweigh about eighty grains of
fountain water, from which also I have seen a liquor distilled which was of
equal weight to the said water, whence it is evident that most of the salt was
left behind.

15. Q.—What have you observed of its virtue?

A.—The congelation of urine by cold is an argument that phlegm is in it; for the

p. 16

salt of urine is not so congealed if a little moistened with a liquid, though it
be water.

16. Q.—But this same phlegm though most accurately separated by distillation,
retains the nature of urine, as may be perceived both by the smell and taste.

A.—I confess it, though little can be discerned by taste, nor can you perceive
more, either by smell or taste, than you may from salt of urine dissolved in
pure water.

17. Q.—What doth pyrotechny teach you concerning urine?

A.—It teacheth this, to make the salt of urine volatile.

18. Q.—What is then left?

A.—An earthly, blackish, stinking dreg.

19. Q.—Is the spirit wholly uniform?

A.—So it appeareth to the sight, smell, and taste; and yet it containeth
qualities directly contrary to each other.

20. Q.—Which be they?

A.—By one, through its innate virtue,

p. 17

the Dulech is coagulated; by the other, it is dissolved.

21. Q.—What further?

A.—In the coagulation of urine, its spirit of wine is discovered.

22. Q.—Is there such a spirit in urine?

A.—There is indeed, truly residing in every urine, even of the most healthful
man, most of which may be prepared by Art.

23. Q.—Of what efficacy is this spirit?

A.—Of such as is to be lamented, and indeed may move our pity to mankind.

24. Q.—Why so?

A.—From hence the Dulech, its most fierce enemy, hath its original.

25. Q.—Will you give an example of this thing?

A.—I will. Take urine, and dissolve in it a convenient quantity of saltpetre.
Let it stand a month; afterwards distil it, and there will come over a spirit
which burns upon the tongue like a coal of fire. Pour this spirit on again, and
cohobate it four

p. 18

or five times, abstracting every time not above half; so the spirit becometh
most piercing, yet not in the least sharp; the heat which goeth out in the first
distillation of the liquor, afterwards grows sensibly mild, and at length almost
(if not altogether) vanisheth, and the second spirit may be perceived mild, both
by the smell and taste, which in the former was most sharp.

26. Q.—What have you observed concerning the former spirit?

A.—If it be a little shaked, oily streaks appear sliding here and there, just as
spirit of wine distils down the head of the alembic in streaks like veins.

27. Q.—What kind of putrefaction should the urine undergo that such a spirit may
be got from it?

A.—In a heat scarce to be perceived by sense, in a vessel lightly closed, or
covered rather; it may also be sometimes hotter, sometimes cooler, so that
neither the heat nor cold exceed a due mean.

p. 19

28. Q.—How may this winy spirit become most perspicuous?

A.—By such a putrefaction as causeth a ferment, and exciteth ebullition, which
will not happen in a long time if the urine be kept in a wooden vessel, and in a
place which is not hot, but yet keeps out the cold, as, suppose, behind a
furnace in winter, where let it be kept till of itself a ferment arise in the
urine and stirs up bubbles, for then you may draw from it a burning water which
is somewhat winy.

29. Q.—Is there any other spirit of urine?

A.—There is; for urine, putrefied with a gentle heat, during the space of a
fortnight or thereabouts, sends forth a coagulating spirit, which will coagulate
well rectified Aqua Vitæ.

30. Q.—How is that spirit to be prepared which forms the Dulech of itself with a
clear watery stalagma; and also that which dissolves the same?

A.—Urine putrefied for a month and a-half

p. 20

in a heat most like the heat of horse-dung will give you, in a fit vessel, each
stillatitious stalagma according to your desire.

31. Q.—Doth every spirit coagulate the spirit of wine?

A.—By no means; this second spirit is observed to want that virtue.

32. Q.—What doth urine, thus ordered, contain besides the aforesaid spirits?

A.—Its more fixed urinaceous salt, and, by accident, foreign marine salt.

33. Q.—Can this more fixed salt be brought over the alembic, with a gentle heat,
in form of a liquor?

A.—It may, but art and ingenuity are required.

34. Q.—Where is the phlegm?

A.—In the salt; for in the preparation of putrefaction, the salt, being
putrefied in the phlegm, ascends together with it.

35. Q.—Can it be separated?

A.—It may, but not by every artist.

p. 21

36. Q.—What will this spirit do when it is brought to this?

A.—Try, and you will wonder at what you shall see in the solution of bodies.

37. Q.—Is not this the Alkahest?

A.—This liquor cannot consist without partaking of the virtues of man's blood;
and in urine the footsteps thereof are observable.

38. Q.—In urine, therefore, and blood the Alkahest lies hid?

A.—Nature gives us both blood and urine; and from the nature of these pyrotechny
gives us a salt which art circulates into the circulated salt of Paracelsus.

Q.—You speak short.

39. A.—I will add this; the salt of blood ought so to be transmuted by the
urinaceous ferment that it may lose its last life, preserve its middle life, and
retain its saltness.

40. Q.—To what purpose is this?

A.—To manifest the excellency which is in man's blood above all other blood

p. 22

whatever, which is to be communicated to the urine (after an excrementitious
liquor is separated from it), whence this urine excels all others in a wonderful
virtue.

41. Q.—Why do you add urine?

A.—You must know that to transmute things a corruptive ferment is required, in
which respect all other salts give place to the strong urinous salt.

42. Q.—Cannot the phlegm be collected apart from the salt?

A.—It may, if the urine be not first putrefied.

43. Q.—How great a part of the water is to be reckoned phlegm?

A.—Nine parts of ten, or thereabouts, distilled from fresh urine are to be
rejected, the tenth part (as much as can be extracted in form of liquor) is to
be kept; from that dried urine which remains in the bottom by a gentle fire
(which will not cause sublimation), let the salt be extracted with water, so
that there be as much water as half that urine whence this feces was

p. 23

dried; whatsoever is imbibed by the water, let it be poured off by decanting;
let it be strained, or purged, per deliquium; then filter it through a glass.
Let fresh water be poured on, and reiterate this work till the salt become pure,
then join this vastly stinking salt with your last spirit and cohobate it.

PRAISED BE THE NAME OF THE LORD. — AMEN.

http://www.sacred-texts.com/alc/cc/cc03.htm
----------------

Collectanea Chemica, ed. by A.E. Waite, [1893], at sacred-texts.com

CHAPTER VIII.
Of the Union or Mystical Marriage in the Philosophical Process.

http://www.sacred-texts.com/alc/cc/index.htm
http://www.salvationscience.com
****************************************************************

#1430 From: "salvationscience" <salvationscience@...>
Date: Sun Jun 21, 2009 6:02 pm
Subject: ALCHEMICAL CONFESSIONS OF THE HOLY ROMAN CATHOLIC SAINTS, PART IV
salvationsci...
Offline Offline
Send Email Send Email
 
ALCHEMICAL CONFESSIONS OF THE HOLY ROMAN CATHOLIC SAINTS, PART IV
ALCHEMICAL TRACTATES AT SACRED-TEXTS.COM
http://www.sacred-texts.com/alc/index.htm
http://www.salvationscience.com

These titles are active links to the texts, so, go to their website and read. If
you learn something, we will be better friends.
Jai Om. - Sw. Tantrasangha
--------------------------

ALCHEMICAL TRACTATES AT SACRED-TEXTS.COM

Hermetic Museum Index
VOL. I | VOL. II
http://www.sacred-texts.com/alc/hermmuse/index.htm

The Hermetic Museum

This is the main index for Arthur Edward Waite's Hermetic Museum. This is one of
the largest collections of Alchemical tracts, first published in Latin in 1678.
Waite translated it into English and issued it in two volumes in 1893. It
appears in its entirety here on the Internet for the first time. Full
bibliographic information can be found via either one of the volume index pages,
(here, and here).

VOLUME I

Title Page
Preface to the English Edition
Preface to Latin Original
Contents of Volume I
The Golden Tract Concerning the Stone of the Philosophers
The Golden Age Restored
The Sophic Hydrolith
A Demonstration of Nature
A Short Tract or Philosophical Summary
The Only True Way
The Glory of the World; or, Table of Paradise
A Tract of Great Price
The Book of Alze
The Book of Lambspring
The Golden Tripod

VOLUME II

Title Page
Table of Contents
Believe-Me, or The Ordinal of Alchemy
The Testament of Cremer
The New Chemical Light
New Chemical Light
An Open Entrance to the Closed Palace of the King
A Subtle Allegory Concerning the Secrets of Alchemy

The Three Treatises of Philalethes
Title and Contents

I. The Metamorphosis of Metals
II. A Brief Guide to the Celestial Ruby
III. The Fount of Chemical Truth

Helvetius' Golden Calf
The All-Wise Doorkeeper or A Fourfold Figure
Addendum

http://www.sacred-texts.com/alc/hermmuse/index.htm
------------------

COLLECTANEA CHEMICA
ed. by A.E. Waite [1893]
http://www.sacred-texts.com/alc/cc/index.htm

This is a short collection of some curious Alchemical treatises which was
republished by A.E. Waite in 1893. According to the preface, Waite found these
in a manuscript belonging to a collector of occult books. This etext uses
Unicode to display astrological symbols (here used in an alchemical sense, of
course). For instructions on viewing Unicode in your browser, refer to this
file.

Title Page
Table of Contents
Prefatory Note
The Secret of the Immortal Liquor called Alkahest or Ignis-Aqua
Aurum Potabile: Or the Receipt of Dr. Fr. Antonie
The Oil of Sulphur

The Stone of the Philosophers
Title Page
The Contents
The Preface
Chapter I. The Introduction
Chapter II. Of the Vegetable Tincture
Chapter III. Of the Uses of the Vegetable Tinctures
Chapter IV. Of the Metallic Tincture
Chapter V. Of the Second Matter, or Seed in Metals
Chapter VI. Of the Dissolution and Extraction of the Seed in Metals
Chapter VII. Of the Separation and Further Treatment of our Philosophical Seed
Chapter VIII. Of the Union or Mystical Marriage in the Philosophical Process
Chapter IX. Of the Further Treatment and Ripening of our Seed
Chapter X. Of the Further Process to the Ripening of our Noble Seed
Chapter XI. A Further Description of the Process
Chapter XII. Of the Stone and its Uses
Chapter XIII. Of the Transmutation

The Bosom Book of Sir George Ripley
Preparations of the Sophic Mercury

http://www.sacred-texts.com/alc/cc/index.htm
-----------------

ALCHEMY INDEX AT SACRED-TEXTS.COM
http://www.sacred-texts.com/alc/index.htm

  Triumphal Chariot of Antimony by Basil Valentine
  Golden Chain of Homer
  Emerald Tablet of Hermes
  Glory of the World
  The Six Keys of Eudoxus
  Freher's Process in the Philosophical Work
  The Golden Tractate of Hermes Trismegistus
  The Hermetic Arcanum
  Hortulanus' Commentary on the Emerald Tablet
  The Stone of the Philosophers by Edward Kelly
  Mary the Prophetess
  An Alchemical Mass
  The Mirror of Alchemy
  On the Philadelphian Gold
  Tract on the Tincture and Oil of Antimony by Roger Bacon
  Turba Philosophorum (part 1)
  Turba Philosophorum (part 2)

The Hermetic and Alchemical Writings of Paracelsus
A.E. Waite, Translator (Excerpts)
[1894]
  Coelum philosophorum by Paracelsus
  The Book Concerning The Tincture Of The Philosophers by Paracelsus
  The Treasure of Treasures for Alchemists by Paracelsus
  The Aurora of the Philosophers by Paracelsus
  Alchemical Catechism

http://www.sacred-texts.com/alc/index.htm
http://www.salvationscience.com
**************************************************************

#1429 From: "wisslewj" <wisslewj@...>
Date: Thu Jun 11, 2009 2:21 pm
Subject: questions on urine use (sorry if this posted twice)
wisslewj
Offline Offline
Send Email Send Email
 
hello,

this is my first post and I have some questions.  I dont have cancer as far as I
know, but this was one of the few forum I found where I might get some info on
my issues and whether urine will help.

About 5 months ago my pulse rate shot up to 175 just sirring still.  I went to
the ER and they ran a mess of tests and said they didnt know what was wrong. 
They sent me home when my pulse was back to 110.  my pulse stayed between
110-140 for the next week.  It was truely hell and i thought i was dieing for
sure.

Anyway, it shot up again and I went back to the ER and again they said we dont
know.  Maybe its anxiety.  So they gave me Lorazapam.  It did help some and I
was on it for a month.  Eventually symptoms died down and I was off everything.

But the drug was eeming to have a negative side effect. (imagine that.) I
started getting varicose veins in my legs and now the veins in my forearms get
dilated and puffed up whenever its really hot or if I eat any high protein
amounts.

I have had a stress test, echocardiogram, seen a vascular doc, an endo doc and
all say I am fine.  Yet I can barely eat any meat without veins puffing up.  I
also get short of breath for no reason still on and off.  I imagine this is
related to some deficiencies as I barely eat these days.

My former diet was raw meat from grass fed cows and raw fats. I only occassinaly
ate fruits/veggies.  I felt GREAT for about a year on this diet and gained solid
muscle weight but now things are falling apart big time.  Possible mineral
deficiencies?  My circulation is also whacky and off at time.  (Again doc says
ekg is great and heart is fine, so what sthe deal?)

I want to use the urine therapy but not sure if it will help.  I also thought
about urine enemas but dont know if they are safe.  I drank about a tablesppon
for starters this morning.  So far nothing.

Does anyone have any advice?  Ever heard of my symptoms?  Thanks so much for any
advice.

God Bless
Jeff

#1428 From: Michael Bello <mikebello2351@...>
Date: Fri May 29, 2009 3:03 pm
Subject: Cardiovascular Fitness Not Affected By Cancer Treatment?
mikebello2351
Offline Offline
Send Email Send Email
 
The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies, say researchers from Georgetown University Medical Cancer. That is the finding of a new observational study to be presented today at the American College of Sports Medicine in Seattle.

"We know physical activity is a critical component of cancer survivorship, both during and after cancer treatment," says Jennifer LeMoine, PhD, a post-doctoral research fellow with training in exercise physiology at GUMC's Lombardi Comprehensive Cancer Center. "In order to ... for full story - http://the-cancer-chronicles.blogspot.com/

What are your thoughts?

Thanks
Mike Bello, M.D.
Cancer Advocate
Neoplasm Research Institute


Yahoo! Mail Now Faster and Cleaner. Experience it today!

#1427 From: Joseph Eldor <a1b2c3d4@...>
Date: Thu May 28, 2009 6:52 am
Subject: Fw: What is Urine Therapy?
csen_interna...
Offline Offline
Send Email Send Email
 
----- Original Message -----
From: <info@...>
To: <a1b2c3d4@...>
Sent: Wednesday, May 27, 2009 12:24 PM
Subject: What is Urine Therapy?


> Dear Sir/Madam,
>
> SilkWise.com is a popular question answer website. Some of our users asked
> the above question, and we think you are the domain expert who can provide
> a great answer to it. Can you help to answer the question or improve the
> current answer at the following link?
>
> http://www.silkwise.com/content/viewthread_thread,6290
>
> Everyone has unique expertise. SilkWise is the place to share your wisdom,
> build your networks, and market yourself!
>
> SilkWise Team

#1426 From: "salvationscience" <salvationscience@...>
Date: Fri May 15, 2009 6:41 pm
Subject: COLLOIDAL SILVER: THE BEST WAY TO FIGHT VIRULENT PANDEMICS
salvationsci...
Offline Offline
Send Email Send Email
 
COLLOIDAL SILVER: THE BEST WAY TO FIGHT VIRULENT PANDEMICS
COLLOIDAL SILVER: NATURE'S OWN ANTIVIRAL ANTIBIOTIC
Re: The Age Of The Unthinkable by Joshua Cooper Ramo
http://www.salvationscience.com/v225.htm

The Biblical "Four Horsemen of the Apocalypse", mentioned in the Revelation of
John, are the "Tribulations" of hunger, disease, war, and death. They are
"unthinkable", because thinking about negative things makes you worry. So, you
go into a State of Denial about it, which only makes the problem much worse by
non-preparation.

In the case of fast-moving viruses, slow-moving Urine Therapy will not act fast
enough. You will need the help of nature's own antibiotic - anti-viral Colloidal
Silver. You can buy a good Colloidal Silver maker for around $100. Make sure it
has an automatic cutoff and that it works on both AC current and batteries.

You should also have a good supply of silver, to make your medicine. Colloidal
Silver will greatly enhance the efficacy of Urine Therapy in such viral or
bacterial infections. Cipro is the only anti-viral I know of, and it is doubtful
you can get a prescription for it in time for an emergency case. Don't be
dependent on outside help.

Also, bacteria are developing immunity to antibiotics, so scientists are always
trying to develop a new formula, which in a short time will also be rendered
useless by bacteria's ability to constantly evolve new immunity against attack.
I suppose the same problem might develop for anti-virals. Don't depend on
pharmaceutical drugs.

Colloidal Silver is the answer to all these problems. The fact that the AMA
won't use it, will cause many deaths in the event of a virulent pandemic. So,
get your Colloidal Silver makers now, before it is too late. This is an
inexpensive and very critical addition to your own survival preparations.
Salvation Science is for your own
survival.

Of course, the Americans have little interest in survival and have "quarantined
the cure", while persecuting its advocate - all of them against one good man,
and they enjoy it with sickening relish! The Americans have willfully rejected
Truth without having been forced in any way to do so and without any rational
enquiry whatsoever.

All subservient and subordinate peoples and nations of the USA and the Global
Sectarian Fundamentalist Conspiracy, are endangering themselves by conforming to
such erroneous opinions and behavior. When the "wolf comes", your own proverbial
State of Denial will be like the false shepherd who runs away and leaves you
defenseless.
You must survive to get Saved. Jai Om. - Sw. Tantrasangha
------------------------

The Next Global Panic by Joshua Cooper Ramo
http://www.thedailybeast.com/blogs-and-stories/2009-04-28/the-age-of-the-unthink\
able-swine-flu-and-the-100-days

Info RSS  Joshua Cooper Ramo is Managing Director and a partner at Kissinger
Associates, one of the world's leading strategic advisory firms. Prior to
joining Kissinger Associates, he was Assistant Managing Editor of Time and
worked in the advisory and banking business in China.

Eduardo Verdugo / AP Photo: The arrival of swine flu at Obama's 100-day mark
signals the challenges that will define his presidency. From financial panic to
Islamic fundamentalism, a new wave of dangers is sweeping the planet. Joshua
Cooper Ramo, author of The Age of the Unthinkable: Why the New World Disorder
Constantly Surprises Us and What We Can Do About It, reports.

What's bothering me particularly about the Mexican swine-flu outbreak isn't just
the gory sense of what the disease does once you get it, but rather how you get
it in the first place. H1N1 has an eerily familiar way of sliding into our lives
and it reminds me that this latest epidemic looks unnervingly like so many other
dangers. The spread of swine flu looks similar to the financial flu that blitzed
and crippled our banking system last year. It evokes the virus of Islamic
fundamentalism that we now see infecting the planet at an ever-faster rate—and
that is terrifyingly unresponsive to traditional medicines of politics or even
the best surgical strikes.

Read an excerpt from The Age of the Unthinkable:

Here's what's making me nervous about H1N1: It' a reminder that a dangerous
contagion abounds now, not just a disease contagion. And it's a pretty clear
reminder that in his first 100 days at least, President Obama hasn't yet laid
out the full set of plans we need to deal with an age of infectious danger. But
the weird coincidence of swine flu and the 100 days offers an interesting set of
lessons for the president as he plans for the next 100.

I studied epidemic science in some detail for my book The Age of the Unthinkable
because, frankly, we are now living in a petri dish of infectious risk. Here are
the lessons I learned and how they fit with the larger problems the president
now faces.

1. Virus risk is now everywhere—we can't avoid it and live the way we want.

Maybe the most unnerving feature of our age is that the things we rely on to
make life better often also make it more perilous. Airplanes, financial markets,
computer webs—all of these bind us ever closer together and into shared webs of
risk and danger.

Scientists call dangers like these "systemic risks" because they emerge from the
very way in which the system is organized. Any tightly bound network faces
systemic risk, and the more closely a food web or financial web is linked, the
more dangerous it becomes. In fact, in one of those weird quirks of our world,
the more efficient a network is, the more dangerous it is—this is why financial
markets are so efficient at blowing themselves up. Perturbations in linked nets
spread with astonishing speed; crises in one area (think the subprime crisis)
quickly turn into challenges in another (U.S.-China relations). The lesson:
Obama has to begin to think and speak in terms of how he is preparing all of us
for flu attacks of all kinds: financial, ideological and biological.

2. Think like an epidemiologist, not a politician.

Confronted with big challenges—economic crises, health disasters—the instinct of
most politicians is to hack problems to pieces and then tackle them bit by bit
with targeted legislation or departments or high-level envoys. But in an
interconnected world, that's not enough. Every problem is linked to every other
problem so our solutions need to be broad-based and aim not only at the
particular problem (like bad lending practices), but also at the way these
problems effect everything else. And that offers a crucial lesson for Obama:
Systemic risk means that simply tackling the parts of a challenge—no matter how
brilliantly you do so—can never be enough. In foreign-policy terms, this
systemic sense is called a "Grand Strategy," and it's the thing most obviously
missing from this very active presidency at the 100-day mark.

3. Even the best doctors can't stop a pandemic alone.

What the president has built so far is an administration that looks like a
health-care system filled only with great doctors but without a plan for public
health. Today there is no unifying principle that backs the work of aggressive
diplomats like Richard Holbrooke or smart operational Cabinet members like Janet
Napolitano. In an age of unthinkable pandemic risk, that's a dangerous problem.

Without a grand strategy, the ambitions of Obama's Team of Rivals risk slipping
into incoherent political struggle. And a big strategy hole like the one we have
now encourages our enemies to mistake Obama's valuable openness for
indecisiveness. Worse, it makes it hard to progress in complex areas such as
nuclear proliferation or trade and environment talks because we'll never have a
real plan for where to compromise and where to stand firm. And worst of all,
we'll be poorly prepared for other pandemic surprises that lie ahead.

4. The next 100 days: Build us an immune system.

What Obama needs to deliver now isn't a grand strategy in the old-school style
of the Monroe Doctrine, but rather one that looks like a global immune system:
fast-moving, capable of quickly working across traditional lines to confront
problems, flexible, and with power and responsibility widely distributed. Many
of our enemies have such an immune system. For my book, I spent time with
Hezbollah. Their resilience in the face of Israeli attack is famous.

Building an immune system for the United States would be a political boost to
Obama, helping to reinforce ideas he holds most strongly. Epidemic theory—which
studies everything from runs on banks to forest fires—teaches that it's vital to
focus on the weakest, most vulnerable links in a networked system, a lesson that
supports Obama's actions on poverty and on narrowing the rich-poor gap. Another
epidemic-crisis principle is the importance of resilience, of the ability of a
system to withstand challenge and get stronger—an idea that transforms Obama's
focus on infrastructure, education, and health care from "nice to have" reforms
into urgent priorities. An immune system grand strategy would also help end the
debate about if Obama is "doing too much." Confronted with the potential of more
destabilizing infections, we can never "do too much" to boost our immunity.

Foreign-policy types often like to joke that "Democrats don't do grand
strategy." But in a moment of global viral crisis, that's like saying "doctors
don't do public health." Ultimately this is work only the president can do, a
task that involves at once transcending the tactical minds around him and
uniting them in common purpose. The simultaneous arrival of swine flu and the
100 days may turn out to offer a fortunate reminder to the White House: In an
age of viral dangers, no medicine is of any use without a clear plan for our
long-term health. Obama can learn from the swine flu—and if he wants to succeed,
he must.

Joshua Cooper Ramo is managing director and a partner at Kissinger Associates,
one of the world's leading strategic-advisory firms. Prior to joining Kissinger
Associates, he was assistant managing editor of Time and worked in the advisory
and banking business in China.

http://www.thedailybeast.com/blogs-and-stories/2009-04-28/the-age-of-the-unthink\
able-swine-flu-and-the-100-days
---------------------------

Excerpt: The Age Of The Unthinkable by Joshua Cooper Ramo
NPR.org, March 23, 2009
http://www.npr.org/templates/story/story.php?storyId=102064994

You probably didn't need to hear it from Greenspan to have a sense of the
confused navigation of our leaders. How can the president of the United States
declare a war won just as it becomes more violent? Why are Russian bombers
flying off American coasts again? How did China, a country with an average daily
income of $7 per person, amass nearly $2 trillion in U.S. debt in less than a
decade? How is it that the secretary of the treasury of the United States, a
near- billionaire financier, can say that the worst of a crisis is over in May
and then find himself in August furiously battling to save the global financial
system? Why is it we can agree on an immense collection of problems, such as
global warming or the spread of nuclear weapons, that must be solved now — and
then make no real progress or only move backward?

http://www.npr.org/templates/story/story.php?storyId=102064994
http://www.salvationscience.com/v225.htm
**************************************************************

#1425 From: "salvationscience" <salvationscience@...>
Date: Thu May 14, 2009 6:34 pm
Subject: SHIVAMBU CHIKITSA (MANAV MOOTRA) IN THE WEST
salvationsci...
Offline Offline
Send Email Send Email
 
SHIVAMBU CHIKITSA (MANAV MOOTRA) IN THE WEST
RE: THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
IN BEAUTIFUL GUADALAJARA, MEXICO! !HAY JALISCO!
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.paraisodelasalud.org
http://www.salvationscience.com

I recently posted the message you see below, having forgotten to proof-read it,
so it had a lot of mistakes. This is the now-corrected version of that article.
There is no Rasa Tantra Sadhana, without first practicing Urine Therapy for many
years. Therefore, in the Damar Tantra, Siva included the chapter on Shivambu
Chikitsa, entitled, "The Shivambu Kalpa Vidhi".

When prejudice bagan against this practice, it went underground, and still can
be found in the enigmatic parables of Our Lord Jesus Christ (or that incarnation
of our eternal Lord Sivaji). As the public became more hostile to the True
Sanatana Dharma, it went deeper underground. Finally, the secret itself was
lost. Now the only secret is: They they forgot what the secret was!
Jai Om. - Sw. Tantrasangha

THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
IN BEAUTIFUL GUADALAJARA, MEXICO!
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.paraisodelasalud.org
http://www.salvationscience.com

Please forgive the many errors in spelling and grammar here. As you know, the
first language of Mexico is Spanish. Obviously, Sra. Rodriguez is trying to
translate what she wants to say, so that you and others may benefit, thereby,
from this highly efficaceous free therapy, freely and easily available to all.
But greed and timidity get in the way.

And let us never forget that the best cure is also a "preventative medicine" to
keep you in good health. Nature's own Naturopathy is far superior to man's
artificial chemicals and the whole greedy patent process, which gave rise to
such medical menace madness. Priests, politicians and physicians profit more
from their own failures.

Like Jesus said: "I have come that ye may have Life and have it more
abundantly." That means He would Save you from suffering by Way of a Longer,
Happier Life. Jesus once cured a man, then told him: "Your sins are forgiven".
They asked Him how He could forgive another man's sins. Jesus asked: "Is he not
now cured of his disease?"

When you no longer pay the dues, you know longer owe the debt. Try to see the
concepts which words only represent, for, if you don't, there will be only words
without meaning - what Jesus called "the letter of the Law without the Spirit of
the Law". You must know the meanings of words, define things, specifically, etc.
No vagaries.

Martin Luther King Jr. looked forward to the day when: "Men will be judged not
by the color of their skin but by the content of their character". For now, good
theological character only makes Americans mad. You are expected to be a moral
coward and to conform to an erroneous theological norm. Your moral courage only
makes cowards jealous.

Your Righteousness is measured by your Honesty, Intelligence, and Compassion.
These attributes cause you to care about the moral issues of good and bad, right
and wrong, and true and false. Those who don't care about doing the right thing,
are already wrong. Moral cowardice is the root cause of this hell on earth.

For now, Righteousness means about as much to Americans as it does to a pig.
That is why Americans "quarantined the cure" and have promoted a shorter, more
miserable life, instead of what our beloved Lord Jesus Christ intended. We fight
for life, while our enemies fight for death. The devil has chosen to oppose us.

It's all because the devil despises the good, and, psychologically, is a
"suicidal crime waiting to happen", as is anybody preferring harm over help.
That Dark Daze would be, in effect, a Mass Murder-Suicide. What terrorism
isworse than the one who would force you to "bite the bullet" of erroneous
theology which saves not?
Jai Om. - Sw. Tantrasangha
--------------------------

WORLD INFORMATION ABOUT UROTHERAPY

ALL HUMAN BEINGS HAVE DRUNK THERE OWN URINE IN THE WOMB
OF THEIR OWN BLESSED MOTHER. IT IS OUR PRIMORDIAL FOOD.

In the natural biological heaven of the human reproduction, inside the maternal
womb while the formation of our body took place. The first step was the
formation of mother cells, the heart, brain, kidneys, bones, basic organs, nerve
cells that receives and transmit, and, above all, the coordination between
sensorial organs and the incredible balance of genetic information, biochemist,
cell reproduction, and the bio-energetic stimulant. Inside the maternal womb, we
are in complete peace and harmony preparing ourselves to come out to a new life
in the exterior.

The man's perfect time on earth is during the gestation period.
The Urotherapy is literally a gift from God, it is part of nature.
There is no human on earth that has not taken his or her own urine, we are born
inside a womb and after six weeks, he or she will start urinating a few drops
into the amniotic liquid, that is water and his or her own urine!

Through the umbilical cord, the baby receives from the mother special nutrients
as immunoglobulin, vitamins, but most of all oxygen.

When the baby reaches the age of 5 months, they urinate from 400 to 500 ml. Each
day inside the amniotic sac, and between 8 to 9 months the baby urinates 20 to
30 times every 24 hours.

98% of the composition of the Urine is water. Therefore, 1% is elements - are
cells and filaments, and the other 1% is more than 1000 healing chemical
substances in form of ions. Powerful substances found in milligrams, that carry
the genetic information of what works well or not in the body. When you take
your own urine, you take an auto vaccine.

In other words Urotherapy is part of be beginning of life and we believe that we
grow up with nature. It is a wonderful cycle of life that should never be
interrupted.

Who can live without water?…………Nobody
For that reason the water is an element ....SACRED
Who can live without air ?.................Nobody
For that reason the air is an element…SACRED
Who can live without the sun.................Nobody
For that reason the sun is an element…SACRED
Who can live (prenatally) without taking the urine inside the
mother?...........................Nobody
For that reason the urine is an element…SACRED.

HISTORY OF THE UROTHERAPY

Etiologically speaking Urotherapy means: Treatment utilizing our own urine . The
word URO comes from the Greek that means urine and Therapy means treatment. The
Urotherapy has always existed, is the oldest therapy of humanity and one of the
first therapies created by God, it is older than Chinese Medicine. One of the
oldest therapies utilized by man and applied with wisdom by mystics and
intuition.

Urotherapy was born in all Countries at the same time. In the Old Testament it
is mentioned in Proverbs chapter 5 versus 15 thru 18th. These remedies are
written in the oldest written book known as The "Gootour Schastar"(?) from 6000
years B.C.(!), with recopies, medications, treatments based on drinking or
applying his or her urine.

THE UROTHERAPY has always existed, it is a method commonly known as Urine
Therapy to different cultures long times past such as the
Egyptian pharaohs, Tibet Lamas, Greeks and Romans. In Mexico, the Native Indians
also had valued information and knowledge in regards to this type of therapy. In
the European Continent, they also have stories of Greek Doctors that utilized
the Urine for healing wounds.

In the book No. 28 of the encyclopedia's NATURALIS HISTORY, (Natural History) of
the Roman writer, C. Plinius Secundus writes about the treatment with urine in
wounds for dog bites and snakes, as well as venomous spiders, skin diseases,
along with eye infections, burns and scars.*

* The Historie of the World, Commonly called,
THE NATURALL HISTORIE OF C. PLINIUS SECUNDUS.
Translated into English by PHILEMON HOLLAND
Doctor in Physic, 1601

Orient as well as Occident were familiar with this treatment.

INDIA HAS A SACRED BOOK

That has existed more than 500 years from the past, and it is called Damar
Tantra, with a chapter about the Shivambu Kalpa (therapy of auto-urine). Hindu
version from before Christ were written in Sanskrit. It is a description of the
therapeutic systems by utilizing the Urine Therapy directed by the god Shiva to
the goddess Parvati. Where the god Shiva describes its benefits to his wife
Parvati in this precious book that has a very interesting content of 108 verses
that speaks about what happens to the human body through the years when you
practice the Urinetherapy.

The Damar Tantra* states: "He whoever continues with this practice for twelve
years will live as much as the moon and the stars and there is no danger with
animals like serpents, because no poison can kill you. Your body will be
liberated from aging and its destruction, and you will have the strength of
10,000 elephants and will free the body of all illnesses."*

* The Shivambu Kalpa Vidhi from the Damar Tantra, is found several times in The
Tantrayudha of Salvation Science.

IN MANY COUNTRIES OF THE AMERICAN CONTINENT

As in Argentina, Peru, the natives from the mountains Serrano Andina, Mapuches
in Chile and other communities of the Trahumaras in México, along with areas in
U.S.A. continue to practice this therapy to this days.

Nowadays in Mexico, there are valued verbal and written testimonies from people
that had recommended this treatment for burns, such as soldiers during war time
that had burns due to the gunpowder, so they applied their own urine to
alleviate the pain. The NASA Astronauts and survivors from disasters such as
earthquakes and shipwrecks, have saved their lives in these types cases of
emergency by drinking their own urine.

For stomach aches, wounds, along with bites from venomous animals or insects,
grandmothers have recommended putting baby diapers on skin for the spots, and we
have two books from the year's 1514 and 1552 that stated that native Indians
used their urine for healings. The
first book is called:

CODIGO BADIANO

In México, Martin de la Cruz, Aztec physician in 1552, in the
Badiano Code, makes specific references to the urine treatment.

En la curación de heridas en la cabeza se usaban: orina (URINE) –para lavarla–,
matlaxíhuitl. The Aztecs used to call the urine  "huitztly", they used it for
the treatment of spiders and serpent's bites, as well as any other poisonous
animal or insect, along with other uses for the urine treatments.

For hemorrhages, they applied urine with maguey secretion, also in treatment for
scars. - Florentin Code, lib. X, f. 113r.

NEW SPAIN GENERAL HISTORY OF THINGS
("HISTORIA GENERAL DE LAS COSAS DE NUEVA ESPANA")
BY PADRE BERNARDINO DE SAHAGUN, 1514)

Written by Fray Bernardino de Sahagún in the year 1514. He is one of the Priests
that came with Hernán Cortes to México and learned from the Native Indians whom
used the Urine therapy from pages 585, 585, 587, 593, 594 Cáp. XXVIII and
states:

For the pain of the "horquilla" that usually starts in the hair, the best way is
to cut the hair as short as possible and scrape it well, along with washing it
with urine, then apply a plant called
"Nanacae", to remove the herb it needs to be washed with urine.

When you cut the hair it needs to be washed with urine.…to combat dandruff cut
the hair very short and then wash it with urine.

For the illness of "postilla" and "sarna" that normally starts in the head area,
you must use the same remedy as before adding these add ional healing agents….
following washing with urine the head area apply the avocado seed's grounded up.
Etc. Etc.

In this Century, many people have come to know this wonderful secret. Hospitals
in the Unites States and Europe actually are creating several medications with
the urine, along with Pharmaceutical Industries that are purchasing the urine of
several people to manufacture medications, cosmetics, as well as dental
toothpaste.

Carmen Thomas, a German reporter states that some pharmaceutical firms have
united to the "Shangay" movement. The urine is recollected in public latrines,
and is sold to companies that manufacture medications by extracting the
Urokinase, and then they export it. - (Published in the Newspaper "El Diario"
dated 26th of April of 1996. InGuadalajara, Jalisco. México).

In 1971 in the University of Medicine of Kyoto Japan, it was discovered that the
antibodies in the urine, such as "interokin", "renina" and "prostaglandin", are
important hormones used to combat infections or malign tumors.

In the Unites States, a scientific team from Harvard University discovered
several hormones from the Urine that are called "S.P.U". and "interferón", which
are being released during the sleep time and re-utilized as antibodies,
anticoagulant for circulatory problems, and they act as pain relief and a
stimulant for the hormones. The melatonin is a substance that helps with memory,
as well as other substances. The Urotherapy helps to improve the immunological
system, which, as a result, brings on cures of many illnesses.

In 1992 Hayashibara Institute of Chemistry in Japan, discovered, during a formal
study investigation, that urine had many important substances for our health
such as the one called, "Interferon" that has analgesic effects and is a natural
antibody.
----------------------

THE SCIENTIFIC PRINCIPAL OF THE UROTHERAPY

One's antibodies are in one's blood. For the patient that has a
determinate disease, at the same time you may find specific antigen in the urine
(sinnce urine is a blood derivative). The antigen (the biochemical immune
response to the antigen) is that which the patient eliminates in his urine. It
is a non-toxic protein, produced by the body itself. When a daily intake of this
urine is taken, the immune system of the body reacts and "learns" to combat the
external agents, along with this it is very efficient in the elimination of
cancer cells.

THE UROTHERAPY IS AN AUTO-VACCINE THAT ACTS AS INMUNO-MODULAR -
VERY SPECIFIC AND PERSONAL.

The Urinary Antigen in the urine of the patient, being a natural protein that
the body eliminates, has no risk or side effects and can be taken in combination
with other natural resources, allowing us to diminish slowly the
inmunosupressors and chemotherapy medications required (in modern Allopathic
medicine).

We have the ability to create our own vaccine by all the micro-organisms that
infect our systems, and form toxins and endotoxins (antigens), and stimulate our
immunologic system to form antitoxins (antidotes, antibodies), which are
discarded thru the urine, and
when we take it back inside us, we force the bacteria to take their own toxins,
that is why we say "poison kills poison" (the basic Law of Innoculation, first
mentioned in the Srimad Bahagavatam, Canto I, when Krishna states that the same
thing that causes a disease, can be used to cure it. Better yet, as an
innoculation, it can prevent the disease from happening.)

The Urotherapy is an auto-vaccine that has the same elements of our own illness;
it has an antiviral action, antineoplastic, antispasmodic, diuretic,
antiallergenic, anticonvulsive, and cardiovascular stimulant, anti-
inflammatory, bactericidal and antifungal as well.

UROTHERAPY AND ITS BIOCHEMICAL ACTION IN CANCER

Immunologic system, stimulated to cellular and humoral (bioplasma?) level.
Blocks the reproduction of tumor cells.
Breaks the tumor's protection because the urine has specific "antigens".
Diminishes the release of toxic substances, promoting its elimination by
reducing the free radicals.
Diminishes the damage from Chemotherapy and Radiation Therapy,
by increasing the cells' defense.
Increases the (efficacy of the) immune system.
Has an Inmunomodular function.
Promotes changes in the Psychobioenergetic equilibrium of the patient.

THE UROTHERAPY FOR THE TREATMENT OF OTHER ILLNESSES

The Urotherapy has proven to be satisfactory for the treatment of the following
illnesses:
Systematic Lupus Erythematosus
Rheumatic Illness
Poliarteritis Node
Hemolytic Anemia Type Acquired Autoimmune
Malign lymphoma
Chronic Anemia
Immunological Neutropenia
Thrombocytopenic Purple
Uveitis or Coriorentitis
Esclerosis Multiple
Polineuritis Idiopathic
Leukemia mielocitica
Severe Leukemia linfocitic
Thyroid or Hashimoto's illness
Graves' illness
Addison illness
Arthritis Rheumatoid
Espondilitis Anquilosant
Miastenia Gravis
Dermatomiositis
Sclerodermia (sclerosis Progressive systematic
Síndrome Guillen Barre
Síndrome de Sjogren
Colitis Ulcerative
Active Chronic Hepatitis
Primary Cirrosis gallbladder
Glomerulo nefritis by inmune complex
Dermatitis by contact
Eczema A topic
Itching
Psoriasis
Schizoaffective syndrome (one type of the schizophrenia)
Autism
Rinitis Allergic
Asma Bronquitis
Alveolitos
Carcinoembriogenics
Metaplasia scave Tumors
Severe Displacía
Insistu Cáncer
Metastátic Cáncer in bones
Invasive Carcinoma
Metastátic Cáncer
Prostate Cáncer
HIV <AIDS>
Human Papiloma
Pillory Helicobacter
Diabetes

MOTHER CELLS, UROTHERAPY, & EMBRYONIC STEM CELL THERAPY

The mother cells are obtained from two ways: Embryos in the first phase of
development, or the reserves that the adult organism maintains with the purpose
to repair the damage that is done to the tissues. The investigators state that
only the "embryo" cells have the capability to convert into vital organs or any
tissue (plural potentials). An example is the hematopoyetic cells that exist on
the
bone marrow that transform into blood cells, like white, red as well as
plaquets.

After all the application of this transference, techniques from adult
mother cells for the change and repair of the damaged tissues (Embryonic Stem
Cell Therapy) is yet too new. In reality, there is a substance of great
importance that we have forgotten: it is the liquid (bioplasma) that surrounds
the cells that also carries the genetic information (and is secreted as Genetic
Efflux) and the biochemical element. The Amniotic liquid also carries specific
substances the fetus drinks that has the genetic information too.

(We drink Genetic Efflux in our own mother's womb, so it is our "Primodial Food
and Medicine". Like the Holy Bible states:
"...The Tree of Life: Its fruit for food and its leaf for medicine." In other
words, Jai Om. - Sw. Tantrasangha)

EMBRYONIC CELLS

These are obtained from the blastocist, in this case the embryo is a mass of 150
cells with a ball shape. Some of these cells form the sphere that is inside
liquid, which has the cellular mass, a group of mother cells, these cells are
pluripotential. In other words they can create any body tissue, which is why it
has a great therapeutic potential. After the eight week, the fetus will urinate
inside the sac and is part of the amniotic liquid that carries all the genetic
information that is recycled and comes out with new information.

• THE SCIENTIFIC PRINCIPLE OF THE UROTHERAPY (Immunal, hormonal, enzymztic, Urea
as a protein substitute, etc.)

• THE MYSTIC PRINCIPLE OF THE UROTHERAPY (As in its marital application, which
we call Rasa Tantra.)

• THE HOMEOPATHIC PRINCIPLE OF THE UROTHERAPY (Once again pertaining to the
Immune Principle that "like fights like". In other words, urine contains
antigens and antibodies which bolster immunity to those very same microbes. The
Srimad Bhagavatam, Canto I, states:
"Is it not true that by taking into the body the same thing which made it sick,
the disease is thereby cured?" This is the Law of Innoculation: By giving you a
weakened or similar microbe, you will then be able to fend it off when it is
more virulent.
Jai Om. -  Sw. Tantrasangha.)

www.paraisodelasalud.org
SONIA RODRIGUEZ, BIOCHEMIST, RE: FASTING WITH URINE

FASTING IS IMPORTANT

The fasting is a very important task since the urine intake produces acidosis in
the organism that reflects a movement of the defense mechanisms that neutralize
the toxins and repair the cells.

http://www.paraisodelasalud.org
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.salvationscience.com
**************************************************************

#1424 From: mikebello2351@...
Date: Wed May 13, 2009 4:33 pm
Subject: Re: Conflicts of interest found in many cancer studies
mikebello2351
Offline Offline
Send Email Send Email
 
#1423 From: "salvationscience" <salvationscience@...>
Date: Wed May 13, 2009 11:54 pm
Subject: RE: THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
salvationsci...
Offline Offline
Send Email Send Email
 
THE 5TH WORLD CONGRESS ON UROTHERAPY, NOV. 5-9, 2009
IN BEAUTIFUL GUADALAJARA, MEXICO!
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.paraisodelasalud.org
http://www.salvationscience.com

Please forgive the many errors in spelling and grammar here. As you know, the
first language of Mexico is Spanish. Obviously, Sra. Rodriguez is  trying to
translate what she wants to say, so that you and others may benefit, thereby,
from this highly efficaceous free therapy, freely and easily available to all.
But greed and timidity get in the way.

And let us never forget that the best cure is also a "preventative medicine" to
keep you in good health. Nature's own Naturopathy is far superior to man's
artificial chemicals and the whole greedy patent process, which gave rise to
such medical menace madness. Priests, politicians and physicians profit more
from their own failures.

Like Jesus said: "I have come that ye may have Life and have it more
abundantly." That means He would Save you from suffering by Way of a Longer,
Happier Life. Jesus once cured a man, then told him: "Your sins are forgiven".
They asked Him how He could forgive another man's sins. Jesus asked: "Is he not
now cured of his disease?"

When you no longer pay the dues, you know longer owe the debt. Try to see the
concepts which words only represent, for, if you don't, there will be only words
without meaning - what Jesus called "the letter of the Law without the Spirit of
the Law". You must know the meanings of words, define things, specifically, etc.
No vagaries.

Martin Luther King Jr. looked forward to the day when: "Men will be judged not
by the color of their skin but by the content of their character". For now, good
theological character only makes Americans mad. You are expected to be a moral
coward and to conform to an erroneous theological norm. Your moral courage only
makes cowards jealous.

Your Righteousness is measured by your Honesty, Intelligence, and Compassion.
These attributes cause you to care about the moral issues of good and bad, right
and wrong, and true and false. Those who don't care about doing the right thing,
are already wrong. Moral cowardice is the root cause of this hell on earth.

For now, Righteousness means about as much to Americans as it does to a pig.
That is why Americans "quarantined the cure" and have promoted a shorter, more
miserable life, instead of what our beloved Lord Jesus Christ intended. We fight
for life, while our enemies fight for death. The devil has chosen to oppose us.

It's all because the devil despises the good, and, psychologically, is a
"suicidal crime waiting to happen", as is anybody preferring harm over help.
That Dark Daze would be, in effect, a Mass Murder-Suicide. What terrorism is
worse than the one who would force you to "bite the bullet" of erroneous
theology?
Jai Om. - Sw. Tantrasangha
--------------------------

WORLD INFORMATION ABOUT UROTHERAPY

ALL HUMAN BEINGS HAVE DRUNK THERE OWN URINE IN THE WOMB
OF THEIR OWN BLESSED MOTHER. IT IS OUR PRIMORDIAL FOOD.

In the natural biological heaven of the human reproduction, inside the maternal
womb while the formation of our body took place. The first step was the
formation of mother cells, the heart, brain, kidneys, bones, basic organs, nerve
cells that receives and transmit, and above all the coordination between
sensorial organs and the incredible balance of genetic information, biochemist,
cell reproduction, and the bio-energetic stimulant. Inside the maternal womb, we
are in complete peace and harmony preparing ourselves to come out to a new life
in the exterior.

The man's perfect time on earth is during the gestation period.
The Urotherapy is literally a gift from God, it is part of nature.
There is no human on earth that has not taken his or her own urine, we are born
inside a womb and after six weeks, he or she will start urinating a few drops
into the amniotic liquid, that is water and his or her own urine!

Through the umbilical cord, the baby receives from the mother special nutrients
as immunoglobulin, vitamins, but most of all oxygen.

When the baby reaches the age of 5 months, they urinate from 400 to 500 ml. Each
day inside the amniotic sac, and between 8 to 9 months the baby urinates 20 to
30 times every 24 hours.

The 98% of the composition of the Urine is water. Therefore, 1% is elements are
cells and filaments, and the other 1% is more than 1000 healing chemical
substances in form of ions. Powerful substances found in milligrams, that carry
the genetic information of what works well or not in the body. When you take
your own urine, you take an auto vaccine.

In other words Urotherapy is part of be beginning of life and we believe that we
grow up with nature. It is a wonderful cycle of life that should never be
interrupted.

Who can live without water?…………Nobody
For that reason the water is an element ....SACRED
Who can live without air ?.................Nobody
For that reason the air is an element…SACRED
Who can live without the sun.................Nobody
For that reason the son is an element…SACRED
Who can live without taking the urine inside the
mother?………………...........................Nobody
For that reason the urine is an element…SACRED.

HISTORY OF THE UROTHERAPY

Etiologically speaking Urotherapy means: Treatment utilizing our own urine . The
word URO comes from the Greek that means urine and Therapy means treatment. The
Urotherapy has always existed, is the oldest therapy of humanity and one of the
first therapies created by God, it is older than the Chinese Medicine. One of
the oldest therapies utilized by man and applied with wisdom by mystic and
intuition. The Urotherapy was born in all Countries at the same time. In the Old
Testament it is mentioned in Proverbs chapter 5 versus 15 thru 18th. These
remedies are written in the oldest written book known as The "Gootour Schastar"
from 6000 years B.C., with recopies, medications, treatments based on drinking
or applying his or her urine. THE UROTHERAPY has always existed, it is a method
commonly known as Urinetherapy to different cultures long times past such as the
Egyptian ferrous, Tibet Lamas, Greeks and Romans. In Mexico, the Native Indians
also had valued information and knowledge in regards to this type of therapy. In
the European Continent, they also have stories of Greek Doctors that utilized
the Urine for healing wounds. In the book No. 28 of the encyclopedia's NATURALIS
HISTORY, (Natural History) of the Roman writer, C. Plínius Secundus writes about
the treatment with urine in wounds for dog bites and snakes, as well as venomous
spiders, skin diseases, along with eye infections, burns and scars.

The Historie of the World.
Commonly called,
THE NATURALL HISTORIE OF
C. PLINIUS SECUNDUS.
Translated into English by PHILEMON HOLLAND
Doctor in Physic.
1601

Orient as well as Occident were familiar with this treatment.

INDIA HAS A SACRED BOOK

That has existed more than 500 years from the past, and it is called Damar
Tantra, with a chapter about the Shivambu Kalpa (therapy of auto-urine). Hindu
version from before Christ were written in Sanskrit. It is a description of the
therapeutic systems by utilizing the Urinetherapy directed by the god Shiva to
the goddess Parvati. Where the god Shiva describes its benefits to his wife
Parvati of this precious book that has a very interesting content of 107 verses
that speaks about what happens to the human body through the years when you
practice the Urinetherapy.

And states in the book… "He whoever continues with this practice for twelve
years will live as much as the moon and the stars and there is no danger with
animals like serpents, because no poison can kill you. Your body will be
liberated from aging and its destruction, and you will have the strength of
10,000 elephants and will free the body of all illnesses."

IN MANY COUNTRIES OF THE AMERICAN CONTINENT

As in Argentina, Peru, the natives from the mountains Serrano Andina, Mapuches
in Chile and other communities of the Trahumaras in México, along with areas in
U.S.A. continue to practice this therapy to this days.

Now days in Mexico exist a valued verbal and written testimonies from people
that had recommended this treatment for burns, such as soldiers during war time
that had burns due to the gunpowder, so they applied their own urine to
alleviate the pain. The NASA Astronauts and survivors from disasters such as
earthquakes and shipwrecks, have saved their lives in these types cases of
emergency by drinking their own urine. For stomach aches, wounds, along with
bites from venomous animals or insects, grandmothers have recommended putting
baby diapers on skin for the spots, and we have two books from the year's 1514
and 1552 that stated that native Indians used there urine for healings. The
first book is called:

CODIGO BADIANO

In México, Martin de la Cruz Aztec physician from the XVl Century in 1552 in the
Badiano Code makes specific references to the urine treatment.

En la curación de heridas en la cabeza se usaban: orina –para lavarla–,
matlaxíhuitl –The Aztecs used to call the urine as… huitztly, they used it for
the treatment of spiders and serpent's bites, as well as any other poisonous
animal or insect, along with other uses for the urine treatments.

For the hemorrhages, they applied urine with maguey secretion, also in treatment
for scars. Florentin Code, lib. X, f. 113r.

NEW SPAIN GENERAL HISTORY OF THINGS.
("HISTORIA GENERAL DE LAS COSAS DE NUEVA ESPANA"
BY PADRE BERNARDINO DE SAHAGUN, 1514)

Written by Fray Bernardino de Sahagún in the year 1514. He is one of the Priests
that came with Hernán Cortes to México and learned from the Native Indians whom
used the Urine therapy from pages 585, 585, 587, 593, 594 Cáp. XXVIII and
states:

For the pain of the "horquilla" that usually starts in the hair, the best way is
to cut the hair as short as possible and scrape it well, along with washing it
with urine, then apply a plant called "Nanacae", to remove the herb it needs to
be washed with urine.

When you cut the hair it needs to be washed with urine.…to combat dandruff cut
the hair very short and then wash it with urine.

For the illness of "postilla" and "sarna" that normally starts in the head area,
you must use the same remedy as before adding these add ional healing agents….
following washing with urine the head area apply the avocado seed's grounded up.
Etc. Etc.

In this Century, many people have come to know this wonderful secret. Hospitals
in the Unites States and Europe actually are creating several medications with
the urine, along with Pharmaceutical Industries that are purchasing the urine of
several people to manufacture medications, cosmetics as well as dental
toothpaste.

Carmen Thomas, a German reporter states that some pharmaceutical firms have
united to the "Shangay" movement. The urine is recollected in public latrines,
it is sold to companies that manufacture medications by extracting the
Urokinase, and then they export it.

(Published in the Newspaper "El Diario" dated 26th of April of 1996. In
Guadalajara, Jalisco. México).

In 1971 in the University of Medicine of Kyoto Japan, it was discovered that the
antibodies in the urine such as "interokin", "renina" and "prostaglandin", are
important hormones used to combat infections or malign tumors.

In the Unites States, a Scientific team from Harvard University discovered
several hormones from the Urine that are called "S.P.U". and "interferón", which
are being released during the sleep time and re utilized as antibodies,
anticoagulant for circulatory problems, and they act as pain relive and
stimulant for the hormones. The melatonin is substance that helps with memory as
well as other substances. The Urotherapy helps to improve the immunological
system, which as a result brings on cures of many illnesses.

In 1992 Hayashibara Institute of Chemistry in Japan, discovered during a formal
study investigation that urine had many important substances for our health such
as the one called, "Interferon" that has analgesic effects and is a natural
antibody.
----------------------

THE SCIENTIFIC PRINCIPAL OF THE UROTHERAPY

It is the realization of immunologic test of a fix surface, it revels the
simultaneous presence of antibodies in the blood. For the patient that has a
determinate disease, at the same time you may find specific antigen in the
urine. The antigen is that which the patient eliminates in his urine, it is a
protein non-toxic, produced by the body itself. When a daily intake of this
urine is taken, the immune system of the body reacts and "learns" to combat the
external agents, along with this it is very efficient in the elimination of
cancer cells.

THE UROTERAPHY IS AN AUTO-VACCINE THAT ACTS AS INMUNOMODULAR VERY SPECIFIC AND
PERSONAL.

The Antigen Urinary in the urine of the patient, being a natural protein that
the body eliminates, has no risk or side effects and can be taken in combination
with other natural resources, allowing us to diminish slowly the
inmunosupressors and chemotherapy medications required.

We have the ability to create our own vaccine, all the micro-organisms that
infect our systems form toxins and endotoxins, and stimulates our immunologic
system to form antitoxins (antidotes), which are discarded thru the urine and
when we take it we force the bacteria to take their own toxins, that is why we
say "poison kills poison".

The Urotherapy is an auto-vaccine that has the same elements of our own illness;
it has an antiviral action, antineoplastic, antispasmodic, diuretic,
antiallergenic, anticonvulsive, and cardiovascular stimulant, anti inflammatory,
bactericide and antifungal as well.

THE UROTHERAPY AND ITS BIOCHEMIST ACTION IN CANCER

Immunologic system stimulated to cellular and humeral level
Blocks the reproduction of and in tumor cells.
Breaks the tumor's protection because the urine has specific "antigens"
Diminish the release of toxic substances, promoting its elimination by reducing
the free radicals.
Diminish the damage of the Chemotherapy and Radiotherapy by increasing the
cells' defense.
Increase the immune system in this white and red form.
Has an Inmunomodular function.
Promotes changes in the Psychobioenergetic equilibrium of the patient.

THE UROTHERAPY FOR THE TREATMENT OF OTHER ILLNESSES

The Urotherapy has proven to be satisfactory for the treatment of the following
illnesses:
Systematic Lupus Erythematosus
Rheumatic Illness
Poliarteritis Node
Hemolytic Anemia Type Acquired Autoimmune
Malign lymphoma
Chronic Anemia
Immunological Neutropenia
Thrombocytopenic Purple
Uveitis or Coriorentitis
Esclerosis Multiple
Polineuritis Idiopathic
Leukemia mielocitica
Severe Leukemia linfocitic
Thyroid or Hashimoto's illness
Graves' illness
Addison illness
Arthritis Rheumatoid
Espondilitis Anquilosant
Miastenia Gravis
Dermatomiositis
Sclerodermia (sclerosis Progressive systematic
Síndrome Guillen Barre
Síndrome de Sjogren
Colitis Ulcerative
Active Chronic Hepatitis
Primary Cirrosis gallbladder
Glomerulo nefritis by inmune complex
Dermatitis by contact
Eczema A topic
Itching
Psoriasis
Schizoaffective syndrome (one type of the schizophrenia)
Autism
Rinitis Allergic
Asma Bronquitis
Alveolitos
Carcinoembriogenics
Metaplasia scave Tumors
Severe Displacía
Insistu Cáncer
Metastátic Cáncer in bones
Invasive Carcinoma
Metastátic Cáncer
Prostate Cáncer
HIV <AIDS>
Human Papiloma
Pillory Helicobacter
Diabetes

MOTHER CELLS AND UROTHERAPY

The mother cells are obtained from two ways: Embryos in the first phase of
development, or the reserves that the adult organism maintains with the purpose
to repair the damage that is done to the tissues. The investigators state that
only the "embryo" cells have the capability to convert into vital organs or any
tissue (pluralpotencials). An example is the hematopoyetic that exist on the
bone marrow that transform into blood cells, like white, red as well as
plaquets. After all the application of this transference, techniques from adult
mother cells for the change and repair if the damage tissues are yet too new. In
reality, there is a substance of great importance that we have forgotten: it is
the liquid that surrounds the cells that also carry the genetic information and
biochemic element. Until today there is a general, belief that these mother
cells are limited to generate only specialized cells. The Amniotic liquid also
carries specific substances drunken by the fetus that has the genetic
information too.

EMBRYONIC DEVELOPMENT

The Cigot that is formed right after the fecundation between an egg and sperm
they are cells capable to form a complete individual, it is a cell totiponent,
capable of reproduce a human with all the tissues. Between the day's one and
four of the development, the original cell will divide itself into several more.
Each one of these cells is separated from the rest as totitoponet cells that we
mentioned before. After the fourth day, the bastocit is formed and is made of
two cells with a big interior cavity. The external shell forms the placenta and
the embryon's cover; it is the trobobast and the cell's mass that will form all
the human tissues, which is called embryoblast.

EMBRYONIC CELLS

These are obtained from the blastocit, in this case the embryo is a mass of 150
cells with a ball shape. Some of these cells form the sphere that is inside
liquid, which has the cellular mass, a group of mother cells, these cells are
pluripotential, in other words they can create any body tissue, which is why it
has a great therapeutic potential. After the eight week, the fetus will urinate
inside the sac and is part of the amniotic liquid that carries all the genetic
information that is recycled and comes out with new information.

• THE SCIENTIFIC PRINCIPLE OF THE UROTHERAPY (Immunal, hormonal, enzymztic, Urea
as a protein substitute, etc.)
• THE MYSTIC PRINCIPLE OF THE UROTHERAPY (As in its marital application, which
we call Rasa Tantra.)
• THE HOMEOPATHIC PRINCIPLE OF THE UROTHERAPY (Once again pertaining to the
Immune Principle that "like fights like". In other words, urine contains
antigens and antibodies which bolster immunity to those very same microbes. The
Srimad Bhagavatam, Canto I, states:
"Is it not true that by taking into the body the same thing which made it sick,
the disease is thereby cured?" This is the Law of Innoculation: By giving you a
weakened or similar microbe, you will then be able to fend it off when it is
more virulent. This short comment is by Sw. Tantrasangha.)

www.paraisodelasalud.org
SONIA RODRIGUEZ, BIOCHEMIST, RE: FASTING WITH URINE

FASTING IS IMPORTANT

The fasting is a very important task since the urine intake produces acidosis in
the organism that reflects a movement of the defense mechanisms that neutralize
the toxins and repair the cells.

http://www.paraisodelasalud.org
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.salvationscience.com
**************************************************************

#1421 From: "ipzumeus" <ipzumeus@...>
Date: Tue May 12, 2009 7:36 pm
Subject: UROPHAGIANS / Urine Drinkers ~ Those who enjoy drinking urine!
ipzumeus
Offline Offline
Send Email Send Email
 
UROPHAGIANS / Urine Drinkers ~ Those who enjoy drinking urine for rejuvenation,
refreshment, stimulation, enlightment. ~ Join -Up!

UROPHAGIANS / Urine Drinkers Yahoo! Group
http://groups.yahoo.com/group/Urophagians

#1420 From: "salvationscience" <salvationscience@...>
Date: Sat Apr 18, 2009 6:22 pm
Subject: A THEORETICAL ANALYSIS OF THE POSSIBILITIES OF RASA TANTRA
salvationsci...
Offline Offline
Send Email Send Email
 
A THEORETICAL ANALYSIS OF THE POSSIBILITIES OF RASA TANTRA
HOW RASA TANTRA MIGHT SAVE US FROM SUFFERING
A HYPOTHETICAL LIST OF HOW RASA TANTRA MIGHT HELP US
http://www.salvationscience.com

There are eight general classifications of suffering. I shall list
them, along with how Urine Tantra might alleviate each suffering:

1. Hunger (and thirst). We already know that there is water,
calories and nutrition in one's Genetic Efflux, of which urine is
the main component. We have recorded the lives of many Breatharians.
My own Paramguruji spoke of advancing to the stage in which urine
and water would be his only food. In India, this was known
as "living entirely on Prana", which (Prana) we interpret to be
Genetic Efflux - not air, but air (or Oxygen) would obviously be the
only other ingredient for survival.

2. Disease (and Physical Pain). We have published the many Urine
Therapy case histories and testimonials, in which a host of diseases
were miraculously cured, in a manner no other kind of fasting can
equal. We postulate that Urine Tantra (Urine Therapy for two,in a
heterosexual "Merge Supper") might have the same efficacy (or even
more, because of the joining of male and female DNA) than Urine
Therapy, which one practices on one's self.

3. Senescence (the "Universal Disease" of degeneration from aging,
caused by Intrinsic Mutagenesis). To overcome this physical
degradation, one would have to be Rejuvenated Genetically. Since a
host of chronic diseases are the byproducts of aging, we postulate
that such Genetic Rejuvenation (the Rebirth of a New Genome, as in
Meiosis), would be as efficaceous as "solo" Urine Therapy, which
acts mainly on one's Immune System. Physical Immortality cannot be
had by Urine Therapy. Rasa (Bioplasma) Tantra is the only
Experimental Protocol for such a possibility.

4. Death (but not as in accidental death, in which the body is
damaged beyond "mind-over-matter" repair, as demonstrated by
the "miracle" cures, performed by Our Beloved Lord Jesus Christ).
Overcoming one's senescence, is the Way to Physical Immortality.

5. Low Mental Intelligence. I.Q. is very much related to the
condition of the body. Because of their more Androgynous DNA (more
than the sexually separate DNA of old people), children learn much
quicker than adults. Most notably, children can learn many languages
without effort, but old folks cannot, even after strenuous study.
Once again, this is related to the Youth Factor within the DNA
Genome, and the only known possible Way to change one's DNA Genome
is Rasa Tantra.

6. Emotional Depression. This is also more genetically related than
we imagine. The degeneration and pain from aging, and the many
lifestyle and social changes involved, are a real "bummer". Like
Mick Jagger sang: "It is a drag growing old". The homeliness of
senescence, restricts our pleasurable sexual encounters, which is
the very Sexual Repression Freud called the main cause of neuroses.
Health and Youth are two main keys to happiness.

7. Spiritual Entrapment of one's Spirit-Soul Consciousness within
the physical dimension. As scripture saith: We must first be (Re)
Born of water, before we can attain Holy Spirit "Fire". In the east,
our Yoga Shastra states: Prana (Bioplasma) must be in Shushumna Nadi
(the Central Channel or "river"), before Kundalini Shakti can rise
up the spine and exit, either from the third eye or the top of the
head.

8. The Impermanence of a near-endless round (Samsara) of many
painful appearances in various bodies and dimensions. The one thing
most of us never imagined, is that a Permanent State of Bliss might
be more easily attained not in the Spirit without a body, but in the
Immortal Body with the Holy Spirit. To that end... Jai Om. - Sw.
Tantrasangha

THE HOLY TRINITY AS MALE, FEMALE & THE "CHILD" OF HOLY SPIRIT

RADHAKRISHNA RASAMISHRA (TWO BIOPLASMAS AS ONE)
SIVASAKTI ADVAITAMRITA (TWO BIOPLASMAS AS ONE)
ADAM & EVE AS ONE FLESH (TWO BIOPLASMAS AS ONE)
YINYANG UNION AS ZYGOTE (TWO BIOPLASMAS AS ONE)
BLOOD BETWEEN THE 2 LINTELS (TWO BIOPLASMAS AS ONE)
PRAJNAUPAYA CROSS-BREATHING VAJRATANTRA (TWO BIOPLASMAS AS ONE)
BETWEEN 2 WATERS IN THE RED SEA (TWO BIOPLASMAS AS ONE)
SHUSHUMNA NADI RIVER CONFLUENCE (TWO BIOPLASMAS AS ONE)
MEDICINE BUDDHA'S MIDDLE PATH (TWO BIOPLASMAS AS ONE)
THE GNOSTIC HOLY TRINITY (TWO BIOPLASMAS AS ONE)
ECKONKAR SAT NAM (TWO BIOPLASMAS AS ONE)
VARANASI TRIVENI (TWO BIOPLASMAS AS ONE)
QUOTATIONS OF CHAIRMAN TAO (TWO BIOPLASMAS AS ONE)
PASSOVER LAMB BLOOD AT-ONE-MENT (TWO BIOPLASMAS AS ONE)
MARRIAGE SUPPER OF THE LAMB OF GOD (TWO BIOPLASMAS AS ONE)
OM IS LINGUM & YONI JOINED IN WATER (TWO BIOPLASMAS AS ONE)
Jai Om. - Sw. Tantrasangha

http://www.salvationscience.com/v224.htm
************************************************************

#1419 From: "salvationscience" <salvationscience@...>
Date: Tue Apr 14, 2009 9:43 pm
Subject: YOGA TATTVA UPANISHAD: VAJROLI BESTOWS SIDDHIS & IMMORTALITY
salvationsci...
Offline Offline
Send Email Send Email
 
YOGA TATTVA UPANISHAD: VAJROLI BESTOWS SIDDHIS & IMMORTALITY
Yoga Tattva Upanishad translated by K. Narayanasvami Aiyar
Abridged, with Tantric commentaries by Swami Tantrasangha
http://www.celextel.org/108upanishads/yogatattva.html

It is quite obvious that the unique terminology, concepts and yoga techniques
found in the Nath Yoga Sastra, originated around a thousand years before in the
Upanishads. The Vedas are mostly concerned with Soma Pavamana, which is Genetic
Efflux, and with Agni (Fire), which is Kundalini Shakti or Holy Spirit. They
have only a passing reference to the fact that this is to be practiced by a
Tantric man and woman. They try to both reveal and hide the secret.

As we have noted so many times before, Alternate Nostril Breathing is a symbolic
allegory for the "Cross-Breathing" of Prana or Genetic Efflux between a man and
woman, in the practice of Rasa Tantra. Kumbhaka or "Cessation of Breath" is the
practice of restricting the intake of any fluids except for the Genetic Efflux
of one's spouse. Khechari Mudra is an unproven doctrine, if taken literally and
practiced that way, which is widely taught today.

If taken symbolically, it describes the stimulation of a woman's clitoris with
the man's tongue, in order to drink her ejaculation or climax of semen. If one
takes Khechari Mudra literally, he must cut the phrenum muscle underneath the
tongue, which is quite painful. I have never met anybody who has had any success
with this erroneous literal misinterpretation of the allegorical explicative for
Rasa Tantra Sadhana. Jai Om. - Sw. Tantrasangha
------------------

Yoga Tattva Upanishad translated by K. Narayanasvami Aiyar

41-44. Drawing the air through the left nostril for about sixteen Matras and
having retained it (within) for about sixty-four Matras, one should expel it
again through the right nostril for about thirty-two Matras. Again fill the
right nostril as before (and continue the rest). Practise cessation of breath
four times daily (viz.,) at sunrise, noon, sunset and midnight, till eighty
(times are reached). By a continual practice for about three months, the
purification of the Nadis takes place. When the Nadis have become purified,
certain external signs appear on the body of the Yogin.

(The Principle Nadis are the Gnostic Trinity of man, woman, and Child or
Rebirth, depending on if their sexual encounters are Tantric or mere
fornication. Fornication Engenders a Birth of a child, and Tantra Re-Engenders
the Rebirth of the Tantric couple. When speaking of many Nadis, it imples one's
own bioplasma, and eventually one's Genome or Genetic Code.)

45-46(a). I shall proceed to describe them. (They are) lightness of the body,
brilliancy of complexion, increase of the gastric fire, leanness of the body and
along with these, absence of restlessness in the body.

46(b)-49. The proficient in Yoga should abandon the food detrimental to the
practice of Yoga. He should give up salt, mustard; things sour, hot, pungent, or
bitter vegetables... During the early stages of practice, food of milk and ghee
is ordained; also food consisting of wheat, green pulse and red rice are said to
favour the progress. Then he will be able to retain his breath as long as he
likes.

(The eating of wheat and rice indicates that the original author was unaware
that one must fast on liquids only, and even then, only to stave off starvation.
"Retaining the breath" means to recycle all Genetic Efflux, so that there is no
apana or outflow of these five fluids: male and female urine, male and female
semen, milk of Shakti Ma, male and female saliva, and female menstruum. Like
Jesus said in the Nag Hammadi Gospels: "Of all the Father hath given me, I let
none escape." He also told the parable of the leaky water jar.)

50-53. By thus retaining the breath as long as he likes, Kevala Kumbhaka
(cessation of breath without inspiration and expiration) is attained. When
Kevala Kumbhaka is attained by one and thus expiration and inspiration are
dispensed with, there is nothing unattainable in the three worlds to him. In the
commencement (of his practice), sweat is given out; he should wipe it off. Even
after that, owing to the retaining of the breath, the person practising it gets
phlegm. Then by an increased practice of Dharana, sweat arises.

54. As a frog moves by leaps, so the Yogin sitting in the Padma posture moves on
the earth. With a (further) increased practice, he is able to rise from the
ground.

55. He, while seated in Padma posture, levitates. There arises to him the power
to perform extraordinary feats.

56. He does (or should) not disclose to others his feats of great powers (in the
path). Any pain small or great, does not affect the Yogin.

57. Then excretions and sleep are diminished; tears, rheum in the eye, salivary
flow, sweat and bad smell in the mouth do not arise in him.

58-60. With a still further practice, he acquires great strength by which he
attains Bhuchara Siddhi, which enables him to bring under his control all the
creatures that tread this earth; tigers, Sarabhas (an animal with eight legs),
elephants, with bulls or lions die on being struck by the palm of the Yogin. He
becomes as beautiful as the god of love himself.

61-62. All females being taken up with the beauty of his person will desire to
have intercourse with him. If he so keeps connection, his virility will be lost;
so abandoning all copulation (but not Tantra) with women, he should continue his
practice with great assiduity. By the preservation (no outflow) of the semen
(seed, Genetic Efflux), a good odour pervades the body of the Yogin.

63. Then sitting in a secluded place, he should repeat Pranava (OM) with three
Pluta-Matras (or prolonged intonation) for the destruction of his former sins.

73-74. Then various wonderful powers are attained by the Yogin, such as
clairvoyance, clair-audience, ability to transport himself to great distances
within a moment, great power of speech, ability to take any form, ability to
become invisible and the transmutation of iron into gold when the former is
smeared over with his excretion.

75-76. That Yogin who is constantly practising Yoga attains the power to
levitate. Then should the wise Yogin think that these powers are great obstacles
to the attainment of Yoga and so he should never take delight in them. The king
of Yogins should not exercise his powers before any person whatsoever.

77. He should live in the world as a fool, an idiot, or a deaf man, in order to
keep his powers concealed.

81-83(a). Then by this constant practice is gained the Parichaya state (the
third state). Vayu (or breath, Prana, bioplasma) through arduous practice
pierces along with Agni the Kundalini through thought and enters the Susumna
uninterrupted. When one's Chitta(mind, consciousness) enters Susumna along with
Prana, it reaches the
high seat (of the head probably) along with Prana.

121(b)-122(a). Through Mula-Bandha, Prana and Apana as well as Nada (Inner
Sound) and Bindu (seed, Genetic Efflux) are united and gives success in Yoga;
there is no doubt about this.

126. He who practises only for a period of a Yama (twenty-four minutes) every
day conquers time. He who practises VAJROLI (Rasa Tantra) becomes a Yogin and
the repository of all Siddhis.

127-128. If the Yoga Siddhis are ever to be attained, he only has them within
his reach. He knows the past and the future and certainly moves in the air. HE
WHO DRINKS OF THE NECTAR IS THUS RENDERED IMMORTAL day by day (by daily Genetic
Rejuvenation). He should daily practise Vajroli (Rasa Tantra, "drinking from the
diamond thunderbolt"). Then it is called Amaroli. (Amaroli means to drink one's
own urine as in Urine Therapy, also known as Manav Mootra or Shivambu Chikitsa.)

129-131(a). Then he obtains the Raja-Yoga (Yoga of the mind) and certainly he
does not meet with obstacles. When a Yogin fulfils his action by Raja-Yoga, then
he certainly obtains discrimination and indifference to objects. Vishnu, the
great Yogin, the grand one of great austerities and the most excellent Purusha
is seen as a lamp in the path of truth.

131(b)-134(a). That breast from which one suckled before (in his previous birth)
he now presses (in love) and obtains pleasure. He enjoys the same genital organ
from which he was born before. She who was once his mother will now be wife (as
Shakti Ma) and she who is now wife is (or will be) verily mother (will give her
huband and herself Rebirth or Regeneration - the Dwij of the Twice-Born
Brahmins). He who is now father (by "giving birth" to himself by Genetic
Rejuvenation) will be again (his own) son and he who is now son will be again
father. Thus are the egos of this world wandering in the womb of birth and death
like a bucket in the wheel of a well and enjoying the worlds.

(Like Jesus said: "The father and the Son are as One." The Tantra Dharma, the
Gnostic Gospel and the Koranic Resurrection are all about the practice which
leads to Genetic Rejuvenation, which cures all ills, and activates the Siddhis
and Higher Consciousness. But the Maya or ignorance of this Kali Yuga or Age of
Darkness is a constant danger to the Truth which can Save all from undue
suffering. "State Samsara" or government-enforced "hell on earth" is spawned
from the depths of bestial stupid arrogance and rules over this demonic world
today. Repent of it, or die!
Jai Om. - Sw. Tantrasangha)

Here ends the Yogatattva Upanishad belonging to the Krishna-Yajur-Veda.

http://www.celextel.org/108upanishads/yogatattva.html
http://www.salvationscience.com/v224.htm
**************************************************************

#1418 From: "salvationscience" <salvationscience@...>
Date: Mon Apr 13, 2009 4:38 pm
Subject: THE BRIHAD JABALA UPANISHAD: A SECRET SIVA-SHAKTI NECTAR BATH
salvationsci...
Offline Offline
Send Email Send Email
 
THE BRIHAD JABALA UPANISHAD: A SECRET SIVA-SHAKTI NECTAR BATH
FOR THE HOLY DEATHLESS STATE!
With Tantric Commentaries by Swami Tantrasangha
Brihad Jabala Upanishad, translated by P.R. Ramachander
Published by celextel.org
http://www.celextel.org/108upanishads/brihadjabala.html
http://www.salvationscience.com/v223.htm

Jesus said: "Ye must be Born Again of water and Spirit, in order to enter the
Kingdom of Heaven." - from the Biblical Gospels. What could be more Heavenly
than Physical Immortality in a State of Bliss?
We keep telling you that the meaning of "Born Again" is literally Genetic
Rejuvenation - what the Holy Bible calls the "Washing of Regeneration".

This "Rebirth" or "Resurrection of the dead" is not a mere symbol or allegory,
but was meant, by its original author, to be taken quite literally! Only a fool
would cling to the symbolic bread and wine when he could have the literal "flesh
and blood of Christ" made manifest within his own body. Above all, be honest
with yourselves. Jai Om. - Sw. Tantrasangha
--------------

Brihad Jabala Upanishad, translated by P.R. Ramachander

For winning over death, the bath of nectar is recommended. Where is the question
of death for one who has been touched by nectar (Prana or bioplasma and Apana or
outflow of Genetic Efflux) of Shiva and Shakthi (Advaitamrita or shared
bioplasma, Benares, Triveni, the Confluence of Two Nadis or rivers, Rasa
Tantra)? 14

The one who knows this holy secret method, would purify moon (Soma) and fire
(Agni, Kundalini Shakti, Holy Spirit) and will not take birth (as a new-born
baby) again. 15 (Had you known about it, it wouldn't have been a secret.)

The one whose body is burnt by the fire (Kundalini Shakti) of Shiva and made wet
by the nectar of (the) moon (Soma Pavamana, Genetic Efflux) and entering the
path of yoga would become eligible for deathless state (by the process of
Genetic Rejuvenation). 16

http://www.celextel.org/108upanishads/brihadjabala.html
http://www.salvationscience.com/v223.htm
***************************************************************

#1417 From: "salvationscience" <salvationscience@...>
Date: Sun Apr 12, 2009 5:37 pm
Subject: THE THEERTHA OR SACRED WATER IN THE ATHARVASIRAS UPANISHAD
salvationsci...
Offline Offline
Send Email Send Email
 
THE THEERTHA OR SACRED WATER IN THE ATHARVASIRAS UPANISHAD
SWAMIJI'S EASTER SERMON: ULTIMATE MINGLING OF ALL SACRED WATERS
The Atharvasiras Upanishad, Translated by P. R. Ramachander
Published by celextel.org
http://www.shastras.com/108upanishads/atharvasiras.html
http://www.salvationscience.com/v223.htm

He (God) is called "theertha (sacred water)" because he is the ULTIMATE MINGLING
OF ALL SACRED WATERS which are sought after... (This "mingling" of waters
implies Rasa Tantra.)

Deeply drinking the Somapana (Soma Pavamana, a holy drink, pani is water) of
your grace we have become deathless (physically immortal). We have reached the
ultimate. We have seen the devas (by Higher Consciousness). Who can cause any
harm to us? We humans do not have any shortage of that nectar. 3-2

You (Androgynous Divine Body of Higher Consciousness) who are primeval are older
than the sun (male) and the moon (female). 3-3

For the sake of this world, this deathless primeval being, catches hold of this
world which is created by Prajapathi and which is minute and peaceful, without
touching it and attracts its shape of things by shape, peacefulness by peace,
minuteness by minuteness and airy nature by its airy nature and swallows it.
Salutations and salutations to that great swallower. 3-4

Those gods who reside in the heart reside in the soul of the heart. And you who
live in that heart are beyond the triad nature. 3-5

The head of "the sound of Om" is on your left side. Its feet are on your right
side. That "Sound of Om" is the Pranava(primeval sound). That Pranava is spread
everywhere. That which is everywhere is the greatest. That which is limitless,
shines like a white star. That which is also called Shuklam (seminal fluid - the
basic unit of life, sperm) is very very minute. That which is minute (DNA
molecule) is like a lightning power. That which is like lightning power is the
ultimate Brahman. That Brahman is one and only one. That one and only one is
Rudra (the ancient name for Siva), it is also Eeshana (the form of Lord Shiva
with tuft and riding on a bull), it is also the ultimate God and it is also the
lord of all things. 3-6

Rudra is called the personification of Pranva Prana) because he sends the souls
towards heaven, at the time of death (dissolution, OOBE's, exiting the body from
the God Chakra).

He is called the "one who has the shape of Pranava", because the Brahmins read
and propagate the Rik, Yajur, Sama and Atharva Vedas only after reading "om".

He is called "all pervading" because like oil in gingili (Til), he peacefully
pervades all over the world and its beings, from top to bottom and from right to
left. (Subjectively, all those with Prana in Shushuman and Kundalini Shakti in
the God Chakra, will literally experience an expansion of consciousness as the
Union of subject and object. The Hindu mantra, Tat Vam Asi means "That art
thou." This is the basis of Sankaracharya's Advaita, which is Non-Separation of
male and female and subject and object.)

He is called "Anantha (endless)", because his end is neither at the top nor
bottom, nor right nor left (nadis or channels - male and female).

He is called "thara (protector)" because he protects one from the fear of life
which consists of the fear of staying in the womb, fear at time of birth, fear
from diseases, fear from old age and fear from death.

He is called "Shukla (shukra, white, seminal fluid), because by "pronouncing his
name" (by the DNA or seed of a couple) we get rid of all pains.

He is called "sookshma (minute)", because he pervades in a minute form all over
the body without touching any of the organs.

He is called "vaidhyutha (electric)" because as soon as "his name is pronounced"
(i.e. one attains Advaitamrita or Androgynous Bioplasma), in the state of
darkness where nothing is visible, the holy knowledge comes like a ray of
lightning. (Jesus said: "When thine eye is single, thy whole body will be filled
with Light. My Light shines from East to West.")

He is called "Para Brahmam (God, the ultimate reality)", because, though he is
inside every thing, he is in and out of everything, he is the refuge of every
thing and bigger than the big, he is inside every thing. (The Yogi tries to
convey the experience of Higher Consciousness.)

He is called "Eka (single)" because he singly destroys everything  (i.e. the
degenerating body) and recreates everything (by the Biblical "Washing of
Regeneration").

He is called "theertha (sacred water)" because he is the ultimate mingling of
all sacred waters which are sought after, in the east, south, north ad west.

http://www.shastras.com/108upanishads/atharvasiras.html
http://www.salvationscience.com/v223.htm
**************************************************************

#1416 From: "salvationscience" <salvationscience@...>
Date: Thu Apr 9, 2009 11:55 pm
Subject: THE PHALLIC SIVA LINGUM: HOW THE STONE SYMBOLIZES THE WATER
salvationsci...
Offline Offline
Send Email Send Email
 
THE PHALLIC SIVA LINGUM: HOW THE STONE SYMBOLIZES THE WATER
Interpretations of Shiva Lingam (Conjoined Phallus and Vagina)
http://www.thaiexotictreasures.com/shiva_lingam.html
http://tinyurl.com/cbjuzv
http://www.salvationscience.com/v223.htm

"The stone that was rejected by the masons ('a stone of stumbling'), is the
headstone of the corner. Upon this rock (stone, pietros) I build my Church"
(Tantra Sangha, Gnostic Monastic Commune). - Jesus in the Holy Bible. "Moses
brought water out of a rock." "Cows Conceived by drinking water from a trough
with (phallic) rods in it." - from the Old Testament. "Ye must be Born Again of
water and Spirit." - Jesus in the Biblical Gospels. "A seed (Genetic Efflux)
will serve Him (God)." - from the Biblical Old Testament.

This is the only permitted icon for iconoclasts, since it is a good symbol for
the practice of Rasa Tantra. Each morning, a ritual offering of water (like
Elijah's) is poured onto the "altar". The Sacred Water drips down the protruding
male phallic lingum and onto the female vagina, in the form of the base of the
table, where it passes out a spout, pouring down into the trough of Holy Water.
This again portrays the joining of male and female Rasa into one AdvaitAmrita.
We are (Re)Engendered by joining male and female.

Compare this with the flat Egyptian offering tables. I looked at some online,
but they were not as detailed as the ones I saw in the Egyptian Museum in Cairo,
Egypt. The Egyptian offering tables resemble the Hindu Siva Lingums, except
there are no protruding phalluses, although phallic symbols are often carved
into the flat surface of the table. The ones I saw portray two pools of water,
merging as one - the symbol of the Hindu Triveni. The Siva Lingum is the main
symbol in India and Nepal. Jai Om. - Sw. Tantrasangha
---------------------

There are various interpretations on the origin and symbolism of the Shiva
lingam. While the Tantras and Puranas deem the Siva lingam a phallic symbol
representing the regenerative aspect of the material universe, the Agamas and
Shastras do not elaborate on this interpretation, and the Vedas fail altogether
to mention the Shiva Lingam.

Shiva Lingam as a Phallic symbol

Hinduism conceptualizes Brahman, the supreme power, as having three main roles:
that of God the Creator, God the Preserver and God the Destroyer. This trinity
is represented iconically by the deities Brahma, Vishnu and Shiva respectively.
Thus, it is Shiva, the destructive form of the Almighty, who is represented by
the Lingam or Phallus, which is manifestly the CREATIVE or generative power of
Man. This points to an origin of the tradition of using the Lingam as a divine
symbol that is utterly sublime in its philosophical underpinnings.

The form of the Shiva Linga serves to further emphasize this inference. The base
of the Lingam is the Yoni also known as 'Parashakti'. The upright portion of the
Lingam is shown as being protuberant through the yoni, and the two form a
unified structure. Thus, the Lingam represents the very instant of creation, or
rather of regeneration, when the perishable and eventually destructible Old
renews and regenerates itself in another form, the New that is to come.

Tantra

The Tantras consider the lingam to be a phallic symbol and to be the
representation of Shivas phallus, in its erect form. Accordingly, the lingam
contains the soul-seed containing within it the essence of the entire cosmos.
The lingam arises out of the base (Yoni) which represents Parvati according to
some or Vishnu, Brahma in female and neuter form according to some.

Puranas

The puranas, especially the Vamana purana, Shiva purana, Linga purana, Skanda
Purana, Matsya Purana, and Visva-Sara-Prakasha, have narratives of the origin
and symbolism of the Shiva lingam. Many puranas attribute the origin to the
curse of sages leading to the separation of and installation of the phallus of
Lord Shiva on earth; many also refer to the endlessness of the lingam, linked to
the egos of Lord Vishnu and Lord Brahma.

Possible Biblical Reference to Lingam

There is a portion of the Bible in which the Hebrew patriarch Jacob appears to
be performing something very similar to a Lingam ceremony, in which a precious
substance such as milk or oil is poured on the stone artifice as a sacrificial
intent. "And Jacob rose up early in the morning, and took the stone that he had
put for his pillows, and set it up for a pillar, and poured oil upon the top of
it.",(Ge 28:18). also: "And Jacob set up a pillar in the place where he talked
with him, even a pillar of stone: and he poured a drink offering thereon, and he
poured oil thereon.",(Ge 35:14). It is sometimes pointed out that the term for
oil or drink used in this verse is the Hebrew Shemen, which appears like English
word semen and thus seems to be appropriate to the phallic nature of the Lingam.

http://www.thaiexotictreasures.com/shiva_lingam.html
http://tinyurl.com/cbjuzv
http://www.salvationscience.com/v223.htm
***********************************************************

#1415 From: Joseph Eldor <a1b2c3d4@...>
Date: Thu Apr 2, 2009 10:08 am
Subject: Immunotherapy for liver tumors: present status and future prospects
csen_interna...
Offline Offline
Send Email Send Email
 

Review

Immunotherapy for liver tumors: present status and future prospects

Pablo Matar1,3 email, Laura Alaniz2,3 email, Viviana Rozados1 email, Jorge B Aquino2,3 email, Mariana Malvicini2 email, Catalina Atorrasagasti2 email, Manuel Gidekel4 email, Marcelo Silva2 email, O Graciela Scharovsky1 email and Guillermo Mazzolini2,3 email

1Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Santa Fe 3100, (2000) Rosario, Argentina

2Gene Therapy Laboratory, Liver Unit, School of Medicine, Austral University, Av. Presidente Perón 1500, (B1629ODT) Derqui-Pilar, Buenos Aires, Argentina

3CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Buenos Aires, Argentina

4VentureL@b, Escuela de Negocios, Universidad Adolfo Ibañez, Av. Diagonal Las Torres 2700, Peñalolen 791000, Santiago, Chile

author email corresponding author email

Journal of Biomedical Science 2009, 16:30doi:10.1186/1423-0127-16-30

The electronic version of this article is the complete one and can be found online at: http://www.jbiomedsci.com/content/16/1/30

Received: 28 October 2008
Accepted: 6 March 2009
Published: 6 March 2009

© 2009 Matar et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors. Progress in immune-based strategies has opened new therapeutic avenues using a number of techniques destined to eliminate malignant cells. In the present review, we overview current knowledge on the importance, successes and difficulties of immunotherapy in liver tumors, including preclinical data available in animal models and information from clinical trials carried out during the lasts years. This review shows that new options for the treatment of advanced liver tumors are urgently needed and that there is a ground for future advances in the field.

Background

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide [1]. Unfortunately, the incidence and mortality associated with HCC is increasing steadily [2] as a consequence of epidemics of hepatitis C virus (HCV) and hepatitis B virus (HBV). HCV and HBV infections are causally associated with the majority of HCC in the world [3].

Current therapeutic options are extremely disappointing since less than 30% of the patients evaluated in referral medical institutions can receive a curative therapy, consisting in either resection or transplantation [4]. Thus, in the majority of advanced HCC cases surgery is not possible and the prognosis is dismal due to underlying cirrhosis as well as to poor tumor response to chemotherapeutic agents [4-6].

Unfortunately, advanced colorectal carcinoma (CRC) depict similar scenario [7]. Colorectal carcinoma is one of the most common malignancies and a leading cause of cancer-related death [1]. Hepatic metastases are present in 15–25% of patients at the time of CRC diagnosis [8]. Surgical resection, which is accepted as first-line CRC treatment, cannot be performed in the majority of patients [9]. Following diagnosis, the median survival of untreated patients with liver metastases is 6–12 months [10]. The application of new chemotherapeutic cocktails, including irinotecan or oxaliplatin, result in higher rates of objective responses and survival [11-15] and the recent incorporation of monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptors provides additional, although limited, improvement in patients survival [15,16].

Thus, new strategies are needed for treatment of patients with advanced liver tumors and immunotherapy approaches might play a significant role among them. Cancer immunotherapy can be defined as a set of techniques aimed to eliminate malignant tumors through mechanisms involving immune system responses [17,18]. The goal of cancer immunotherapy is to understand how to direct against tumors similar kind of extremely potent immune responses such as those naturally occurring against microbial antigens, and subsequently how to apply these results to human cancer diseases. It has been observed in patients with HCC that the presence of a lymphocyte infiltrate is associated with a better prognosis after resection and transplantation [19]. Similarly, presence of lymphocyte infiltration in tumors was correlated with patient survival in CRC: survival rate of patients with large numbers of CD3+-T cells was 5-years higher [20,21].

There is a limited clinical experience regarding the application of immunotherapy in liver tumors contrary to more immunogenic tumors such as melanoma, lymphoma or renal cell carcinoma. Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors (Fig. 1). Unfortunately, the presence of chronic HCV or HBV infection complicates the success of immunotherapy in patients with HCC because these viruses were found to be able to modulate the immune response against tumors and to counteract the immune system of the host [22-24].

thumbnailFigure 1. Immunotherapeutic strategies for liver tumors: administration of recombinant cytokines, adoptive transfer of tumor-reactive T cells generated in vitro, gene therapy with cytokines and costimulatory molecules, immunotherapy with dendritic cells, stimulation with immunogenic vaccines or antibodies.

The immune system and the induction of antitumor immunity – basic concepts

The immune system is clearly capable of recognizing and eliminating tumor cells, although cancer cells are considered as poorly immunogenic [25]. Compelling evidence suggests that immune cells can eventually play a crucial role in the control of cancer. First, both occasional spontaneous tumor regressions have been described in immunocompetent hosts while increased cancer incidence has been reported in immunocompromised individuals [26]. Second, tumor immunity was demonstrated experimentally in several animal models [27]. Third, the immune system often recognizes the presence of tumors, as reflected by an accumulation of immune cells at tumor sites [28].

Despite the ability of the immune system to react against cancer cells, the presence of a tumor indicates that the developing cancer can avoid detection or to escape the immune response [29]. Mechanisms used to elude recognition include tumor-induced impairment of antigen presentation, activation of negative co-stimulatory signals, and production of immunosuppressive factors [30]. In addition, cancer cells may promote the expansion and/or recruitment of regulatory cells that may contribute to the immunosuppressive network; these populations include regulatory T cells (Treg), myeloid suppressor cells, and distinct subsets of immature and mature regulatory dendritic cells [31].

All of the previously mentioned mechanisms were shown to be induced in the liver by hepatitis viruses [32,33] and a concomitant chronic HCV/HBV infection in HCC patients would probably make the scenario for immunotherapeutic approaches more complicated.

The immunosurveillance and the immunoediting hypothesis

In the last 30 years we have witnessed a dramatic change in basic concepts related to tumor immunology, from the strict theory of tumor immunosurveillance postulated by Burnet and Thomas [34,35] to the very recent immunoediting concept developed by Schreiber and colleagues [36]. Using a broader look at tumor immunology, these authors have elegantly described tumor progression as a process following three phases: elimination; equilibrium and, finally, escape, in which tumor cells develop several strategies to avoid their immune-mediated elimination. The variety of processes by which tumors evade the immune response is surprisingly large. Even though cancer cells express new or inappropriate antigens, tumors of diverse origin develop common and/or unique mechanisms that enable them to escape from the immune system.

The liver: an immunological privileged organ

Mechanisms of tolerance and their implications in cancer are of central interest in immunology. The liver is an especial organ for its immunological privileged status which is a consequence of several unique immunological properties causing antigen tolerance rather than immunity [37,38] and relative resistance against liver allograft rejection [39], allowing that 20% of allotransplanted patients could be withdrawn from long-term immunosuppression [40]. Aggressive autoimmune hepatitis is a somewhat uncommon clinical manifestation of systemic autoimmune disease [41]. Moreover, it has been observed in animal models that naïve liver reactive T cells ignore antigens derived from or expressed in the liver [42], generating tolerance to them [37]. It is important to note that effector T-cells alone may not be sufficient for disease induction without additional inflammatory and costimulatory signals. A potential role for TLR3 has been reported as one of the critical mechanisms of hepatic immune privilege [43].

As it was excellently reviewed by Abe and Thomson [38], liver immunoprivilege properties are likely due to its unique repertoire of antigen-presenting cell (APC) populations, consisting of Kupffer cells (KCs), liver sinusoidal endothelial cells (LSECs) and dendritic cells (DCs). KCs represent 80–90% of liver resident macrophages and are very efficient in clearing LPS from gut-derived blood circulation but less efficient in activating CD4+ cells. LSECs were shown to efficiently separate leukocytes from hepatocytes [44], are able to express factors involved in T cell death, induce differentiation of CD4+ towards the Th2 anti-inflammatory phenotype and were found to co-stimulate Tregs and inhibit allogeneic T cells. DCs are located in portal areas or circulate through liver sinusoids towards lymph draining vessels, and upon maturation increase their expression levels of IL-12 and CCR7, two molecules involved in CD4+ T cell differentiation towards the Th1 pro-inflammatory phenotype and in DC trafficking towards secondary lymphoid organs, respectively. From all liver APCs, DCs are the most potent to elicit immune responses. Due to the fact that KCs and LSECs constitutively express IL-10 and TGF-beta anti-inflammatory cytokines, T cell differentiation is affected and APC maturation inhibited in the liver [45,46]. As a consequence, the DCs are less immunostimulatory than in spleen [47,48].

In addition, hepatic stellate cells (also known as Ito cells) were shown to be involved in liver immunological processes only in case of chronic liver injury. They are induced to transdifferentiate into myofibroblasts and to secrete a number of cytokines and chemokines, such as transforming growth factor beta (TGF-beta) [49,50]. In fact, activated hepatic stellate cells have been shown to closely interact with lymphocytes [51] and to have potent antigen-presenting properties [52]. Furthermore, stellate cells from hepatitis patients have been shown to get further activated by lymphocyte proximity, especially by CD8+ cells, and to phagocyte CD45+ cells [53]. Those facts suggest that stellate cells are likely implicated in the down-regulation of the immune response in HCV/HBV-derived cirrhosis and might also be involved in HCC. These findings open new therapeutic opportunities aimed to specifically targeting hepatic stellate cells in advanced cirrhosis and HCC.

Finally, when HCC coexists with HBV/HCV derived cirrhosis, these viruses as shown in chronic hepatitis, would likely exert direct and indirect effects on further downregulation of the immune response through complex and not fully understood mechanisms. They might influence the activity of hepatic stellate cells as well as that of resident and recruited immune cells, such us DCs, through direct viral protein interaction [54-57]. As reviewed by Liu et al. [33] in chronic B/C-viral hepatitis a reduction in the myeloid and plasmacytoid DC liver populations, down-regulation in IL-12 and IFN-gamma levels, an up-regulation of IL-10 and an impairment in DCs capacity to prime naïve T cells may account for the insufficient immune response observed. Similarly, a reduction in circulating DC numbers was found in the peripheral blood of patients with either chronic-B-hepatitis [58] or chronic-C-hepatitis [59,60]. HBV/HCV viruses would likely contribute to the DC impaired allostimulatory and IL-12 production capacities observed in HCC patients [61], although this remains to be elucidated.

Hepatic tumors escape from the immune response

Hepatic tumors use two main strategies to escape from the immune response – attack and defense – the first is designed to attack the immune cells, hence avoiding their antitumor action and the other to defend tumor cells by enabling them to pass unnoticed by the immune response (Table 1).

Table 1. Mechanisms of hepatic tumor-immune escape.

Attack strategies

Fas ligand (FasL), a type II transmembrane protein reported to induce apoptosis of Fas-bearing cells [62] was shown to confer immunological privilege to certain tissues and organs such as eye, placenta and central nervous system [63-65]. More recently, the interaction of FasL or its secreted isoform (sFASL) produced by tumor cells, with their specific Fas receptor, expressed on T lymphocytes, was implicated in tumor cell evasion from immune surveillance [66]. The α-fetoprotein (AFP), an oncofetal protein overexpressed in some HCC, was shown to induce Fas-L and tumor necrosis factor [TNF]-related apoptosis expression in HCC Bel7402 cells, as well as TRAIL receptor and Fas in lymphocytes [67,68]. Another pathway developed to attack immune cells involves the interaction of PD-1 (programmed death-1) with its ligands PD-L1 and PD-L2. Immunotherapy with an expression plasmid encoding the extracellular domain of PD-1 (sPD-1) in H22 HCC cells was shown to improve the immune response against tumors [69]. One further mechanism might implicate Galectin-1 (Gal-1) – a β-galactoside binding protein with immunoregulatory properties, which is known to play a role in cytotoxic immune cells elimination. It is likely that Gal-1 contributes to tumor immune escape by killing activated T cells [70,71]. In fact, the expression of Gal-1 was shown to be induced in primary HLF, HuH7 and HepG2 cells [72].

Defense strategies

The pressure that the immune system exerts on the growth of tumor cells seems to have led them to develop several protection mechanisms against any immune attack. It has been shown that human HCC-related factors not only induce and expand the regulatory CD4+CD25+ T cell population (Tregs), but also enhance their suppressor ability [73]. A high prevalence of Tregs infiltrating HCC seems to be an unfavorable prognostic indicator [74]. Another mechanism frequently used by tumors is the down-regulation of MHC-I [75], B7-1/B7-2 co-stimulatory molecules [76] or transporter associated with antigen processing (TAP)1/2 molecules in human HCC [77]. In addition, HCC cells might escape from CTL-induced apoptosis by increasing Bcl-2 and decreasing Bcl-xs expression [78] and/or raising the Survivin level, an important member of the inhibitor of apoptosis (IAP) family [79,80].

Indoleamine 2,3 dioxygenase (IDO) catalyses the degradation of the essential amino acid tryptophan and synthesizes immunosuppressive metabolites [81]. Larrea and colleagues [82] reported that IDO constitutes an important mediator of peripheral immune tolerance in chronic hepatitis C virus (HCV) infection. Induction of IDO expression may reduce T-cell reactivity to viral antigens in chronic HCV infection and may also influence the immune response against HCC in patients chronically infected with HCV. Understanding of the immune-escape mechanisms should help us to design immunotherapy protocols to increase the efficacy of therapeutic success.

Systemic use of immunostimulatory cytokines

There is a broad experience regarding the use of cytokines to induce immune and inflammatory responses against cancer [83,84]. Cytokines have been shown to act through different mechanisms: i) stimulation of antitumor immune responses; ii) induction of tumor cell apoptosis (e.g. through induction of TRAIL) [85]; iii) interference in uncontrolled proliferation of cancer cells, and iv) anti-angiogenesis.

One of the most explored cytokines is interferon alpha (IFN-α) [86,87]. The IFN-α antitumor mechanism of action includes direct effect on tumor cells, induction of lymphocyte and macrophage cytotoxic activities and anti-angiogenesis [88,89]. Two controlled trials comparing IFN-α with symptomatic treatment in patients with HCC were reported. In one of them the use of high doses of IFN-α (50 MU/m2, tiw) resulted in a response rate of 36% [90]. In the other trial, in which lower doses of IFN-α (3 MU/m2, tiw) were administered, the response rate was poor (7%) [91]. Even though it is clear that the different responses are related to the administered doses, the toxicity associated with the higher IFN-α dose is not acceptable, especially for patients with end-stage liver disease. Nevertheless, systemic administration of IFN-α [92] or IFN-β [93] should be considered as a supportive treatment after hepatectomy or tumor ablation, which may prevent or delay tumor relapses in patients with HCC [94]. A combination of IFN-α and chemotherapy was applied to patients for treatment of advanced HCC [95,96] and metastatic CRC to the liver [97]; however, randomized controlled studies failed to demonstrate that combination protocol results in improved outcome when compared to chemotherapy treatment alone [98,99].

Interleukin-2, an immunostimulatory cytokine, has been administered alone or in combination with other treatments against liver tumors. The non-controlled nature of most studies precludes from any definitive conclusion. Systemic IL-2 was able to produce objective responses against HCC when given alone [100] or in combination with melatonin [101] or lymphokine activated killer (LAK) cells [102]. On the other hand, hepatic artery infusion of interleukin 2, with or without chemotherapy, induced objective remissions in 5% to 15% of liver metastases from CRC [95,103,104]. In a phase II clinical trial, Correale and colleagues showed that the combination of polychemotherapy with granulocyte macrophage colony-stimulating (GM-CSF) factor and low-dose IL-2 in colorectal carcinoma patients, results in high number of objective responses and low toxicity [105].

There is one report on combination of hepatic trans-arterial chemotherapy with IFNγ plus IL-2 in patients with advanced HCC [106]. The achieved objective responses highlight some biological effect of this treatment combination. In another study, when IL-2 was administered together with IFNγ and GM-CSF to advanced HCC patients, clinical results were poor [107]. However, in spite of some stimulating results, the clinical development of IL-2 has been proved unsuitable because in parallel to their efficacy the results involved severe toxicity, including systemic vascular leak syndrome.

No trials were reported on the application of other cytokines such as IL-12, TNFα, or TRAIL, known to have a potential effect against primary or metastatic liver cancer in humans. Nevertheless, concerns were raised following reports on the development of severe toxicity after systemic treatment with IL-12 or TNFα [108,109] in other type of tumors.

Although being able to obtain some positive outcomes in the treatment of liver tumors, systemic application of cytokines is accompanied by toxic effects which can be overcome by local delivery. A possible role of some of the immunostimulatory cytokines, e.g. IL-12, could be reasonable in the context of vaccination as an adjuvant administered at low doses.

Immunostimulating monoclonal antibodies

In the field of cancer therapy mAbs can act directly against tumor cells or indirectly by interfering with several processes such as survival, cellular proliferation or angiogenesis. The immunostimulating monoclonal antibodies which are those corresponding to the latter group, are defined as a new family of drugs aimed to augment immune responses. They consist in either agonistic or antagonistic mAbs which are aimed to bind key immune system receptors, thereby enhancing antigen presentation, providing co-stimulation or counteracting immune-regulation [110].

Regulation of T-cell responses

T-cells express several co-signalling molecules, typically cell-surface glycoproteins classified as co-stimulators or co-inhibitors [111,112]. The outcome of T-cell responses depend on the balance between co-stimulatory and co-inhibitory molecules. Thus, antigenic signalling in the absence of co-stimulatory molecules results in suboptimal immune activation and may lead to T-cell deletion or unresponsiveness. Monoclonal antibodies targeting co-stimulatory molecules expressed on T-cells may act agonistically, working as surrogate ligands and augmenting T-cell proliferation and survival. Alternatively, mAbs may act antagonistically, counteracting the inhibitory effects of co-inhibitor molecules or Treg-cells.

Costimulation with agonistic mAbs

Diverse costimulatory molecules appear to regulate T-cell response, working specifically at different time points [113,114]. Antibodies against CD28 are known to potentiate antitumor immunity in combination with bi-specific antibodies that bind to both the tumor antigen and the TCR-CD3 complex [112]. Some anti-CD28 antibodies, termed superagonist antibodies, can activate T-cells without concomitant TCR engagement. Unfortunately, concerns were raised following reports of severe toxicity in a Phase I dose-escalation trial with an anti-CD28 mAb (TGN1412) [115].

Another costimulatory molecule, CD137 (also known as 4-1BB), is a member of the TNF-receptor superfamily, expressed in antigen-activated T-cells (CD4+, CD8+, Treg and NK cells), DCs, cytokine-activated NK cells, eosinophils, mast cells and, intriguingly, endothelial cells of some metastatic tumors [116-118]. The natural ligand for CD137 (CD137 ligand) is constitutively produced by activated APCs. Agonistic anti-CD137 Abs strongly promote survival of T-cells and prevent activation-induced cell death [119,120]. Antitumor effects of anti-CD137 mAbs were first recognized by Melero et al. [121] in established Ag104 sarcoma and P815 mastocytoma. These effects are thought to be involved in the activation of naive T-cells which are specific for tumor antigens cross-presented by DCs. Repeated systemic injections of agonistic anti-CD137, in two mouse models of CRC, induced tumor eradication in 3 out of 5 mice [122]. Unfortunately, this therapeutic modality may have serious drawbacks. Niu and colleagues found that a single injection of anti-CD137 given to BALB/c or C57BL/6 control mice led to the development of a series of anomalies such as splenomegaly, lymphadenopathy, hepatomegaly, multifocal hepatitis, anemia, altered trafficking of B cells and CD8+ T-cells, loss of NK cells, and a 10-fold increase in bone marrow cells bearing the phenotype of hematopoietic stem cells [123].

OX40 (also known as CD134 and TNR4) is another member of the TNF receptor family, specifically expressed in activated CD4+ and CD8+ T lymphocyte, B-cells, DCs and eosinophils [124]. OX40 ligand (OX40L) is expressed in activated APCs and can also be found in activated T-cells and in endothelial cells [125]. OX40 seems to be particularly important to ensure T-cell long-term survival, probably through up-regulation of the anti-apoptotic proteins Bcl-xL and Bcl-2 [126]. Weinberg [127] showed that systemic OX40 ligation increases tumor immunity, with a role for CD4+ cells in the B16 melanoma model. Phase I clinical trials, using a murine anti-human OX40 mAb, have been initiated in patients with advanced cancer of multiple tissue origins; however, it can not be administered in several repeated doses because of its xenogeneic nature, which is likely to trigger immune responses against murine sequences [128].

Thus, agonistic mAbs have been found to produce some benefits in treatment of liver tumors although their systemic application causes serious undesired secondary effects. Intratumoral application of low doses of them might overcome some of the systemic delivery problems.

Counteracting immunoregulation with antagonistic mAbs

The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is an inhibitory receptor with a structural homology to the co-stimulatory receptor CD28 [111,129]. Under antigenic stimulation, ligand binding to CTLA-4 generates inhibitory signals mediating reduction in T-cell proliferation and in IL-2 secretion. Administration of antagonistic anti-CTLA-4 mAbs demonstrated antitumor effects in different murine tumor models including colon, prostate and renal carcinomas, as well as fibrosarcoma and lymphoma [130,131].

As mentioned earlier, PD-1 and its ligands B7-H1 (also known as PD-L1) and B7-DC (also known as PD-L2) [111,132] deliver inhibitory signals to T cells. Administration of mAbs anti-PD-1 and B7-H1 produced CTL-mediated antitumor effects in mice [133].

The finding that HCC-associated antigen HAb18G/CD147, a member of the CD147 family, enhances tumor invasion and metastasis through induction of matrix metalloproteinases [134] led to the development of an anti-CD147 therapy. By using an orthotopic model of HCC in nude mice, Ku and colleagues [135] showed that the application of two different anti-CD147 mAbs (HAb18 and LICARTIN) resulted in consistent inhibition of both tumor and metastasis growth.

In animal models, immunostimulatory mAbs antitumor effects were demonstrated when used either alone or in combination with radiotherapy or chemotherapy [136,137]. Clinical experience with mAbs is scarce; however, several immunostimulatory mAbs have now been introduced in clinical trials and early results suggest that they might enhance antitumor responses with accepted toxicity. Therapy with immunostimulatory antibodies alone or in combination with other strategies should be carefully designed in order to avoid induction of autoimmune toxicity as a consequence of uncontrolled stimulation of the immune system effector arm.

Gene transfer of cytokines and costimulatory molecules. Genetic vaccination

Gene therapy is a promising novel therapeutic strategy for treatment of several heritable and non-heritable human diseases [138,139]. Since about 20 years ago, when the first clinical trial was initiated, and after more than 1300 clinical trials performed all around the world http://www.wiley.co.uk/genmed/clinical/ webcite, we learned that the core concept of gene therapy may be applicable: genes introduced into patients can be safely expressed [140]. However, we have also learned that vector efficiency in clinical applications is not as good as expected [141,142]. Cancer represents almost 70% of the clinical trials conducted in patients and 25% of these studies consisted in the application of cytokine genes.

Gene transfer of immunostimulatory cytokines (e.g. IL-2, IL-4, IL-6, IL-7; IL-12, INF-γ, TNF-α, GM-CSF) was shown to overcome the immune tolerance against tumors, facilitating their eradication in some cases [143-145] (Table 2). Two main approaches have been used [144]: i) direct injection of vectors expressing cytokines/chemokines/costimulatory molecules into tumor lesions, or ii) use of tumor cells/DCs transduced ex vivo with vectors expressing cytokines/costimulatory molecules.

Table 2. Gene transfer immunostimulatory molecules.

Interleukin 12 (IL-12) is a potent cytokine that showed antitumor activity in a number of tumor models [146,147]. Multiple action mechanisms mediating its activity are known, including the activation of NK cells, cytotoxic T lymphocytes and the induction of a TH1 type of response [146]. It also inhibits tumor angiogenesis and enhances the expression of adhesion molecules on endothelial cells, thus facilitating the homing of activated lymphocytes to the tumor [148,149]. However, IL-12 was shown to eventually induce severe toxicity when administered systemically as a recombinant protein [150]. Thus, unspecific toxic effects of systemic IL-12 administration might be solved by the use of gene therapy strategies, allowing local production of IL-12 at the tumor milieu and resulting in high local levels with low systemic concentrations [151]. Consistently, the potential usefulness of IL-12 gene transfer for liver tumors treatment in animal models was demonstrated by different groups including ours [152-154]. We also reported that intratumor injection of an adenovirus encoding IL-12 genes (AdIL-12) into rats with orthotopic HCC induced the complete tumor elimination in the majority of animals [155]. Potent effects of this vector have also been shown in a very aggressive multifocal HCC model developed in rats, by treatment with DENA [155,156] as well as in mice bearing hepatic metastases of colorectal carcinoma [157,158] and in woodchucks chronically infected with woodchuck hepatitis virus (WHV) [159]. The toxicity observed under high IL-12 levels is partly due to induction of IFN-γ overproduction [160]. An encouraging result is that IL-12 gene transfer in combination with another vector expressing the chemokine IP-10 (AdIP-10) allowed the reduction in the AdIL-12 dose with a similar outcome efficacy [161]. The underlying mechanism is the following: lymphocytes get attracted to tumors due to a local IP-10 expression and subsequently they are activated by IL-12. In addition, a combination of IL-12 with MIP3α demonstrated similar synergistic antitumor effects [162].

The effects of IL-12 gene transfer were assessed in patients with advanced gastrointestinal carcinomas in a phase I clinical trial consisting mainly in liver tumors. Patients were administered with up to 3 intratumor injections of AdhIL-12[163]. Treatment feasibility and safety were studied. Even though maximal tolerated dose has not been reached, some evidence of biological and antitumor activities were observed. One partial response, two minor regressions and six stabilizations were achieved. In four out of 10 patients, a significant lymphocyte infiltrate was observed in injected tumors.

It has been stated that abnormal elevated levels of Th2 cytokines such as IL-10 are able to skew an immune response that favors tumor growth [164]. In contrast, Lopez et al. [165] have recently shown that tumor cell vaccines producing a combination of IL-10 and IL-12 act synergistically in eradicating established CRC, with the underlying mechanisms being not fully addressed.

Systemic injection of recombinant IL-2 used extensively in clinical oncology for patients with metastatic renal carcinoma and melanoma has shown low efficacy and high toxicity. A phase I-II clinical trial consisting in the administration of a recombinant adenovirus encoding for IL-2 gene was carried out in patients with advanced digestive carcinomas [166]. Only one of the treated patients showed a positive tumor response with necrosis of the tumor mass.

Molecules such as HLA-B7 are essential to promote specific T-cell responses. A reduced expression of MHC-I was observed in CRC. In an attempt to make CRC more visible to the immune system, Rubin et al [167] carried out a phase I clinical trial consisting in an indirect intralesional gene transfer of both HLA-B7 and β2-microglobulin into CRC hepatic metastases. Treatment with a single plasmid construction encoding for both genes in a lipid formulation (Allovectin-7) was feasible and safe in 15 patients, however, details regarding antitumor effect have not been reported. Such an approach could produce significant therapeutic improvements if aimed to deliver functionally relevant genes.

The interaction between CD40 ligand (CD40L, CD154) and its receptor CD40, expressed in DCs, is essential for the initiation of cellular and humoral immune responses. Gene transfer of CD40-L led to regression of established CRC [168] and HCC [169] in a CD8+ T cell dependent manner.

Replication-selective viral agents (oncolytic virotherapy) hold promise as a novel cancer treatment platform. Oncolytic virotherapy is based on the ability of these vectors to selectively replicate in cancer cells as a result of different mechanisms of action [170]. This novel class of targeting viral vectors exerts direct antitumor effects, but can also be engineered to produce immunostimulatory genes, such as GM-CSF, augmenting its efficacy. A potent in vivo antitumor effect of an oncolytic vector carrying HSV and GM-CSF genes has been demonstrated against murine CRC CT26 and murine HCC Hepa 1.6 [171].

The mutant adenovirus dl1520, also called ONYX-015, was the first described oncolytic adenovirus [172]. It contains a deletion in the E1B 55 K gene that achieves preferential replication in cancer cells by different mechanisms. In the case of liver tumors, this virus showed a partial antitumor effect on murine models but no evident antitumor effect was found when applied to HCC patients. Two separate clinical trials showed that ONYX-015 has limited therapeutic effect as monotherapy in patients with liver tumors, especially if systemic routes are used [173,174]. Other oncolytic adenoviruses have been developed, and show promising results in animal models of HCC. However, their performances in clinical trials have not been tested so far [175].

In conclusion, gene transfer of cytokines and the use of oncolytic viruses are two developing immunotherapy strategies which hold promise in treatment of liver tumors. The former strategy is being widely applied and after further improvements might assure sufficient tumor levels of inflammatory cytokines circumventing toxic systemic effects. The latter strategy is in early stages of development and it largely needs to be applied into the clinics.

Immunotherapy with dendritic cells

The armamentarium for immunotherapy protocols has been boosted by the identification of DCs as protagonists of antigen presentation [176]. The final outcome of DC cross-presentation could be either T-cell activation or T-cell tolerance, depending on its activation/maturation status [177]. Thus, while mature DCs are able to induce antitumor immunity, antigen presentation by immature DCs results in the induction of tolerance [177]. In addition, IL-4 which is overexpressed in the liver under recurrent hepatitis C [178] was shown to influence DCs to induce CD4+ T cell differentiation into the Th2 lineage and to suppress DC response to IFN-gamma [179]. Up to now, several clinical studies consisting in the application of DCs were performed and, as a general outcome, no significant side effects were observed in the majority of these trials with important biological effects showing the augmentation of cellular immune responses against tumor antigens [180].

Direct injection of DCs into tumor tissue has been exploited experimentally and clinically with diverse results [181-183]. Chi KH and colleagues [184] conducted a phase I trial in patients with advanced HCC after conformal radiotherapy. Intratumoral injections of autologous immature naïve DCs prior and after radiotherapy resulted in 2 partial and 4 minor responses. Induction of specific immune responses against AFPs and enhancement in NK activity were observed.

DCs ex vivo-engineered to produce IL-12 were shown to induce antitumor immunity in mice [182,183]. Similar results were reported after application of DCs genetically modified to express IL-7 [185] or IL-15 [186]. A phase I clinical trial consisting in the intratumoral injection of autologous DCs, transfected with Ad-IL-12, in patients with metastatic gastrointestinal carcinomas was carried out [187]. This strategy was feasible and very well tolerated in doses up to 50 × 106 DCs. One partial response and 2 stabilizations were observed. In 3 out of 10 treated patients, a marked increased in CD8+ T lymphocyte infiltrates was found, and in 5 of them NK activity was significantly induced. One of the possible reasons behind the limited antitumor activity might be that DCs would likely be retained within the malignant tissue due to increased intratumoral levels of IL-8 expression as well as other chemotaxis signals, preventing their mobilization to the secondary lymphoid organs for further amplification of immune responses. Consistently, scintigraphic tracking of injected 111In-labelled DCs showed retention of DCs inside tumors [188].

As previously discussed, CD40-L is a costimulatory molecule expressed mainly on activated CD4+ T cells, which is essential for the initiation of antigen-specific T-cell responses [189]. Crystal and colleagues [190,191] showed elimination of CRC nodules after intratumoral administration of CD40-L exogenously expressing DCs. Although this approach has not yet been applied in clinical trials, it seems promising.

Another technique employed to load antigens to DCs consists in the cellular transfection with mRNA molecules. Chu et al. transfected total mRNA from CT26 CRC cells to DCs and showed strong specific CTL activity as well as protective immunity in vivo [192]. Immunization of CEA-transgenic mice, using mature DCs loaded with an anti-idiotype antibody that mimics CEA, resulted in a potent antitumor response against CEA-expressing CRCs, while immunization with DCs loaded with CEA showed less potent response [193]. Morse et al. reported a phase I clinical trial consisting in the administration of autologous DCs loaded with CEA RNA (peptide CAP-1) into 21 patients with resected CRC liver metastases [194]. The procedure was well tolerated, one patient had a minor response, and one had stable disease. More recently, the same group carried out another phase I study in 14 patients (12 CRC and 2 non-small lung cancer) on the effects of immunotherapy combined with DCs transduced with a fowlpox vector encoding CEA and costimulatory molecules. Immunization of these patients was safe and it was able to activate potent CEA-specific immune responses. In a phase I clinical trial with the aim of increasing the amount of circulating DCs, Fong et al. incubated DCs with the hematopoietic growth factor Flt3 ligand before injecting DCs loaded with CEA-derived peptide into 12 patients with colon or non-small cell lung cancer [195]. Two patients showed objective responses and two had stable disease.

Stift and colleagues reported that vaccinations with autologous DCs pulsed with tumor lysates in a cohort of advanced cancer patients (including two with HCC) was safe and feasible [196]. Delayed-type hypersensitivity (DTH) skin test was positive in the majority of vaccination-treated patients and induction of IFN-γ producing T cells was achieved in 4 other patients (not HCC). Another similar DC-based strategy was applied by Iwashita and colleagues [197]. They carried out a phase I clinical trial in patients with advanced HCC. DC-based strategy consisted in the subcutaneous injection of DC pulsed with tumor extract in 10 patients. One patient showed a partial response and in 2 of them AFP levels were decreased. Seven out of 10 showed positive DTH tests for KLH. Tamir and colleagues [198] evaluated the effectiveness of tumor-lysate loaded DC vaccines in the treatment of advanced CEA-positive CRCs.

Itoh et al. combined both DCs pulsed with a CEA peptide (restricted to HLA-A24) and adjuvant cytokines (IFN-α and TNF-α) in the treatment of patients with CEA-expressing metastatic tumors [199]. Ten HLA-A24 patients with advanced digestive tract or lung cancer were treated. No significant adverse effects were observed and the disease in 2 positive DTH test was stabilized [200]. A few years later, Ueda and colleagues conducted a phase I clinical study in which DCs previously pulsed with a CEA-derived peptide were administered to HLA-A24-restricted patients. Eighteen compatible patients were enrolled. No severe toxicity was observed. In some patients, stabilization of the disease and decrease in CEA levels were reported. Accordingly, patients with clinical responses were positive in skin tests and developed specific CTLs [201]. Finally, Babatz and colleagues demonstrated that immunotherapy with DCs pulsed with a CEA-derived peptide is able to induce specific IFN-gamma producing CD8+ T cells [202].

We and others have observed that DCs and NK cell interaction plays an important role in tumor immunity [187,203,204]. In this regard, Osada and colleagues found in patients with metastatic CRC that immunization with DCs transduced with a fowlpox vector encoding CEA was able to increase NK activity in 4 of 9 patients [205]. Importantly, increased NK activity was correlated with clinical response. In order to in vivo-activate DCs and thereby avoiding ex vivo manipulation, Furumoto et al. injected MIP3α chemokine together with CpGs inside CRC tumors [206]. They observed an increase in DC number within tumors which were finally eradicated through the development of specific CTLs.

The use of cytokines as a vaccine adjuvant has been shown to be a promising option for cancer therapy, due to its potential effectiveness against disseminated disease without causing systemic toxicity [207-211]. However, the weakness of these strategies lies in: 1) the need of culturing autologous cancer cells from each patient, 2) the problems in the selection of positively modified cancer cells, 3) the lack of an efficient APC activity in tumor cells and, 4) the limited amount of tumor cells that precludes repeated immunizations. Investigators have looked into other strategies to carry cytokines genes or tumor antigens (such as the use of allogeneic tumor cell lines) but, unfortunately, allogeneic tumor cells may lack sole TAA present within the patient's own tumor, thus reducing its efficacy.

In conclusion, different strategies involving DCs have been developed during the lasts years. Although for some of them no clinical trials have been conducted yet, for other strategies a proportion of patients responded to treatment with minor tumor regression or stabilization, with variable induction of the immune response. Further studies are required for improving the benefits of manipulating the main kind of APCs involved in immune reactions.

Contribution of adoptive T-cell therapy strategies

In several animal models, solid tumors were shown to be susceptible to elimination after infusion of large amounts of tumor-specific T-lymphocytes [212]. However, the translation of these enthusiastic successes into patients are not yet feasible, partly due to difficulties in generating tumor antigen-specific T-cells ex vivo [213].

Adoptive therapy involves the transfer of ex vivo expanded and stimulated immune effector cells to tumor-bearing hosts, aiming at augmenting the antitumor immune response [212,214]. In general, adoptive therapy is accomplished by harvesting cells from the peripheral blood, tumor sites (tumor infiltrating lymphocytes), or draining lymph nodes from which, the effector cells could eventually be expanded ex vivo, in either a specific or non-specific fashion.

One of the major aims of the adoptive T-cell therapy is the identification of tumor-associated antigens (TAAs) that are ectopically expressed or overexpressed in tumor cells relative to normal tissues or, tumor-specific antigens (TSAs) that are expressed exclusively in tumor cells. Despite aberrant expression of TAAs in tumor cells, many of these proteins are also expressed at some level in non-malignant adult tissues and, as a consequence, the immune system may recognize TAAs as self-antigens and limit the T-cell immune response. In addition, as previously discussed the liver immune system usually generates tolerance to proteins expressed by its own cells and HCC induces immune response suppression [215]. Moreover, it was demonstrated that many malignant tumors find the way of down-regulating, modifying or losing its own antigens, in order to avoid immune recognition [29].

No TSA with high prevalence have been identified for liver tumors, so far. PLAC-1, which in normal tissues is only expressed in placenta, was recently found to be expressed in 1/3rd to 1/4th of the analyzed human HCC samples and 3,8% of patients were shown to present humoral responses against this antigen [216]. Among TAAs described in HCC the most important one is AFP. Several AFP-based immunotherapeutic approaches have been applied against HCC [217,218]. Additional TAAs recently found to be expressed in HCC are several members of the tumor-specific "cancer-testis" antigens (the MAGE, GAGE and BAGE genes, NY-ESO, CTA, TSPY and FATE/BJ-HCC-2, among others) [219-221];, Aurora-A [222], SCCA [223], and Glypican-3. In between them, Glypican-3, a specific immunomarker for HCC that can be used to distinguish it from benign hepatocellular mass lesions, is highly immunogenic in mice and can induce effective antitumor immunity with no evidence of autoimmunity [224]. Several TAA antigens are also known for CRC liver tumors, including CEA and CP1 [225]. Clinical studies must be conducted in order to evaluate the potential use of these antigens in immunotherapy for liver tumors.

The lack of TSAs for HCC may be the most important limit to immunotherapy applications aimed to specifically target liver tumor cells. Several technological strategies such as serologic recombinant expression cloning (SEREX), gene expression profiling and proteomics, are being applied to discover any of those specific markers [226] but, until now, the results are limited [227].

Another important negative factor limiting the success of this type of immunotherapy is the low survival of adoptively transferred T-lymphocytes in cancer patients is. Currently, some strategies are being evaluated to increase the proliferation rate of transferred T-cells, including pre-treatment with cyclophosphamide [228].

T cells are the cellular model predominantly chosen for adoptive cellular therapy, although a role for NK cells and other cytokine-induced lymphocytes have also been investigated. Pilot clinical trials of adoptive T cell immunotherapy were initiated in cancer soon after the discovery of IL-2 (in the late 1970s), which enabled large-scale culture of T cells [229]. Although certain clinical success has been observed in melanoma, renal cancer, and lymphoma [230,231], phase II studies in HCC patients have shown objective response rates of only about 20% [232,233].

To date, no randomized clinical trials, but one, had demonstrated efficacy of adoptive T cell transfer approaches. Takayama et al. [234] reported benefits of adoptive transfer with an adjuvant setting for HCC after surgical resection of the primary tumor. In this study, autologous peripheral blood T cells were pre-cultured in medium supplemented with CD3-specific antibody and IL-2, and cell infusion was shown to reduce the risk of cancer recurrence by 41% when compared to a control group receiving only surgery. However, this trial remains unconfirmed, and the mechanism involved in the antitumoral effect remains unknown.

In order to enhance the effector capacity of tumor-specific T cells, different cytokines such as IL-18 and IL-12, were tested as potential biological response modifiers in the setting of adoptive immunotherapy. Nakamori et al. [235] demonstrated that adoptive transfer of IL-18-transduced cytotoxic T-lymphocytes in combination with IL-12 showed marked inhibitory effects on primary tumors and metastasis in a mouse model of orthotopic CRC.

Synergistic effect of combined therapy

Combinatorial strategies against cancer could either consist in a simultaneous application of different immunotherapeutic approaches or in a combination of classic chemo- or radio-therapeutic protocols with immunologic tools. Some chemotherapeutical agents were shown to induce upregulation of tumor-associated antigen expression (such as CEA) or to reduce tumor cell resistance to specific cytotoxic T lymphocytes. Some of these combinations have been found to produce synergistic rather than additive effects.

The immune-inhibitory mechanisms developed by tumor cells, such as overproduction of immunosuppressive cytokines (TGF-β and IL-10) or induction of Treg cells, are important obstacles that a successful cancer immunotherapy strategy has to face. Inhibition of one or more of these mechanisms appear to be a good strategy to induce antitumor immunity [236]. Elimination or inhibition of Treg activity by low-dose cyclophosphamide [237] or antibodies against CD25 or CTLA-4 may modify tumor immunosuppressive microenvironment, thereby increasing the efficacy of immunotherapy.

It has been shown, both in mice and humans, that pre-treatment with cyclophosphamide, known to induce lymphodepletion, results in a sustained function of adoptively transferred T-cells. Adoptive transfer efficacy can also be enhanced by alternative immunotherapies such as cytokine administration [238] and in some cases by standard cytotoxic chemotherapy and radiotherapy [239,240].

Preclinical models support the rationale for combining cancer vaccines with conventional therapies, such as radiation, chemotherapy, surgery, hormone therapy, as well as other immunotherapies. One of the most promising results was obtained from clinical trials combining antibodies against CTLA-4 with other immunotherapies such as application of GM-CSF-transduced tumor-cell vaccines. This treatment resulted in the alteration of the intratumor balance of Tregs-T effector cells and in tumor rejection [241]. Further research is required to optimize the combination of different immunotherapies to obtain maximal clinical benefits.

What have we learned from the clinic? Conclusion

Conducting immunotherapy clinical trials in patients with liver tumors is challenging and several strategies have been opened for clinical applications. However, the high efficacy of different immunotherapy strategies at eliminating liver tumors in animal models is in contrast with the very limited results achieved in patients. There are many explanations to why immunotherapy strategies fail or have little impact on patient survival. In general, for all solid tumors, the common scenario chosen to test immunotherapeutic protocols almost always involves patients with advanced diseases that precludes, or at least decreases, the possibility of success. Then, due to the advanced status of the cancer disease, the immune system of the majority of treated patients is deteriorated and unable to recognize tumor antigens. For the specific case of HCC and partially to CRC liver tumors, apart from the immunological privilege status of the liver, there are some particular aspects that add further difficulties when aiming for a clinical response such as the immunosuppressant effect of chronic HBV/HCV infection on cells of the immune system (e.g. DCs) or complications derived from developed cirrhosis which usually undermine efforts to stimulate the immune response. There is a general agreement in that different forms of immunotherapy should be tested for overall clinical benefits along with conventional treatment regimens evidencing improvements in survival. It would be desirable to evaluate the possibility of immunotherapy strategies as neoadjuvancy in patients at early stages of the disease such as after surgical removal of HCC and hepatic metastases of CRC, two diseases with increased likelihood of recurrence. Finally, new ways of long-term local delivery of signals inducing CD4+ T cell differentiation towards the Th1 lineage or vaccination against liver tumor antigens would eventually overcome the drawbacks of the pro-tolerogenic liver influence and the impairment or reduced immune response capacity caused by HBV/HCV viruses.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MP and VR: The immune system and the induction of antitumor immunity – basic concepts; Contribution of adoptive T-cell therapy strategies. JBA: The liver: an immunological privileged organ. OGS and JBA: Immunostimulating monoclonal antibodies. LA and MM: Immunotherapy with dendritic cells. GM: Introduction; The liver: an immunological privileged organ; Systemic use of immunostimulatory cytokines; Gene transfer of cytokines and costimulatory molecules; Genetic vaccination; Conclusions.

MG did a deep revision of the English grammar and style because English is not our native language. CA constructed the figure and the tables. MS was involved in the analysis and revision of the data included in the paper. GM outlined the topics of the manuscript and invited to each author to write specific chapters of the paper. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Miguel Rizzo and Soledad Arregui for their technical assistance. GM work is supported in part by grants from Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) (PICT-2005/34788 and PICTO-CRUP-2005/31179), Agencia Española de Cooperación Internacional and Programa Bicentenario-Banco Mundial, Conicyt, Chile CTE-06 (MG). LA work is supported in part by Mitzutani Foundation. CA and MM are fellows from ANPCyT. GM acknowledges the continuous support of Mrs. Ines Bemberg.

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.

    CA Cancer J Clin 2005, 55:74-108. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  2. El-Serag HB, Mason AC: Rising Incidence of Hepatocellular Carcinoma in the United States.

    N Engl J Med 1999, 340:745-750. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma.

    Gastroenterology 2008, 134:1752-1763. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma.

    Lancet 2003, 362:1907-1917. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

    J Hepatol 2001, 35:421-430. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  6. Bruix J, Sherman M: Management of hepatocellular carcinoma.

    Hepatology 2005, 42:1208-1236. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  7. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Colorectal cancer.

    Lancet 2005, 365:153-165. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  8. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study.

    Cancer 2007, 109:718-726. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  9. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A, Muller HH: Surgical resection of liver metastases of colorectal carcinoma: short and long-term results.

    Semin Oncol 2000, 27:112-119. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  10. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors influencing the natural history of colorectal liver metastases.

    Lancet 1994, 343:1405-1410. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

    J Clin Oncol 2000, 18:2938-2947. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

    Lancet 2000, 355:1041-1047. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  13. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

    J Clin Oncol 2004, 22:23-30. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

    N Engl J Med 2000, 343:905-914. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

    N Engl J Med 2004, 350:2335-2342. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    N Engl J Med 2004, 351:337-345. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  17. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC: Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

    J Clin Invest 2004, 113:1515-1525. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  18. Gilboa E: The promise of cancer vaccines.

    Nat Rev Cancer 2004, 4:401-411. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  19. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ: Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation.

    J Hepatol 2006, 45:246-253. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  20. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

    Cancer Res 1998, 58:3491-3494. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

    Science 2006, 313:1960-1964. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  22. Bertoletti A, Ferrari C: Kinetics of the immune response during HBV and HCV infection.

    Hepatology 2003, 38:4-13. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  23. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection.

    Nat Rev Immunol 2005, 5:215-229. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  24. Dustin LB, Rice CM: Flying under the radar: the immunobiology of hepatitis C.

    Annu Rev Immunol 2007, 25:71-99. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  25. Rosenberg SA: Progress in human tumour immunology and immunotherapy.

    Nature 2001, 411:380-384. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

    Nature 2001, 410:1107-1111. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  27. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting.

    Annu Rev Immunol 2004, 22:329-360. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  28. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

    N Engl J Med 2003, 348:203-213. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  29. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.

    Cancer Immunol Immunother 2007, 56:1687-1700. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  30. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.

    Immunol Rev 2002, 188:97-113. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  31. Zou W: Regulatory T cells, tumour immunity and immunotherapy.

    Nat Rev Immunol 2006, 6:295-307. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  32. Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, Langhans B, Sauerbruch T, Spengler U: Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.

    Hepatology 2006, 44:945-954. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  33. Liu B, Woltman AM, Janssen HL, Boonstra A: Modulation of dendritic cell function by persistent viruses.

    J Leukoc Biol 2008, 85(2):205-214. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  34. Burnet FM: The concept of immunological surveillance.

    Prog Exp Tumor Res 1970, 13:1-27. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  35. Thomas L: On immunosurveillance in human cancer.

    Yale J Biol Med 1982, 55:329-333. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  36. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting.

    Immunity 2004, 21:137-148. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  37. Luth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Bruck W, Wraith DC, Herkel J, Lohse AW: Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs.

    J Clin Invest 2008, 118:3403-3410. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  38. Abe M, Thomson AW: Antigen processing and presentation in the liver. In Liver Immunology: Principles and Practice. Edited by: Gershwin ME, Vierling JM, Manns MP. Totowa: Humana Press Inc; 2007:486. OpenURL

    Return to text

  39. Kamada N, Davies HS, Roser B: Reversal of transplantation immunity by liver grafting.

    Nature 1981, 292:840-842. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  40. Seyfert-Margolis V, Turka LA: Marking a path to transplant tolerance.

    J Clin Invest 2008, 118:2684-2686. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  41. Diamantis I, Boumpas DT: Autoimmune hepatitis: evolving concepts.

    Autoimmun Rev 2004, 3:207-214. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  42. Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H: Break of T cell ignorance to a viral antigen in the liver induces hepatitis.

    J Immunol 2000, 165:2415-2422. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  43. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, Harris NL, Junt T, Odermatt B, Clavien PA, Pircher H, Akira S, Hengartner H, Zinkernagel RM: Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

    J Clin Invest 2006, 116:2456-2463. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  44. Limmer A, Sacher T, Alferink J, Kretschmar M, Schonrich G, Nichterlein T, Arnold B, Hammerling GJ: Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment.

    Eur J Immunol 1998, 28:2395-2406. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  45. Crispe IN: Hepatic T cells and liver tolerance.

    Nat Rev Immunol 2003, 3:51-62. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  46. Bissell DM, Wang SS, Jarnagin WR, Roll FJ: Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation.

    J Clin Invest 1995, 96:447-455. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  47. De Creus A, Abe M, Lau AH, Hackstein H, Raimondi G, Thomson AW: Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin.

    J Immunol 2005, 174:2037-2045. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  48. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP: Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

    J Immunol 2004, 172:1009-1017. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  49. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF: Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

    Gastroenterology 2007, 132:1937-1946. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  50. Friedman SL: Liver fibrosis – from bench to bedside.

    J Hepatol 2003, 38(Suppl 1):S38-53. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  51. Muhanna N, Horani A, Doron S, Safadi R: Lymphocyte-hepatic stellate cell proximity suggests a direct interaction.

    Clin Exp Immunol 2007, 148:338-347. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  52. Viñas O, Bataller R, Sancho-Bru P, Ginès P, Berenguer C, Enrich C, Nicolás JM, Ercilla G, Gallart T, Vives J, Arroyo V, Rodés J: Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation.

    Hepatology 2003, 38:919-929. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  53. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R: Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis.

    Hepatology 2008, 48:963-977. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  54. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

    Gastroenterology 2001, 120:512-524. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  55. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borras-Cuesta F, Prieto J: Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

    J Virol 2003, 77:10862-10871. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  56. Waggoner SN, Hall CH, Hahn YS: HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production.

    J Leukoc Biol 2007, 82:1407-1419. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  57. Zimmermann M, Flechsig C, La Monica N, Tripodi M, Adler G, Dikopoulos N: Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes.

    J Hepatol 2008, 48:51-60. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  58. Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS: Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2).

    J Gastroenterol Hepatol 2005, 20:234-242. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  59. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N: Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.

    J Infect Dis 2004, 190:1919-1926. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  60. Wertheimer AM, Bakke A, Rosen HR: Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease.

    Hepatology 2004, 40:335-345. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  61. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M: Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma.

    J Hepatol 1999, 31:323-331. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  62. Curtin JF, Cotter TG: Live and let die: regulatory mechanisms in Fas-mediated apoptosis.

    Cell Signal 2003, 15:983-992. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  63. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.

    Immunity 1996, 5:7-16. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  64. Ohshima K, Nakashima M, Sonoda K, Kikuchi M, Watanabe T: Expression of RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible role in immune privilege.

    Clin Exp Immunol 2001, 123:481-486. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  65. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege.

    Immunol Today 1997, 18:240-244. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  66. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U: Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

    Br J Cancer 2001, 85:1047-1054. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  67. Li M, Liu X, Zhou S, Li P, Li G: Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.

    BMC Cancer 2005, 5:96. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  68. Li MS, Ma QL, Chen Q, Liu XH, Li PF, Du GG, Li G: Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.

    World J Gastroenterol 2005, 11:2564-2569. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  69. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH: Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.

    J Immunol 2004, 173:4919-4928. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  70. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.

    Cancer Cell 2004, 5:241-251. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  71. Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scharovsky GO: The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression.

    Cancer Immunol Immunother 2002, 50:597-603. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  72. Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, Kimura F, Wakatsuki T, Yamamoto M: Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements.

    Int J Oncol 2003, 23:1575-1583. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  73. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR: Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.

    Lab Invest 2007, 87:582-590. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  74. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

    Clin Cancer Res 2007, 13:902-911. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  75. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA: Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma.

    Hepatology 1996, 23:1181-1188. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  76. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shiratori Y: Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.

    J Gastroenterol Hepatol 2004, 19:1121-1127. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  77. Matsui M, Machida S, Itani-Yohda T, Akatsuka T: Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.

    J Gastroenterol Hepatol 2002, 17:897-907. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  78. Chiu CT, Yeh TS, Hsu JC, Chen MF: Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.

    Dig Dis Sci 2003, 48:670-676. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  79. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C: Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome.

    Mod Pathol 2004, 17:1378-1385. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  80. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M: Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

    Int J Gastrointest Cancer 2005, 35:53-60. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  81. Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

    Curr Opin Immunol 2006, 18:220-225. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  82. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-Cuesta F, Lasarte JJ, Prieto J: Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.

    J Virol 2007, 81:3662-3666. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  83. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy.

    Nat Rev Cancer 2004, 4:11-22. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  84. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumour-cell death and immunogenicity: a question of choice.

    Immunol Today 1997, 18:32-36. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  85. Humphreys RC, Halpern W: Trail receptors: targets for cancer therapy.

    Adv Exp Med Biol 2008, 615:127-158. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  86. Ahmed FY, Cassidy J: The treatment of advanced colorectal cancer with interferon-alpha: a review.

    Expert Opin Investig Drugs 1999, 8:13-18. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  87. Kirkwood J: Cancer immunotherapy: the interferon-alpha experience.

    Semin Oncol 2002, 29:18-26. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  88. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

    Proc Natl Acad Sci USA 1995, 92:4562-4566. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  89. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM: Interferon-alpha in tumor immunity and immunotherapy.

    Cytokine Growth Factor Rev 2002, 13:119-134. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  90. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

    Hepatology 1993, 17:389-394. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  91. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodes J, Bruix J: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.

    Hepatology 2000, 31:54-58. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  92. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.

    Ann Intern Med 2001, 134:963-967. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  93. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.

    Hepatology 2000, 32:228-232. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  94. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

    Ann Intern Med 2003, 138:299-306. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  95. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

    J Clin Oncol 2003, 21:421-427. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  96. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

    Cancer 2002, 94:435-442. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  97. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, et al.: Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

    J Clin Oncol 1993, 11:1737-1745. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  98. Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H: Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

    Eur J Cancer 1999, 35:380-385. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  99. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, et al.: Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

    Oncology 2000, 58:227-236. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  100. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A: Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

    Am J Clin Oncol 2002, 25:224-226. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  101. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maestroni GJ: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.

    Eur J Cancer 1994, 30A:167-170. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  102. Ishikawa T, Imawari M, Moriyama T, Ohnishi S, Matsuhashi N, Suzuki G, Takaku F: Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

    J Cancer Res Clin Oncol 1988, 114:283-290. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  103. Okuno K, Hirohata T, Nakamura K, Jinnai H, Shigeoka H, Koh K, Shindo K, Yasutomi M: Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer.

    Clin Ther 1993, 15:672-683. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  104. Lygidakis NJ, Savanis G, Pothoulakis J, Kapetanakis A: Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours.

    Anticancer Res 1994, 14:643-646. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  105. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

    J Clin Oncol 2005, 23:8950-8958. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  106. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.

    J Interferon Cytokine Res 1995, 15:467-472. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  107. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C: Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma.

    J Immunother 2002, 25:489-499. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  108. Hieber U, Heim ME: Tumor necrosis factor for the treatment of malignancies.

    Oncology 1994, 51:142-153. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  109. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O: TRAIL in cancer therapy: present and future challenges.

    Expert Opin Ther Targets 2007, 11:1299-1314. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  110. Zhu Y, Chen L: Cancer therapeutic monoclonal antibodies targeting lymphocyte co-stimulatory pathways.

    Curr Opin Investig Drugs 2003, 4:691-695. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  111. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited.

    Annu Rev Immunol 2005, 23:515-548. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  112. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

    Cell 1992, 71:1093-1102. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  113. Riley JL, June CH: The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

    Blood 2005, 105:13-21. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  114. Bertram EM, Dawicki W, Watts TH: Role of T cell costimulation in anti-viral immunity.

    Semin Immunol 2004, 16:185-196. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  115. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

    N Engl J Med 2006, 355:1018-1028. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  116. Myers LM, Vella AT: Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation.

    Trends Immunol 2005, 26:440-446. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  117. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB. Analysis of expression and function.

    J Immunol 1993, 150:771-781. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  118. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

    Cell Immunol 1998, 190:167-172. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  119. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

    J Exp Med 1997, 186:47-55. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  120. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.

    J Immunol 1999, 162:5037-5040. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  121. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

    Nat Med 1997, 3:682-685. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  122. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzalez A, Melero I: Immunotherapy and immunoescape in colorectal cancer.

    World J Gastroenterol 2007, 13:5822-5831. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  123. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS: Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

    J Immunol 2007, 178:4194-4213. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  124. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27.

    Cytokine Growth Factor Rev 2003, 14:265-273. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  125. Watts TH: TNF/TNFR family members in costimulation of T cell responses.

    Annu Rev Immunol 2005, 23:23-68. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  126. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

    Immunity 2001, 15:445-455. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  127. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C, Shields J: Engagement of the OX-40 receptor in vivo enhances antitumor immunity.

    J Immunol 2000, 164:2160-2169. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  128. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy.

    Nat Rev Cancer 2007, 7:95-106. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  129. Teft WA, Kirchhof MG, Madrenas J: A molecular perspective of CTLA-4 function.

    Annu Rev Immunol 2006, 24:65-97. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  130. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade.

    Science 1996, 271:1734-1736. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  131. Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

    Annu Rev Immunol 2001, 19:565-594. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  132. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

    Nat Rev Immunol 2004, 4:336-347. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  133. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

    Cancer Res 2005, 65:1089-1096. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  134. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN: HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma.

    Mol Cancer Res 2007, 5:605-614. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  135. Ku XM, Liao CG, Li Y, Yang XM, Yang B, Yao XY, Wang L, Kong LM, Zhao P, Chen ZN: Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147.

    Scand J Immunol 2007, 65:435-443. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  136. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

    Cancer Res 1998, 58:5301-5304. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  137. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

    Clin Cancer Res 2005, 11:728-734. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  138. Miller AD: Human gene therapy comes of age.

    Nature 1992, 357:455-460. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  139. Mulligan RC: The basic science of gene therapy.

    Science 1993, 260:926-932. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  140. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989–2004-an overview.

    J Gene Med 2004, 6:597-602. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  141. Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, Gao G, High KA, Leen AM, Lemoine NR, McNeish IA, Meneguzzi G, Peschanski M, Roncarolo MG, Strayer DS, Tuszynski MH, Waxman DJ, Wilson JM: Progress and prospects: gene therapy clinical trials (part 2).

    Gene Ther 2007, 14:1555-1563. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  142. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials (part 1).

    Gene Ther 2007, 14:1439-1447. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  143. Cao L, Kulmburg P, Veelken H, Mackensen A, Mezes B, Lindemann A, Mertelsmann R, Rosenthal FM: Cytokine gene transfer in cancer therapy.

    Stem Cells 1998, 16(Suppl 1):251-260. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  144. Qian C, Liu XY, Prieto J: Therapy of cancer by cytokines mediated by gene therapy approach.

    Cell Res 2006, 16:182-188. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  145. Schmidt-Wolf GD, Schmidt-Wolf IG: Cytokines and gene therapy.

    Immunol Today 1995, 16:173-175. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  146. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity.

    Nat Rev Immunol 2003, 3:133-146. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  147. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy.

    Cytokine Growth Factor Rev 2002, 13:155-168. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  148. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.

    J Exp Med 1995, 182:155-162. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  149. Mazzolini G, Narvaiza I, Bustos M, Duarte M, Tirapu I, Bilbao R, Qian C, Prieto J, Melero I: Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment.

    Mol Ther 2001, 3:665-672. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  150. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

    Blood 1997, 90:2541-2548. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  151. Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with interleukin-12.

    Curr Pharm Des 2003, 9:1981-1991. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  152. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O: IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response.

    Gene Ther 1999, 6:1705-1712. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  153. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, Prieto J: Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

    Cancer Gene Ther 1999, 6:514-522. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  154. Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Carbone C, Chernajovsky Y, Podhajcer OL: Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.

    Cancer Res 2000, 60:6696-6703. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  155. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

    Hepatology 2001, 33:52-61. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  156. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

    Hepatology 2001, 33:52-61. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  157. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X, Duarte M, Melero I, Prieto J: Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level.

    Hum Gene Ther 2000, 11:113-125. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  158. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.

    Proc Natl Acad Sci USA 1996, 93:11302-11306. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  159. Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Damen U, Tennant B, Scherer C, Graham FL, Roggendorf M: Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes.

    J Natl Cancer Inst 2001, 93:472-479. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  160. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, Ruiz J, Prieto J, Melero I: Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

    Gene Ther 2001, 8:259-267. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  161. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.

    J Immunol 2000, 164:3112-3122. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  162. Mazzolini G, Narvaiza I, Martinez-Cruz LA, Arina A, Barajas M, Galofre JC, Qian C, Mato JM, Prieto J, Melero I: Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

    Gene Ther 2003, 10:1067-1078. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  163. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olagüe C, Sola J, Sádaba B, Lacasa C, Melero I, Qian C, Prieto J: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

    J Clin Oncol 2004, 22:1389-1397. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  164. Clerici M, Shearer GM, Clerici E: Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm.

    J Natl Cancer Inst 1998, 90:261-263. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  165. Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL: IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.

    J Immunol 2005, 175:5885-5894. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  166. Gilly FN, Beaujard A, Bienvenu J, Trillet Lenoir V, Glehen O, Thouvenot D, Malcus C, Favrot M, Dumontet C, Lombard-Bohas C, Garbit F, Gueugniaud PY, Vignal J, Aymard M, Touraine Moulin F, Roos M, Pavirani A, Courtney M: Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report.

    Hepatogastroenterology 1999, 46(Suppl 1):1268-1273. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  167. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.

    Gene Ther 1997, 4:419-425. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  168. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J: In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.

    Gene Ther 2000, 7:1467-1476. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  169. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C: Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma.

    Hepatology 2001, 34:72-81. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  170. Liu TC, Kirn D: Gene therapy progress and prospects cancer: oncolytic viruses.

    Gene Ther 2008, 15(12):877-884. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  171. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y: Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

    Surgery 2007, 141:520-529. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  172. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

    Science 1996, 274:373-376. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  173. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, Mitry R, Havlik R, Seth P, Hartwigsen J, Bhushan R, Nicholls J, Jensen S: Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

    Cancer Gene Ther 2002, 9:254-259. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  174. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF: Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

    J Clin Oncol 2003, 21:1498-1504. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  175. Hernandez-Alcoceba R, Sangro B, Prieto J: Gene therapy of liver cancer.

    Ann Hepatol 2007, 6:5-14. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  176. Banchereau J, Steinman RM: Dendritic cells and the control of immunity.

    Nature 1998, 392:245-252. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  177. Reis e Sousa C: Dendritic cells in a mature age.

    Nat Rev Immunol 2006, 6:476-483. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  178. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, Chouzenoux S, Soubrane O, Calmus Y, Conti F: Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway.

    Lab Invest 2008, 88:973-985. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  179. Sriram U, Biswas C, Behrens EM, Dinnall JA, Shivers DK, Monestier M, Argon Y, Gallucci S: IL-4 suppresses dendritic cell response to type I interferons.

    J Immunol 2007, 179:6446-6455. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  180. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer.

    Curr Opin Immunol 2005, 17:163-169. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  181. Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG: Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

    Cancer Res 1999, 59:2802-2805. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  182. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.

    Cancer Res 1999, 59:4035-4041. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  183. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, Bustos M, Qian C, Prieto J: Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.

    Gene Ther 1999, 6:1779-1784. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  184. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.

    J Immunother 2005, 28:129-135. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  185. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS, Dubinett SM: Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication.

    Hum Gene Ther 2000, 11:53-65. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  186. Vera M, Razquin N, Prieto J, Melero I, Fortes P, Gonzalez-Aseguinolaza G: Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.

    Mol Ther 2005, 12:950-959. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  187. Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I: Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

    J Clin Oncol 2005, 23:999-1010. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  188. Feijoó E, Alfaro C, Mazzolini G, Serra P, Peñuelas I, Arina A, Huarte E, Tirapu I, Palencia B, Murillo O, Ruiz J, Sangro B, Richter JA, Prieto J, Melero I: Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.

    Int J Cancer 2005, 116:275-281. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  189. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity.

    Annu Rev Immunol 1998, 16:111-135. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  190. Kikuchi T, Miyazawa N, Moore MA, Crystal RG: Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.

    Cancer Res 2000, 60:6391-6395. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  191. Kikuchi T, Moore MA, Crystal RG: Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.

    Blood 2000, 96:91-99. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  192. Chu XY, Chen LB, Zang J, Wang JH, Zhang Q, Geng HC: Effect of bone marrow-derived monocytes transfected with RNA of mouse colon carcinoma on specific antitumor immunity.

    World J Gastroenterol 2005, 11:760-763. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  193. Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M: Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.

    Cancer Res 2004, 64:4995-5003. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  194. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

    Clin Cancer Res 1999, 5:1331-1338. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  195. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

    Proc Natl Acad Sci USA 2001, 98:8809-8814. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  196. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M: Dendritic cell-based vaccination in solid cancer.

    J Clin Oncol 2003, 21:135-142. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  197. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K, Kitano S: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.

    Cancer Immunol Immunother 2003, 52:155-161. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  198. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G: Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.

    Cancer Immunol Immunother 2007, 56:2003-2016. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  199. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

    Clin Cancer Res 1999, 5:1331-1338. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  200. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.

    Cancer Immunol Immunother 2002, 51:99-106. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  201. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.

    Int J Oncol 2004, 24:909-917. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  202. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Kohne CH, Ehninger G, Schmitz M, Bornhauser M: Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

    Cancer Immunol Immunother 2006, 55:268-276. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  203. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB: Natural killer-dendritic cell cross-talk in cancer immunotherapy.

    Expert Opin Biol Ther 2005, 5:1303-1315. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  204. Rodriguez-Calvillo M, Duarte M, Tirapu I, Berraondo P, Mazzolini G, Qian C, Prieto J, Melero I: Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12.

    Exp Hematol 2002, 30:195-204. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  205. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA: NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.

    Cancer Immunol Immunother 2006, 55:1122-1131. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  206. Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

    J Clin Invest 2004, 113:774-783. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  207. Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK: Current immunotherapeutic strategies in colon cancer.

    Surg Oncol Clin N Am 2007, 16:873-900. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  208. von Mehren M: Colorectal cancer vaccines: what we know and what we don't yet know.

    Semin Oncol 2005, 32:76-84. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  209. Prieto J, Qian C, Sangro B, Melero I, Mazzolini G: Biologic therapy of liver tumors.

    Surg Clin North Am 2004, 84:673-696. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  210. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE: Biological treatment for liver tumor and new potential biomarkers.

    Dig Dis Sci 2008, 53:836-843. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  211. Elkord E, Hawkins RE, Stern PL: Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy.

    Expert Opin Biol Ther 2008, 8:385-395. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  212. Ho WY, Yee C, Greenberg PD: Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

    J Clin Invest 2002, 110:1415-1417. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  213. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

    Nat Rev Cancer 2008, 8:299-308. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  214. June CH: Principles of adoptive T cell cancer therapy.

    J Clin Invest 2007, 117:1204-1212. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  215. Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, Xing Q, Yu X, Gong L, Yin YH, Zhang Y, Chen WF: The immunosuppressive tumor microenvironment in hepatocellular carcinoma.

    Cancer Immunol Immunother 2008.PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  216. Dong XY, Peng JR, Ye YJ, Chen HS, Zhang LJ, Pang XW, Li Y, Zhang Y, Wang S, Fant ME, Yin YH, Chen WF: Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients.

    Int J Cancer 2008, 122:2038-2043. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  217. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, Eisele S, Encke J, Blum HE, Geissler M: Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice.

    Gastroenterology 2000, 119:1104-1112. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  218. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.

    Cancer Res 1999, 59:3064-3067. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  219. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS, Sheu JC: Expressions of cancer-testis antigens in human hepatocellular carcinomas.

    Cancer Lett 2001, 164:189-195. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  220. Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaneyoshi T, Toshikuni N, Kariyama K, Nakayama E, Tsuji T: Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma.

    J Hepatol 2000, 32:612-617. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  221. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, Niho Y: High frequency of the MAGE-1 gene expression in hepatocellular carcinoma.

    Hepatology 1996, 24:1437-1440. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  222. Jeng YM, Peng SY, Lin CY, Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma.

    Clin Cancer Res 2004, 10:2065-2071. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  223. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S: Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma.

    Int J Cancer 2005, 116:579-583. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  224. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.

    Clin Cancer Res 2004, 10:8630-8640. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  225. Liu FF, Dong XY, Pang XW, Xing Q, Wang HC, Zhang HG, Li Y, Yin YH, Fant M, Ye YJ, Shen DH, Zhang Y, Wang S, Chen WF: The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients.

    Gastroenterology 2008, 134:998-1006. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  226. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP: Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.

    J Proteome Res 2005, 4:2062-2069. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  227. Evdokimova VN, Butterfield LH: Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer.

    Expert Opin Biol Ther 2008, 8:325-336. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  228. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

    Clin Cancer Res 2007, 13:644-653. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  229. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

    J Immunol 1980, 125:1487-1493. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  230. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

    N Engl J Med 1987, 316:889-897. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  231. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuk I, Ross S, Krane RJ: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.

    Lancet 1990, 335:994-998. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  232. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y: Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.

    Hepatology 1989, 10:349-353. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  233. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al.: Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.

    Cancer 1991, 68:2391-2396. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  234. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

    Lancet 2000, 356:802-807. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  235. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H: Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.

    Clin Cancer Res 2003, 9:2357-2365. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  236. Curiel TJ: Tregs and rethinking cancer immunotherapy.

    J Clin Invest 2007, 117:1167-1174. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  237. Rico M, Matar P, Zacarías Fluck M, Giordano R, Scharovsky O: Low dose Cyclophosphmide (Cy) treatment induces a decrease in the percentage of regulatory T cells in lymphoma-bearing rats.

    Proc Am Assoc Cancer Res 2007, 48:233. OpenURL

    Return to text

  238. Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

    J Exp Med 1982, 155:968-980. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

    Return to text

  239. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ: Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

    Cancer Res 2002, 62:1462-1470. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  240. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.

    J Immunol 2003, 170:6338-6347. PubMed Abstract | Publisher Full Text OpenURL

    Return to text

  241. Quezada SA, Peggs KS, Curran MA, Allison JP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

    J Clin Invest 2006, 116:1935-1945. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL


#1414 From: "salvationscience" <salvationscience@...>
Date: Tue Mar 24, 2009 9:02 pm
Subject: RASA TANTRA SADHANA: THE PRACTICE OF URINE TANTRA
salvationsci...
Offline Offline
Send Email Send Email
 
RASA TANTRA SADHANA: THE PRACTICE OF URINE TANTRA
RE: THE ANCIENT EXPERIMENTAL THEORETICAL RESEARCH DESIGN
FOR GENETIC REJUVENATION, SIDDHIS, AND HIGHER CONSCIOUSNESS
http://www.salvationscience.com/v088.htm

I found some computer-generated errors in this article at the
salvationscience.com website. It contains the "Core Gnosis" of the secret
initiation, so I am reposting it here with the necessary corrections to be
placed at the top of volume 88. We all thank our web-master for his excellent
service to both God and country.
Jai Om. - Sw. Tantrasangha, March 24, 2009
------------

Due to the nature of a Yahoo Group, the knowledge is quite piecemeal and is not
ordered into chapters, etc. Nevertheless, this
"potpourri" of Knowledge can be picked up and reorganized in your minds, and
hopefully some of you will be good disciples of Jesus and will write, as I have,
about this most important of all topics.

Without flattering myself or Sai too much, I doubt that anyone has
had a better explanation of this whole matter in the entire recorded
history of the world. Since we are either single or yoked to an anti-
Tantric spouse, or just in a situation not conducive to practicing
this technique, we are nothing short of being in bondage to the 8-
Fold Suffering. Although a lack of discernment is a characteristic of
these times, it is well to acknowledge that Rasa Tantra Vidya comes
from this source and can be found nowhere else but in my writings
from my publishing days. Still alone after all these years, while
everyone laments the passing of the Pope. Jai Om. - Sw. Tantrasangha

RASA TANTRA SADHANA by Swami Tantrasangha

The Nag Hammadi Gospels state: "There are five trees growing in
Paradise, whose leaves never fall..." And in the Bible, the Tree of
Life bore fruit twelve times a year (a monthly cycle). It's fruit was
for food and its leaves for medicine. Similarly, Mahayana has five
sacraments: URINE, SEMEN, MENSTRUUM, MILK, and the fifth does not
concern us, since it is intended only for those who are already
Reborn or Resurrected. In Mahayana, it is stated that the hellish
states are caused by Apana (outflow).

In ancient Egyptian symbology, the goddess Nut (meaning "female
water"), identical with Soma (Moon) Pavamana (Pure Mother Water or
Pure Food), pours water from the Tree of Life to her male mate, who
drinks it. The Egyptians had an offering stone, many of which can be
found in the world's museums, similar to the Hindu stone Yoni Lingum,
better known as the Siva Lingam, seen in millions of Hindu temples.

The Egyptian offering stone has the image of two waters, joining as
one. The Siva Lingam is of conjoined Lingam (phallus) and Yoni
(vagina). The ritual was the simple pouring of water over the stones - Egyptian
or Hindu - thus making the female and male waters join as one. This is a visual,
sculptural symbol for Rasa Tantra.

From our studies of Urine Therapy, we see that we must simply fast on
water and drink all our urine. Most of us cannot, at present, do this
indefinitely, so we can add liquid nourishment, still abstaining from
solids. The preferred liquids would be milk (preferably
unpasteurized), juices of all kinds (also preferably uncooked), and
(raw) honey and blackstrap molasses.

To "leaven the bread" or increase serum Urea for building tissues,
add a few teaspoons of fine powders, such as soy, brewer's yeast
(cooked), Spirulina or milk powder. Yogurt (curd) and kefir are also
excellent. For oil, take butter, flax seed oil or olive oil, all
preferably uncooked. For salt cravings, there are any number of
flavorings, which can be used to make a soup or broth. This pretty
much covers the supplements to your fast.

Then, it is but the simple process of fasting, taking supplements
preferably only when your ribs start to protrude, which is a sign to
gain a little weight. This is a "Semi-Breatharian" diet. If you have
a craving for a certain food not on the list, eat it once a week, and
make a ceremony out of it. This is recommended as a permanent diet.
It can be practiced as Urine Therapy or as Rasa Tantra (preferably).

The man and woman simply exchange and consume all their secretions,
while on this fast or semi-fast. Distilled water is best and avoid
all chemical additives. Otherwise there could be a buildup of toxins
from Hermetically Sealing what you are consuming. The purpose is to
detox through fasting, while taking in valuable nourishment in the
form of enzymes, vitamins, minerals, antigens or antibodies,
hormones, and DNA or RNA.

To make the process easier, Project Genesis and freeze-drying was
introduced. Project Genesis is simply to connect a man and woman, of
the same blood type, using intravenous (I.V.) tubes. Or secretions
could be freeze dried and taken in capsules, which would leave room
in the body to drink more liquids. Hyperthermia, preferably Far
Infrared Saunas or steam, can be used to sweat out any overabundance
of fluids.

A little sun and exercise can make a big difference. In the
beginning, frequent enemas are advised. These types of austerities
can tax your discipline to the limit, which is a great drawback. I
would recommend a good organic tranquilizer, rather than have a
patient succumb to the cravings for food or the many other torments
of long fasts.

Unfortunately, tranquilizers are getting more difficult to find. A
fasting patient should be treated just like bedridden people in pain
in a hospital. I prefer raw opium, but, of course, that is only
possible in the Far East. The important thing is to complete the fast
and to attain the curing of diseases and senescence, to say nothing
of the advent of Siddhis. I offer this to the Triune God of Father,
Mother, and Child or Rebirth. Jai Om. - Sw. Tantrasangha

http://www.salvationscience.com/v088.htm
****************************************************************

#1413 From: well being <starhealth100@...>
Date: Tue Mar 24, 2009 8:52 am
Subject: (SERVICES) - Are you going through chemo/radio therapy?
starhealth100@...
Send Email Send Email
 
Are you going through chemo/radio therapy?

Would you like to know about a natural formulation that is able to overcome fatigue and nausea and generally give a boost of energy and recover more speedily mentally and physically, putting back all the vitamins, minerals and amino acids to help every system in the body as well as the mental processes.

 

Please phone me to know more on the numbers below and take a look at my website on: http://www.irenesteinrj.com/asp/int.asp?GeneralID=58

 

Irene Stein

Tel: +972 9 9509850

Mobile:+972 545 305125

UK Mobile :+447831641199

E-mail: irenest@...




#1412 From: Joseph Eldor <a1b2c3d4@...>
Date: Mon Mar 23, 2009 10:34 am
Subject: Re: UroTherapy
csen_interna...
Offline Offline
Send Email Send Email
 
Hi,
I do not specialise in urine therapy for cancer patients. I only wrote a hypothesis article on that subject.
Best regards,
Joseph Eldor
 
----- Original Message -----
Sent: Sunday, March 22, 2009 12:41 PM
Subject: UroTherapy

From: sjacrane@...
To: a1b2c3d4@...
Subject: UroTherapy
Date: Fri, 20 Mar 2009 23:03:10 +0000

Hi, do you specialise in urine therapy for cancer patients? If so, could you please provide me with full information on your clinic and programmes etc. I understand alot about urine therapy myself, but it I would like to seek the help of a urine therapy specialist. Thankyou. Stephen

 

Windows Live Hotmail just got better. Find out more!

Beyond Hotmail — see what else you can do with Windows Live. Find out more!

#1411 From: Joseph Eldor <a1b2c3d4@...>
Date: Fri Mar 20, 2009 11:13 pm
Subject: Fw: UroTherapy
csen_interna...
Offline Offline
Send Email Send Email
 
 
----- Original Message -----
Sent: Saturday, March 21, 2009 1:03 AM
Subject: UroTherapy

Hi, do you specialise in urine therapy for cancer patients? If so, could you please provide me with full information on your clinic and programmes etc. I understand alot about urine therapy myself, but it I would like to seek the help of a urine therapy specialist. Thankyou. Stephen

Windows Live Hotmail just got better. Find out more!

#1410 From: "salvationscience" <salvationscience@...>
Date: Mon Mar 16, 2009 11:30 pm
Subject: 5th World Congress on Urotherapy
salvationsci...
Offline Offline
Send Email Send Email
 
5th World Congress on Urotherapy
In Guadalajara, Jalisco, México, Nov. 5-7, 2009
http://www.5thworldcongressurotherapy.org/inicio_en.html#end
http://www.salvationscience.com/v222.htm

5th.World Congress Urotherapy,
In Guadalajara, Jalisco, México, Nov. 5-7, 2009

Dear Friends:

It is our great pleasure to greet and welcome you as we gather to share and
learn about our mutual interest in this great event, The Fifth World Congress of
Urotherapy 2009 in Guadalajara Mexico. Here, the World Organization for
Excellence in Health Care will gather to offer and provide knowledge and
experiences in the areas of medicine and chemistry, as well as institutions and
people that participate actively in the implementation of healthy life styles,
along with a better quality of life for Humanity. We are inviting
representatives of many Countries from 5 different Continents: America, Europe,
Asia, Oceania and Africa, where all will participate with this scientific,
experimental and knowledge from many great testimonials, thus contributing to
the wellness of World Humanity.

Atte.

Comité  organizador
Dr. Ryosuke Uryu
Dr Rovere Pierfrancesco
Q.F.B. Sonia Rodriguez
Dr. Coen Van Der Kroon
Pe. Raymundo Reyna
Pe. Jorge E. Zarraga

Japón. Italia  México, Alemania, África, Australia
5th World Congress on Urotherapy, México 2009.
www.5thworldcongressurotherapy.org
worldcongressmexico2009@...
http://www.salvationscience.com/v222.htm
*************************************************************

#1409 From: "salvationscience" <salvationscience@...>
Date: Fri Mar 6, 2009 8:59 pm
Subject: BUDDHA RECOMMENDS URINE AS ONLY MEDICINE IN THERAVADA TIPITAKA
salvationsci...
Offline Offline
Send Email Send Email
 
BUDDHA RECOMMENDS URINE AS ONLY MEDICINE IN THERAVADA TIPITAKA
A URINE FAST - "THE BUDDHA MEDICINE" BY BHIKKU U. DHAMMAJIVA
Edited, with Commentaries by Swami Tantrasangha
http://www.shirleys-wellness-cafe.com/urine.htm
http://www.salvationscience.com/v220.htm

"The Buddha Medicine" By Bhikkhu U. Dhammajiva
Edited by: Swedish novice Dhammasami (Samuel Nordius)
http://www.shirleys-wellness-cafe.com/urine_testimonials.htm#buddha
http://www.shirleys-wellness-cafe.com/urine.htm

"Glad at heart, I pay homage to the supreme sage - the giver of
blissful peace, the great ocean of virtue, the physician for the
samsaric ills of beings, the sun that dispel the pitchy darkness of
false views!" – Lo-wáda Sangarava, 15th century Sinhalese poem
In Burmese meditation-centers, as in monasteries in most Theravada-
Buddhist countries, you often find a peculiar kind of medicine:

Yellow Myrobalan nuts (in Pali: Hritaki, in Latin: Terminalia
Chebula) pickled in cow's urine. The Burmese people calls it Pheya-
se, 'The Buddha Medicine', since it's based on a recipe found in the
oldest Buddhist texts, the Pali Tipitaka. It's considered to be a
panacea for many diseases. But does it really follow the original
concept of the Buddha's recommendation to use muttam (urine) as
medicine? That is what I intend to clarify in this article by
refering to four of the oldest Buddhist scriptures: 1.) The Vinaya-
Pitaka, the ancient collection of Buddhist monastic rules. 2.) The
Sutta Pitaka, the ancient collection of the Buddha's discourses. 3.)
The so-called 'Commentary' and 'Sub-commentary', texts written by
bhikkhus (Buddhist monks) in the centuries following the Buddha's
death to clarify the meaning of the texts found in the two
collections first mentioned.

In an English translation of the Mahakkhandhaka (a text in Mahavagga
found in the Vinaya-Pitaka) the Buddha says:

"The religious life has decomposing urine (PutiMutta or Putrid Urine, which is
now interpreted only as "undesirable" urine - not aged urine) as medicine for
its resource. Thus you must endeavor to live all your life. Ghee, butter, oil,
honey, and molasses are extra allowances." (These are the dietary supplements
for people on Urine Fasts or practicing Rasa Tantra. These supplements can be
found in many scriptures.)

An alternative translation says;

"Going forth [into the Holy Life] has fermented ("puti" in Pali, putrid, meaning
loathesome, not aged. In other words the instructions take into account one's
reluctance to drink urine.) urine (mutta) as its support. For the rest of your
life you are to endeavor at that. The extra allowances are; Ghee, fresh butter,
oil, honey,  (raw) sugar."

There are four such necessary supports/resources listed in the
Vinaya Pitaka. In Pali, the language of the oldest Buddhist texts,
they are called "the Four Requisites", considered to be an absolute
minimum for the bhikkhus to be able to live the Holy Life in line
with the Buddha's teaching. The above mentioned item, fermented ("puti" or
putrid - not fermented but loathesome to the uninitiated)
urine, is the fourth of these resources. All the four must be taught
to the newly ordained bhikkhu in the ordination hall immediately
after his higher ordination ceremony. It's the responsibility of the
preceptor to make sure that all young bhikkhus know them according
to the following prescription of the Buddha.

"I prescribe, O bhikkhus, that he who confers the higher ordination
(on a bhikkhu), tells him the four resources."

These are all the four resources listed in the Vinaya-Pitaka:

1. Robes: robes made of rags taken from a dust heap as a resource (a vow of
poverty)
2. Alms food: morsels of food given in alms as a resource (Better to stay with
recycling and the recommended dietary supplements.)
3. Dwellings: a dwelling at the foot of a tree as a resource (a vow of poverty)
4. Medicines: decomposing ("puti" - not foul or decomposing, but detestable to
the uninitiated) urine as medicine as a resource. Fasting, combined with
recycling one's immune, genetic and nutritional foods and medicines in urine, is
deemed superior to modern medicine, especially in Rasa Tantra Sadhana. The Holy
Bible states: "The Tree of Life: It's fruit I give you for food, and its leaf
for medicine.")

These four requisites/resources the Buddha described as being
indispensable or the bare minimum. Accordingly a Buddhist monk must
endeavor to live all his bhikkhu life dependent only on them. He who
is contented and satisfied with whatever comes across along with
these bare minimums is always phrased in the community, as well as
in the Commentary, as having contentment with whatever four
requisites he has. Whatever extra things he comes across beyond
these four items is just a result of his past good deeds, but they
are usually also allowed for the bhikkhus. As the founder of the
Order, and therefore its first bhikkhu, the Buddha assured all the
bhikkhus that the prescribed bare minimums are quite abundant.
Besides, they were, at that time, free to find wherever a bhikkhu
would go. (The Holy Bible states: "There is much food in the tillage of the
poor." PutiMutta - the urine you don't want(?) - is there wherever you go.)

In the Vinaya Pitaka, the books of monastic discipline, this
medicine (urine) is mentioned in several places. At one occasion,
for example, the Buddha recommend the yellow Myrobalan fruits
pickled in urine for a monk who was sick with jaundice (probably
anaemia or Hepatitis) to be taken orally:

"O, monks! I allow that urine and yellow Myrobalan be drunk."
At another occasion the Buddha included urine as an ingredient in a
mixture to be used as an antidote for poisonous snake bites. The
other ingredients are excrement, soil and hot ash. This quote is
from the Vinaya Pitaka:

"For snake bite a medicine may be made of the four great filthy (once again, a
negative perception of what is being recommended - perhaps to confound or
confuse non-initiates about this doctrine)
things: excrement, urine, ash and clay. If there is someone present
to make these things allowable, one should have him/her make them
allowable. If not, one may take them for oneself and consume them."
The Commentary adds that this medicine is not only for snake bites
but also for any other poisonous animal bite.

Now, let's have a look at the second ancient collection of Buddhist
texts, the Sutta Pitaka. According to the Ariyavaüsa Sutta in
Anguttara Nikaya the Buddha phrases four requisites of noble clans
(or lineages of traditions) in nine terms:

The Commentary to the Ariyavaüsa Sutta says that even though the
list, as it appeares in the Sutta Pitaka, drops the forth item given
in the Vinaya Pitaka (medicines, changed to "meditation") that item should be
included in the second item of the Sutta. (2nd Sutta: Alms food. Urine is both
food and medicine.)

To summarize, in the Sutta Pitaka you find only the first three of
these four requisites, with no urine or medicines mentioned (meditation
instead), but theCommentary says that the forth (urine) should be included in
the list, in the alms food so that all should be in completion to make delight
in development of meditation possible.

Hence decomposing (a misinterpretation of "puti") urine (mutta, mutra) as
medicine can claim for all the above mentioned attributes, that is: urine was
"recognized as a medicine by those gone by, those honored from the past; that it
was recognized by the clan; it was not confusing in the past and it will not
confuse in the future; and it's not blamed (denounced) by recluses, Brahmins and
the wise."

I would like to quote another translation of the same Sutta which
goes as follows:

"O monks, these four noble lineages (requisites) pristine [including
"detestable" urine as medicine], of long standing, traditional, ancient,
unadulterated and never before adulterated, which are not being adulterated and
which will not be adulterated, not despised by wise ascetics and Brahmins."

The authors of this translation added a footnote saying that in
ancient Sri Lanka this was a very popular Buddhist discourse among
people of all walks of life and that it became the inspiration for
an annual festival. In traditional Sinhalese translations, as in
Burmese and Thai ones, the medicine mentioned in the text has been
taken to be cow's urine or, more specifically, Myrobalan fruits
pickled in cow's urine. Owing to this translation, some of the
attributions of this medicine, mentioned by the Buddha, doesn't
appear to be very convincing or practical since it would sometimes
be hard for a bhikkhu to find both the Myrobalan fruit and cow's
urine. However, in recent English translations we get some new
practical sense to this medicine.

Let me add here that it's not only in Buddhism that we find urine as
a medicine but also in other denominations such as Christianity (in
The Holy Bible), Hinduism (in Damar Tantra) and, some claims, in
Islam too (in The Holy Koran). These traditions, however, have a
somewhat different interpretation than the Buddhist texts on how to
use the medicine.

I can think of two reasons for why the usage of urine as medicine
resurfaced again contemporaneously in many traditions in our time.
The first is the increasing number of complications in the
prevailing allopathic or chemotherapeutic treatments of diseases
which has made an increasing number of people interested in
alternative medicines. The second is the general trend of searching
for more holistic health systems, even ancient ones based on
different religious lines. Whatever the reasons may be, the urine
method has its own intriguing nature and might, I believe, still
find a growing group of followers.

A closer look at this therapy, under the current trend, irrespective
of creed, one finds a vast number of convincing testimonies and
subjective evidences on the benefits of the medicine (urine). Buddhism can
contribute in its own way with its canonical and historical references on this
subject – provided that its ideas are presented in correct translations! So far
we've traced some quotations from the Vinaya Pitaka with relevant information
prescribed to bhikkhus. However, I think that the commentarial text has
interfered in a questionable and imperfect manner. In the traditional Buddhist
countries, such as Sri Lanka, Burma or Thailand, no efforts have been made in
resent history to get a clear idea of how the medicine was intended to be used,
or how it was used at the time of the Buddha.

The increasing amount of literature on the subject, with testimonies
and evidences from the other sources, made me think twice and urged
me to renew the way I read the quoted passages in the Buddhist
canonical sources. I went back to the original scriptures, untouched
by the prevalent traditional translations. When investigating the
Sutta Pitaka with this inquisitive pragmatic approach I came across
the following quotation in the Majjima Nikaya (the Middle Length
Discourses of the Buddha), Sutta number 46 called Dhamma Samadana
Sutta:

"Bhikkhu, a man would come along suffering from jaundice and he is
told: 'Friend, there is a drink made out of putrid (puti) urine, with
various kinds of medicines put in it. If you desire – drink.' When
drinking, it would not be agreeable to sight, smell or taste but
drinking it you will get over your illness. (Thus, "puti" does not mean putrid,
but that "it would not be agreeable".) He reflects about it and drinks it. It
would not be agreeable to sight, smell or taste, yet he would get over that
illness. I say this observance of the Teaching is comparable to this, as it is
now unpleasant (puti) and brings pleasant results in the future."

The Commentary to this Sutta says:

"[The Pali word] Putimuttan means just 'urine'. So it's said, that
even if a person is golden in color, his body is described as
repulsive in the scriptures. Even so, extracted in that very moment, the young
(or fresh) urine is called just puti (usually translated as 'putrid' or
'fermented', but meaning only 'repulsive')."

The Sub-commentary continues to explain:

"[The Pali word] Putimuttan means urine which is repulsive in
nature.

Just by consulting the relevant Commentary and its Sub-commentary
all doubts regarding the real meaning can be cleared out. They state
that urine – to be specific: one's own urine – would not be
agreeable to sight, smell or taste and accordingly has puti as an
adjectival prefix. It is puti not because it is rotten or fermented
but because its intrinsic nature is repulsive to the senses. If the
common translations are changed in line with this interpretation the
basic idea of using urine as a medicine becomes more palatable and,
not to diminish, quite agreeable with the current research and
literature on the subject.

It's also interesting to note that the medicine mentioned in the
Dhamma Samadana Sutta (one's own urine mixed up with other herbal
medicine) is recommended to any individual who's suffering from
jaundice rather than to a just to the bhikkhus as is otherwise the
case in the Vinaya Pitaka. This tells that the medicine was not seen
as just a 'last choice' but as a truly effective remedy.

Conclusive remarks

In the light of this information we should look again at the very
first quotation in this essay. The main theme so far is that
repulsive urine as medicine, which is the last of the four
requisites for bhikkhus, is considered to be the absolute minimum of
medicine that a bhikkhu will need through out his life.

The Pali term Putimuttabhesajja is a compounded term made out of at
least three pali roots; puti, mutta and bhesajja. As we've already
seen this word has been (literally) translated as:

1.) Decomposing urine as medicine. Or as: 2.) Fermented urine as
support.

The word puti literally means either decomposing or fermented,
sometimes translated as rancid or putrefied (but figuratively means only
repulsive). Muttam means urine, sometimes translated as cows' urine, and
occasionally as ammonia. Bhesajjam means medicine.

In the Vinaya Pitaka, whether with the consultation of its
Commentary or not, there is little chance to find out what kind of
urine is meant, because neither the Vinaya nor its Commentary adds
any further light on the subject. In the Sutta Pitaka, on the other
hand, especially in MN. Sutta No 46 and its relevant Commentary and
Sub-commentary, there's enough evidence to suggest a more pragmatic
meaning than that commonly accepted today. "It would not be
agreeable to sight, smell or taste" suggests that the adjective
"puti" does not mean any decomposition, fermentation or putrefaction
but that urine is naturally disagreeable to sight, smell or taste –
a statement most people would agree with. The original
recommendation may not have meant any decomposition, fermentation or
putrefaction at all, as the translators have interpreted it so far.
Nor do the scriptures in any way indicate that it was cow's urine
that the Buddha originally referred to.

The Sub-commentary says: "As urine pass out from the genital it is
warm due to the body heat". There is not a word or clue justifying
the assumption that cows' urine is meant.

The interpretation I prefer, on the other hand, is quite in line
with the Commentary and the Sub-commentary to the above mentioned
Sutta and with the contemporary idea of using one's own urine. Hence
the translation to the first quotations could be rectified as
follows:

"The religious life has your own (repulsive) urine as medicine for
its resource. Thus you must endeavor to live all your life. Ghee,
butter, oil, honey, and molasses are extra allowances."

Or: "Going forth [into the Holy Life] has your own (repulsive) urine
as its support. For the rest of your life you are to endeavor at
that. The extra allowances are; Ghee, fresh butter, oil, honey,
sugar." (The Holy Bible states: "I give you honey, oil and fine flour for food."
"Dainty food, that ye eat not much." "Butter and honey will they eat - all who
are left in the land." This, no doubt, refers to surviving a famine or an
epidemic, as well as Salvation from Suffering.)

Likewise, all other quotations could be corrected accordingly. This
should give a radical new approach to the prescription given by the
Buddha. It certainly does give a new hope for a healthier lifestyle –
not only for the bhikkhus but for all who seek to live a more
independent kind of life.

http://www.shirleys-wellness-cafe.com/urine_testimonials.htm#buddha
http://www.shirleys-wellness-cafe.com/urine.htm
http://www.salvationscience.com/v222.htm
*************************************************************

#1408 From: "salvationscience" <salvationscience@...>
Date: Fri Mar 6, 2009 7:43 pm
Subject: MEDICINE WARS: THE IMPACT OF URINE THERAPY IN VIET NAM
salvationsci...
Offline Offline
Send Email Send Email
 
MEDICINE WARS: THE IMPACT OF URINE THERAPY IN VIET NAM
Re: Three Stormy months of Jan., Feb., Mar. 1989
by Nguyen Chuong-Thi, Ho Chi Minh City, Viet Nam
Abridged and edited by Sw. Tantrasangha
http://tinyurl.com/ahvmoq
http://www.salvationscience.com

MEDICINE WARS: THE IMPACT OF URINE THERAPY IN VIET NAM, PART I

PART I: THE OPPOSITION
"THE ROAD TO HELL IS PAVED WITH GOOD INTENTIONS"

This is about an American book about Urine Therapy, which was
translated into Vietnamese, and then published in Viet Nam,
sponsored by the Vietnamese Red Cross, and made part of a TV program
about being your own doctor - a fundamental survivalist prerogative.
I was told that the book was banned, because it was "too popular".
God bless the honorable and courageous Vietnamese people.
Jai Om. - Sw. Tantrasangha
----------------------

Excerpts from newspapers and magazines: KHOA HOC PHO THONH (General
Science), SAIGON GIAI-PHONG (Saigon City Liberated), TUOI TRE
(Youth), kept by and in District 5 Red Cross, Ho-Chi-Minh City. In
most cases, the name and date of the paper are not quoted precisely
(are abridged). Only the most meaningful lines are chosen and
translated.

1. AUTHORITATIVE VOICES OF STRANGERS

A. Alarm Cries

"It is important to pay attention to the real fever caused in the
population by Urine Therapy (UT), which is spreading widely in many
cities and provinces, especially in the Mekong Delta. Unless it is
held back, in due time there would be a regrettable disaster." - Kim-
Son, Truong-Vuong Hospital.

"Urine Therapy is an anti-scientific book. Please everybody not
believe in those anti-scientific things, contained in this widely
propagated book." - Dr. Nu Hieu, Army Clinic 108

"It is regrettable that a book, which had not been subjected to
scientific test, even in the country (USA) where it came into
existence, has been propagated so extensively...from 3,000 copies to
70,000. Some people estimate that the actual number might be double
that!" - Quoc-Te reports

"We found out the original text in English. This book is among those
written by lay people, not graduated from any academic school of
medicine. The book sells well indeed beating all records of re-
impression within a brief lapse of time." - Prof. Ngo-Van-Quy

B. Concert of Angry Branches and Services

Opthalmology: "...In brief, if a person suffering from eyesore,
gets healed by urine, it means that the disease will disappear by
itself, without needing any medical care." - Dr. Nguyen-Cuong-Nam,
Bien-Dien-Phu Clinic.

C. Condemnation by Health Authorities

"This book on Urine Therapy was published by District 5 Red Cross,
re-impressed by the Municipal Editor up to 10,00 copies and soon
afterwards to 40,000. Within some months, the book was diffused in
every southwestern province, and far to the center and north of our
country (Viet Nam). Many provincial editors are now preparing its re-
impression. In that perspective, the effects on the public health
will be incalculable." - Ho-Chi-Minh City Health Service, in its
meeting on March 23rd, 1989. Reported by Kim-Son. Published in Tuoi-
Tre Chu-Nhat, March 26, 1989.

"A document causing seriously harmful effects." - Estimation by the
Techno-Scientific Board of the Municipal Health Service.

In the afternoon of March 23rd, 1989, the Techno-Scientific Board of
the Health Service held a meeting to give an estimation of Urine
Therapy. Dr. Duong-Quang-Trung, Director of the service, presided,
gathering over 20 professors, doctors, and pharmacists in service in
municipal hospitals. Hereafter are summarized the main opinions,
advanced in this meeting:

"We have received the original text in English, from which is some
detailed information about its author, which was...omitted from the
Vietnamese translation." - Dr. Do-Hong-Ngoc, Director of Health
Education Propagating Center.

"By all means, there must be a stop to the harm, due to applying
this Urine Therapy. We propose to the Municipal Culture Information
Service to cease subsequent reprinting of that book, and, if
possible, to withdraw all copies of it from sale." - Dr. Duong-Quang-
Trung.

D. Condemnation by the People's Committee of Ho-Chi-Minh City

"The Municipal Administrative authorities decide to forbid
publication and withdraw from the market, six vicious books on
sale. On May 20, 1989, the People's Committee of Ho-Chi-Minh City
issued decisions forbidding the diffusion and withdrawing from sale
six books, the contents of which are not sound...(5 titles on sex,
and) Urine Therapy. It is known that those six are among 20 books
the contents of which are considered as not sound, causing bad
effects to readers." - T.V.N. reports. Tuoi Tre, May 23rd, 1989.
--------------

Here ends "Part I: The Opposition". With all due respect to these
officials, who rank so high in the scientific community, it is this
honest Swami's educated opinion, that Urine Therapy already has
plenty of clinical trials and case histories to warrant even more
scientific experimental research on this promising self-medication.
This information can be found in The Tantrayudha.

In Part II, we will hear from the courageous advocates of Urine
Therapy. As long as one adheres to Scientific Method and does not
suppress evidence, we will get the right answer. But alas, there
are, once again, those proverbial medical vested interests to
overturn any honest objectivity or rational enquiry.
Jai Om. - Sw. Tantrasangha

http://www.salvationscience.com
-----------------

MEDICINE WARS: THE IMPACT OF URINE THERAPY IN VIET NAM, PART II
Re: Three Stormy months of Jan., Feb., Mar. 1989
by Nguyen Chuong-Thi, Ho Chi Minh City, Viet Nam
Abridged and edited by Sw. Tantrasangha
http://www.salvationscience.com

PART II: THE HONORABLE AND COURAGEOUS ADVOCATES OF URINE THERAPY
"I HAVE COME THAT YE MAY HAVE LIFE AND HAVE IT MORE ABUNDANTLY" -
LORD JESUS, ON INCREASING THE LIFESPAN AND QUALITY OF LIFE
RE: DISREGARDED VOICES OF WITNESSES

This is about an American book about Urine Therapy, which was
translated into Vietnamese, and then published in Viet Nam,
sponsored by the Vietnamese Red Cross, and made part of a TV program
about being your own doctor - a fundamental survivalist prerogative.
I was told that the book was banned, because it was "too popular".
God bless the honorable and courageous Vietnamese people.
Jai Om. - Sw. Tantrasangha
---------------

The following is from three documents, taken and translated from the
first four pages of the Vietnamese version of this American book on
Urine Therapy:

1. Editor's Words

"This book on Urine Therapy has been presented by District 5 Red
Cross to the Municipal Editor, in its good will of having it
published and propagated widely among the population. This is indeed
a simple way of curing diseases scientifically, with little expense,
and it is highly efficient and efficaceous, being applicable for a
host of illnesses.

"In our country, from most ancient times, there has been handed down
an ancestral method of treating diseases through urine. Still visible
today are mothers who, after delivery, every morning drink a bowl of
urine from a son of hers. Our combatants, formerly captured and
confined in jails, drand urine as a tonic and as remedy against
various diseases. Uncle Ho's (Ho Chi Minh's) sodiers, in their long
campaign and hard battles, used urine to appease thirst and strenthen
their legs.

(Other than this American book on Urine Therapy), "It seems that
there is not yet a similar book, dealing systematically in theory and
in practice, with this method of self-healing.

"Willing to expand our ancestors' knowledge in traditional medicine,
in our high esteem for ancient prescriptions still applicable today,
thus contributing our humble part to preventing and curing diseases
of the population, we decided to publish this translated book. We
hope it will give give readers a new and valuable document for study,
reference, and application, in order to heal themselves and many
others.

"We look forward to receiving readers' opinions." - Ho-Chi-Minh
Municipal Editor. (Not the original "Uncle Ho". Possibly referring to
Ho Chi Minh City. - editor.)

2. In Lieu of Preface

"It makes us glad and highly enthusiastic that many diseases, even
serious ones, can be cured if patients know how to apply Urine
Therapy as directed in this book. Its author uses analytical and
synthetical methods to present to us the nature of urine and the
proper method of using it to cure diseases.

"We met many patients who ascertained they had cured themselves
successfully by using their own urine.

"As a humanitarian institution, benefitting from the generous help
of the District 5 Print Firm, we reprint and offer to the public this
book on Urine Therapy. We aim to present a method of self-healing,
which is not expensive and is most efficient. We hope to contribute
to the realization or our guide-line, 'Doctor at Home - Medicine
Indoors', in the vast program of first aid to the population of
District 5 (Ho Chi Minh City, formerly Saigon).

"We are confident that our readers will study carefully this book,
apply it to heal themselves, and make known their experience to
other people. If there are any diseases that our readers have
cured, and their way of treating it, please inform us of that by
writing to: Red Cross, 251 Tran-Phu (formerly Nguyen-Hoang) Street,
District 5.

"Their precious contribution will help us organize a symposium,
gathering facts, proof, and further developing this method of good
health." For District 5 Red Cross - Truong-Van-Hai, President.

3. Words of Gratitude

"I am 58 now. I fought in the resistance army, combatting the French
up and down the mountains and forests on Truong-Son Range. Only as a
prisoner I came to cities, to be subjected to tortures which caused
chronic diseases. Dysentery, most painful and long-lasting,
devastated my digestive system for almost 30 years. Also in recent
years, there was heart and artery problems, rather serious.

"A friend, who knew my pains, advised me to try Urine Therapy. At
first I was reluctant, as many others are. Why to use again such an
old remedy, while there is now modern medicine and many modern
remedies? Alas for me, continuous suffering in heart and digestion
tormented me for a long time. I had to carry lots of pills and
bottles, when going out. I dared not eat unusual food, keeping away
from eggs, shrimp, and crabs. I had to be careful not to make strong
movements.

"Receiving this book, yet in typed manuscript, I read it through,
and after some days' hesitation, I tried to put it into practice. At
once, I felt much relieved. After twenty days' treatment, I felt
completely recovered. My health improved in a spectacular way. I
continued to benefit from this remedy, 'given by the good Heaven'. I
also recommended it to sick friends, who successfully cured
themselves too.

"For such a long time, I had taken so many drugs, spending a lot of
money. I had to appeal to both Oriental and Occidental medicines,
even to some traditional recipes, without any success.I know there
are many countrymen, friends, and soldier comrades, who participated
in the resistance war and suffered from chronic, indomitable
diseases, having to live in bad conditions, having no money to buy
the rare remedies at high prices.

"I found that urine is a universally efficient remedy, given free,
applicable to all people - in cities as well as in the countryside;
to the rich and to the poor; intellectuals and simple people; old
and young - to cure themselves from their own illnesses. It is also
useful to healthy people: It protects and improves one's health. An
overdose of urine does not cause any harm. The important factor in
treating chronic diseases, is the necessity of self-control in one's
way of living: There must be simplicity in eating and drinking.
Especially recommended is the practice of self-massage over the
entire body with urine. Generally speaking, one should correctly
apply every instruction in the book. Some people, who got rid of
heart and artery problems by the practice of Urine Therapy,
said that it is nearly an angelic panacea.

"On the basis of my success and in the cases of many friends of
mine, who recovered from most serious diseases, I wish that this
book on Urine Therapy be propagated very widely, in order to relieve
sick people of their misfortune. My sincere gratitude, January 1989 -
LE-BA, District 5 Red Cross."

http://www.salvationscience.com
--------------------------

MEDICINE WARS: THE IMPACT OF URINE THERAPY IN VIET NAM, PART III
Re: Three Stormy months of Jan., Feb., Mar. 1989
by Nguyen Chuong-Thi, Ho Chi Minh City, Viet Nam
Abridged and edited by Sw. Tantrasangha
http://www.salvationscience.com

PART III: THE HONORABLE CHUONG THI, PLEADING FOR URINE THERAPY
"FROM OUT OF HIS BELLY WILL POUR RIVERS OF LIVING WATER." - OUR
BELOVED LORD JESUS CHRIST

This is about an American book about Urine Therapy, which was
translated into Vietnamese, and then published in Viet Nam,
sponsored by the Vietnamese Red Cross, and made part of a TV program
about being your own doctor - a fundamental survivalist prerogative.
I was told that the book was banned, because it was "too popular".
God bless the honorable and courageous Vietnamese people.
Jai Om. - Sw. Tantrasangha
------------------------------------------------------

Ho Chi Minh City, 1989. The President of the Municipal People's
Committee.

Dear Sir,

As a member of the Oriental Medicine Association (certificate of
membership 1970), I have sought the honor to submit to you this
request for re-considering the Urine Therapy case and re-
establishing this world-wide method of self-healing ourselves from
diseases.

In May 1989, your predecessors in Session III forbade the book on
Urine Therapy, on the basis of opinions given by doctors of the
Municipal Health Service. There were three main charges: Absurdity
of treatment without diagnosis; the author not being an academic
doctor of medicine; and the great harm caused to the common people.

1. The great harm?

One death case reported by Dr. Duong-Quang-Trung. Three other cases
of death reported by Dr. Le-Quang-Tan. All of the four victims had
been suffering from severe diseases before using Urine Therapy -
apparently advanced cases.

Anyway, the number of Urine Therapy victims was too small in
comparison with hundreds of patients who healed themselves by Urine
Therapy. These people wrote down their happy experiences, and sent
this information to District 5 Red Cross, before the day the book
was forbidden.

In this state of things, there was no "great harm" at all. Please
let District 5 Red Cross publicize the result of its collection of
beneficiaries' testimony in favor of Urine Therapy.

2. The author of the book is not an academic doctor of medicine?

The existence of Urine Therapy the world over, is a fact. In many
countries, such as France, England, Germany and Russia, there have
been scientific books and reports on Urine Therapy. There are
several Urine Therapy Clinics in India.

From this world-wide documentation, the author made it his job to be
a synthesizer-reporter, just like a bee collecting the best of
flowers to make honey. He is quite trustworthy, because of the
brevity of his style and the good balance between the two parts of
his booklet: theory and practice.

Instead of condemning his work, you had better send researchers to
India, to benefit from other doctors' knowledge.

3. To treat disease without diagnosis is absurd?

Our national TV and radio are broadcasting a long program of general
medicine, "Doctor at Home - Medicine Indoors", helping adult people
to be their own doctor, pharmacist, and nurse, all at the same time.

In brief, the three charges against Urine Therapy are not sufficient
for condemning it.

CONCLUSION

As conclusion of the above considerations, you representatives,
elected by the people, have every reason for:

1. Revoking the decision of May 20th, 1989, issued by your
predecessors.

2. Favoring and urging the research, started by District 5 Red
Cross, gathering healed patients' experiences in favor of Urine
Therapy. Let the results be published, periodically.

3. Encouraging researchers to go abroad, especially to India, to
profit from the knowledge of other countries about Urine Therapy.

4.Promoting the program of "Doctor at Home - Medicine Indoors",
insisting on oriental and traditional medicine, thus fulfilling the
instructions of the World Health Organization of the United Nations,
in favor of local and traditional medicines, and on the use of
foodstuffs as remedies.

By revoking the condemnation of Urine Therapy and reinstating this
therapy, you will be able to say, as did former Indian Prime
Minister Morarji Desai:

"Personally, I know of many cases of serious diseases, cured
successfully with Urine Therapy. This is a very simple, inexpensive,
and quite harmless health method. It is indeed an inestimable gift
to a country as poor as India now."

Respectfully, CHUONG-THI

NOTE TO READERS

The above pleading letter, prepared in Aug. 1990, was in fact dated
July 24, 1991, and sent in its Vietnamese version. What to do next,
if the rulers in Ho Chi Minh City remain deaf to this supplication?
Please give your advice. Thanks. - Chuong-Thi

http://tinyurl.com/ahvmoq
http://www.google.com/search?hl=en&q=urine+therapy+shirley%27s&btnG=Search
http://tinyurl.com/ahvmoq
http://www.salvationscience.com
*************************************************************

Messages 1408 - 1438 of 1448   Newest  |  < Newer  |  Older >  |  Oldest
Advanced
Add to My Yahoo!      XML What's This?

Copyright © 2009 Yahoo! Inc. All rights reserved.
Privacy Policy - Terms of Service - Guidelines - Help